US3948254A
(en)
*
|
1971-11-08 |
1976-04-06 |
Alza Corporation |
Novel drug delivery device
|
US3996933A
(en)
*
|
1972-10-02 |
1976-12-14 |
Morton Gutnick |
Intrauterine contraceptive devices and processes
|
US4325388A
(en)
*
|
1973-02-05 |
1982-04-20 |
Louis Bucalo |
Apparatus for collecting and processing body fluids
|
US3971376A
(en)
*
|
1973-02-26 |
1976-07-27 |
Ceskoslovenska Akademie Ved |
Method and apparatus for introducing fluids into the body
|
US4177256A
(en)
*
|
1973-04-25 |
1979-12-04 |
Alza Corporation |
Osmotic bursting drug delivery device
|
US4111196A
(en)
*
|
1973-07-27 |
1978-09-05 |
Lionel C. R. Emmett |
Intrauterine contraceptive device of c or omega form with tubular inserter and method of placement
|
GB1465684A
(en)
*
|
1973-07-27 |
1977-02-23 |
Emmett L |
Contraceptive device
|
US4018220A
(en)
*
|
1974-07-19 |
1977-04-19 |
Lionel C. R. Emmett |
Method of insertion for intrauterine device of C or omega form with tubular inserter
|
US4172446A
(en)
*
|
1974-12-20 |
1979-10-30 |
Louis Bucalo |
Apparatus for collecting body fluids
|
US4142526A
(en)
*
|
1974-12-23 |
1979-03-06 |
Alza Corporation |
Osmotic releasing system with means for changing release therefrom
|
US3946734A
(en)
*
|
1975-02-19 |
1976-03-30 |
The United States Of America As Represented By The Secretary Of State |
Apparatus for controlling the release of a drug
|
AU1147476A
(en)
*
|
1975-03-19 |
1977-09-01 |
Procter & Gamble |
Controlled release article
|
US4034758A
(en)
*
|
1975-09-08 |
1977-07-12 |
Alza Corporation |
Osmotic therapeutic system for administering medicament
|
US3977404A
(en)
*
|
1975-09-08 |
1976-08-31 |
Alza Corporation |
Osmotic device having microporous reservoir
|
US4036228A
(en)
*
|
1975-09-11 |
1977-07-19 |
Alza Corporation |
Osmotic dispenser with gas generating means
|
US3987790A
(en)
*
|
1975-10-01 |
1976-10-26 |
Alza Corporation |
Osmotically driven fluid dispenser
|
US4077407A
(en)
*
|
1975-11-24 |
1978-03-07 |
Alza Corporation |
Osmotic devices having composite walls
|
US4031202A
(en)
*
|
1975-12-08 |
1977-06-21 |
The Procter & Gamble Company |
Controlled release contraceptive article
|
US4073833A
(en)
*
|
1975-12-08 |
1978-02-14 |
The Procter & Gamble Company |
Encapsulation process
|
US4058122A
(en)
*
|
1976-02-02 |
1977-11-15 |
Alza Corporation |
Osmotic system with laminated wall formed of different materials
|
US4008719A
(en)
*
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4014334A
(en)
*
|
1976-02-02 |
1977-03-29 |
Alza Corporation |
Laminated osmotic system for dispensing beneficial agent
|
US4203439A
(en)
*
|
1976-11-22 |
1980-05-20 |
Alza Corporation |
Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
|
US4207890A
(en)
*
|
1977-01-04 |
1980-06-17 |
Mcneilab, Inc. |
Drug-dispensing device and method
|
US4218433A
(en)
*
|
1977-03-03 |
1980-08-19 |
Nippon Kayaku Kabushiki Kaisha |
Constant-rate eluting tablet and method of producing same
|
US4160452A
(en)
*
|
1977-04-07 |
1979-07-10 |
Alza Corporation |
Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
|
US4182330A
(en)
*
|
1977-07-25 |
1980-01-08 |
Alza Corporation |
Means for administering amphipathic medicament
|
US4190642A
(en)
*
|
1978-04-17 |
1980-02-26 |
Alza Corporation |
Ocular therapeutic system for dispensing a medication formulation
|
US4265874A
(en)
*
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
US4344929A
(en)
*
|
1980-04-25 |
1982-08-17 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
SE448203B
(sv)
*
|
1980-09-10 |
1987-02-02 |
Johan Alfred Olof Johansson |
formkropp framstelld av agar och/eller agaros och/eller ett derivat derav innehallande farmakologiskt verksamt emne
|
US4439195A
(en)
*
|
1980-10-14 |
1984-03-27 |
Alza Corporation |
Theophylline therapy
|
US4455145A
(en)
*
|
1981-07-10 |
1984-06-19 |
Alza Corporation |
Dispensing device with internal drive
|
US4740198A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Method of administering intravenous drug using rate-controlled dosage form
|
USRE34365E
(en)
*
|
1981-07-13 |
1993-08-31 |
|
Intravenous system for delivering a beneficial agent
|
US4552555A
(en)
*
|
1981-07-31 |
1985-11-12 |
Alza Corporation |
System for intravenous delivery of a beneficial agent
|
US4973307A
(en)
*
|
1981-07-13 |
1990-11-27 |
Alza Corporation |
Method for administering drugs to a patient
|
US4740201A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US5069671A
(en)
*
|
1981-07-13 |
1991-12-03 |
Alza Corporation |
Intravenous medication
|
US4994031A
(en)
*
|
1981-07-13 |
1991-02-19 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4432756A
(en)
*
|
1981-11-27 |
1984-02-21 |
Alza Corporation |
Parenteral controlled therapy
|
US4790820A
(en)
*
|
1981-07-13 |
1988-12-13 |
Alza Corporation |
Parenteral agent dispensing equipment with drug releasing member
|
US4511353A
(en)
*
|
1981-07-13 |
1985-04-16 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4985017A
(en)
*
|
1981-07-13 |
1991-01-15 |
Alza Corporation |
Parenteral therapeutical system comprising drug cell
|
US4857052A
(en)
*
|
1981-07-13 |
1989-08-15 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4871360A
(en)
*
|
1981-07-31 |
1989-10-03 |
Alza Corporation |
System for intravenous delivery of a beneficial drug at a regulated rates
|
GB2107191B
(en)
*
|
1981-07-31 |
1984-08-30 |
Alza Corp |
Parenteral delivery system
|
US4525162A
(en)
*
|
1981-07-31 |
1985-06-25 |
Alza Corporation |
Parenteral controlled delivery
|
US4439194A
(en)
*
|
1981-09-08 |
1984-03-27 |
Merck & Co., Inc. |
Water and drug delivery system for suppository use
|
US4740199A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4740103A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4741735A
(en)
*
|
1981-10-09 |
1988-05-03 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4741734A
(en)
*
|
1981-10-09 |
1988-05-03 |
Alza Corporation |
Releasing means for adding agent using releasing means to IV fluid
|
US4586922A
(en)
*
|
1981-10-09 |
1986-05-06 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4740197A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent via polymer delivery
|
US4740200A
(en)
*
|
1981-10-09 |
1988-04-26 |
Alza Corporation |
Intravenous system for delivering a beneficial agent
|
US4416659A
(en)
*
|
1981-11-09 |
1983-11-22 |
Eli Lilly And Company |
Sustained release capsule for ruminants
|
US4479794A
(en)
*
|
1981-11-27 |
1984-10-30 |
Alza Corporation |
System for intravenous therapy
|
US4552556A
(en)
*
|
1981-11-27 |
1985-11-12 |
Alza Corporation |
Parenteral controlled therapy
|
US4493702A
(en)
*
|
1981-11-27 |
1985-01-15 |
Alza Corporation |
Parenteral administration using osmotically motivated delivery system
|
US4548599A
(en)
*
|
1981-11-27 |
1985-10-22 |
Alza Corporation |
Parenteral controlled therapy
|
US4583981A
(en)
*
|
1981-11-27 |
1986-04-22 |
Alza Corporation |
Parenteral controlled therapy, using a porous matrix with parenteral agent
|
US4479793A
(en)
*
|
1981-11-27 |
1984-10-30 |
Alza Corporation |
Parenteral administration using drug delivery device
|
US4579553A
(en)
*
|
1981-11-27 |
1986-04-01 |
Alza Corporation |
Parenteral controlled therapy
|
US4484909A
(en)
*
|
1981-11-27 |
1984-11-27 |
Alza Corporation |
Parenteral therapy using solid drug
|
US4484921A
(en)
*
|
1982-02-01 |
1984-11-27 |
Alza Corporation |
Theophylline therapy utilizing osmotic delivery
|
US4439196A
(en)
*
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4475916A
(en)
*
|
1982-03-18 |
1984-10-09 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4449983A
(en)
*
|
1982-03-22 |
1984-05-22 |
Alza Corporation |
Simultaneous delivery of two drugs from unit delivery device
|
US4455143A
(en)
*
|
1982-03-22 |
1984-06-19 |
Alza Corporation |
Osmotic device for dispensing two different medications
|
US4908019A
(en)
*
|
1982-05-24 |
1990-03-13 |
Alza Corporation |
Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
|
US4515585A
(en)
*
|
1982-05-24 |
1985-05-07 |
Alza Corporation |
System for parenteral administration of agent
|
US4664650A
(en)
*
|
1982-05-24 |
1987-05-12 |
Alza Corporation |
Apparatus for parenteral infusion of fluid containing beneficial agent
|
US4553973A
(en)
*
|
1982-07-12 |
1985-11-19 |
Alza Corporation |
Process for preparing osmotic device
|
US4519801A
(en)
*
|
1982-07-12 |
1985-05-28 |
Alza Corporation |
Osmotic device with wall comprising cellulose ether and permeability enhancer
|
US4539004A
(en)
*
|
1982-09-22 |
1985-09-03 |
Alza Corporation |
Self-driven pump assembly and method of operation
|
US4522625A
(en)
*
|
1982-09-29 |
1985-06-11 |
Alza Corporation |
Drug dispenser comprising wall formed of semipermeable member and enteric member
|
US4552561A
(en)
*
|
1982-12-23 |
1985-11-12 |
Alza Corporation |
Body mounted pump housing and pump assembly employing the same
|
US4667032A
(en)
*
|
1983-01-21 |
1987-05-19 |
Merck Frosst Canada, Inc. |
Phenothiazone derivatives and analogs
|
US4859667A
(en)
*
|
1983-01-21 |
1989-08-22 |
Merck Frosst Canada, Inc. |
Pharmaceutical compositions of phenothiazone derivatives and analogs
|
US4576604A
(en)
*
|
1983-03-04 |
1986-03-18 |
Alza Corporation |
Osmotic system with instant drug availability
|
US4789516A
(en)
*
|
1983-04-15 |
1988-12-06 |
Damon Biotech, Inc |
Production of sustained released system
|
US4690682A
(en)
*
|
1983-04-15 |
1987-09-01 |
Damon Biotech, Inc. |
Sustained release
|
US4503030A
(en)
*
|
1983-06-06 |
1985-03-05 |
Alza Corporation |
Device for delivering drug to certain pH environments
|
US4610686A
(en)
*
|
1983-11-02 |
1986-09-09 |
Alza Corporation |
Controlled delivery of haloperidol by an osmotic delivery system
|
GB2150830B
(en)
*
|
1983-12-05 |
1987-08-19 |
Alza Corp |
Drug dispenser
|
US5000957A
(en)
*
|
1984-03-19 |
1991-03-19 |
Alza Corporation |
Dispenser comprising hydrophilic osmopolymer
|
US4624945A
(en)
*
|
1984-03-19 |
1986-11-25 |
Alza Corporation |
Dispensing system with means for increasing delivery of beneficial agent from the system
|
US4927633A
(en)
*
|
1984-03-19 |
1990-05-22 |
Alza Corporation |
Dispenser for delivering drug to livestock
|
US4692336A
(en)
*
|
1984-03-19 |
1987-09-08 |
Alza Corporation |
Self controlled release device for administering beneficial agent to recipient
|
US4717566A
(en)
*
|
1984-03-19 |
1988-01-05 |
Alza Corporation |
Dosage system and method of using same
|
US4684524A
(en)
*
|
1984-03-19 |
1987-08-04 |
Alza Corporation |
Rate controlled dispenser for administering beneficial agent
|
US4729793A
(en)
*
|
1985-08-09 |
1988-03-08 |
Alza Corporation |
Composition for manufacturing wall of dispensing device
|
US4844984A
(en)
*
|
1984-03-19 |
1989-07-04 |
Alza Corporation |
Dispensing system with means for increasing delivery of beneficial agent from the system
|
US4612186A
(en)
*
|
1984-03-19 |
1986-09-16 |
Alza Corporation |
Method for establishing blood levels of biocide in animals
|
US4663149A
(en)
*
|
1984-03-21 |
1987-05-05 |
Alza Corporation |
Dispenser comprising inner and outer walls functioning as cooperative unit
|
US4716031A
(en)
*
|
1984-03-21 |
1987-12-29 |
Alza Corporation |
Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
|
US4814180A
(en)
*
|
1984-03-21 |
1989-03-21 |
Alza Corporation |
Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
|
US4692326A
(en)
*
|
1984-03-21 |
1987-09-08 |
Alza Corporation |
Dispenser comprising inner positioned soft or hard capsule
|
US4663148A
(en)
*
|
1984-03-21 |
1987-05-05 |
Alza Corporation |
Dispenser comprising telescopically engaging members
|
GB2155889B
(en)
*
|
1984-03-21 |
1988-03-02 |
Alza Corp |
Dispenser-capsule
|
US4678467A
(en)
*
|
1984-03-21 |
1987-07-07 |
Alza Corporation |
Dispenser comprising capsule with volume displacing member
|
US4615698A
(en)
*
|
1984-03-23 |
1986-10-07 |
Alza Corporation |
Total agent osmotic delivery system
|
US4511351A
(en)
*
|
1984-05-14 |
1985-04-16 |
Alza Corporation |
Parenteral delivery system utilizing a hollow fiber cellular unit
|
US4596555A
(en)
*
|
1984-05-14 |
1986-06-24 |
Alza Corporation |
Parenteral delivery system utilizing a hollow fiber cellular unit
|
US4511352A
(en)
*
|
1984-05-14 |
1985-04-16 |
Alza Corporation |
Parenteral delivery system with in-line container
|
US4968507A
(en)
*
|
1984-06-20 |
1990-11-06 |
Merck & Co., Inc. |
Controlled porosity osmotic pump
|
US4769027A
(en)
*
|
1984-08-15 |
1988-09-06 |
Burroughs Wellcome Co. |
Delivery system
|
EP0246715A3
(en)
*
|
1984-12-03 |
1988-02-03 |
BAXTER INTERNATIONAL INC. (a Delaware corporation) |
Apparatus for the safe delivery of a beneficial agent to a patient
|
US4765985A
(en)
*
|
1985-03-05 |
1988-08-23 |
Ciba-Geigy Corporation |
Devices and methods for treating memory impairment
|
US4680172A
(en)
*
|
1985-03-05 |
1987-07-14 |
Ciba-Geigy Corporation |
Devices and methods for treating memory impairment
|
JPS61153350U
(el)
*
|
1985-03-13 |
1986-09-22 |
|
|
US4693886A
(en)
*
|
1985-04-22 |
1987-09-15 |
Alza Corporation |
Osmotic device with inert core
|
CA1309557C
(en)
|
1985-06-18 |
1992-10-27 |
Robert N. Young |
Leukotriene antagonists
|
US4717718A
(en)
*
|
1985-08-09 |
1988-01-05 |
Alza Corporation |
Device for the controlled delivery of a beneficial agent
|
US4717568A
(en)
*
|
1985-08-09 |
1988-01-05 |
Alza Corporation |
Laminar arrangement for increasing delivery of beneficial agent from dispenser
|
US4883667A
(en)
*
|
1985-08-16 |
1989-11-28 |
Alza Corporation |
Process for forming dispensing device
|
US5098425A
(en)
*
|
1985-08-16 |
1992-03-24 |
Alza Corporation |
Method of administering a ruminant dispensing device comprising density member dispersed in hydrogel member
|
US4704118A
(en)
*
|
1985-08-16 |
1987-11-03 |
Alza Corporation |
Ruminant dispensing device with thermo-activated memory
|
US4955881A
(en)
*
|
1985-08-16 |
1990-09-11 |
Alza Corporation |
Ruminant dispensing device
|
US4865598A
(en)
*
|
1985-08-16 |
1989-09-12 |
Alza Corporation |
Dispensing system for administering beneficial agent
|
US4966767A
(en)
*
|
1985-08-16 |
1990-10-30 |
Alza Corporation |
Ruminant dispensing device comprising agent displacement member
|
US4675174A
(en)
*
|
1985-08-16 |
1987-06-23 |
Alza Corporation |
Veterinary dispenser delivering beneficial agent by gas power generated in situ
|
US4963141A
(en)
*
|
1985-08-16 |
1990-10-16 |
Alza Corporation |
Dispensing system for administering beneficial agent formulation to ruminants
|
US4871544A
(en)
*
|
1985-08-16 |
1989-10-03 |
Alza Corporation |
Ruminant dispensing device
|
US4643731A
(en)
*
|
1985-08-16 |
1987-02-17 |
Alza Corporation |
Means for providing instant agent from agent dispensing system
|
US4756314A
(en)
*
|
1985-10-28 |
1988-07-12 |
Alza Corporation |
Sweat collection patch
|
US4680266A
(en)
*
|
1985-11-21 |
1987-07-14 |
Contraves Ag |
Cell culture chamber with means for automatic replenishment of nutrient
|
US5008112A
(en)
*
|
1985-12-16 |
1991-04-16 |
International Minerals & Chem. Corporation |
Device for the extended delivery of diffusible agents
|
US4971790A
(en)
*
|
1986-02-07 |
1990-11-20 |
Alza Corporation |
Dosage form for lessening irritation of mocusa
|
US4867969A
(en)
*
|
1986-02-07 |
1989-09-19 |
Alza Corporation |
Hydrogel formulation for administering non-steroidal drugs
|
US4865845A
(en)
*
|
1986-03-21 |
1989-09-12 |
Alza Corporation |
Release rate adjustment of osmotic or diffusional delivery devices
|
ATE90076T1
(de)
|
1986-03-27 |
1993-06-15 |
Merck Frosst Canada Inc |
Tetrahydrocarbazole ester.
|
US4755180A
(en)
*
|
1986-06-16 |
1988-07-05 |
Alza Corporation |
Dosage form comprising solubility regulating member
|
US4847093A
(en)
*
|
1986-06-19 |
1989-07-11 |
Alza Corporation |
Dosage form with means for governing rate of gas formation
|
US4838862A
(en)
|
1986-08-04 |
1989-06-13 |
Pharmetrix Corp. |
Portable controlled release osmotic infusion device
|
CH668187A5
(de)
*
|
1986-08-07 |
1988-12-15 |
Ciba Geigy Ag |
Therapeutisches system mit systemischer wirkung.
|
USRE34990E
(en)
*
|
1986-08-07 |
1995-07-04 |
Ciba-Geigy Corporation |
Oral therapeutic system having systemic action
|
DE3868077D1
(de)
*
|
1987-01-14 |
1992-03-12 |
Ciba Geigy Ag |
Therapeutisches system fuer schwerloesliche wirkstoffe.
|
US4801461A
(en)
|
1987-01-28 |
1989-01-31 |
Alza Corporation |
Pseudoephedrine dosage form
|
US5023076A
(en)
*
|
1987-02-27 |
1991-06-11 |
Alza Corporation |
Lamina comprising carboxyvinyl polymer
|
US4915952A
(en)
*
|
1987-02-27 |
1990-04-10 |
Alza Corporation |
Composition comprising drug, HPC, HPMC and PEO
|
US4888416A
(en)
*
|
1987-03-30 |
1989-12-19 |
International Minerals & Chemical Corp. |
Method for stabilizing somatotropins
|
US5499979A
(en)
*
|
1987-06-25 |
1996-03-19 |
Alza Corporation |
Delivery system comprising kinetic forces
|
US4957494A
(en)
*
|
1987-06-25 |
1990-09-18 |
Alza Corporation |
Multi-layer delivery system
|
US5023088A
(en)
*
|
1987-06-25 |
1991-06-11 |
Alza Corporation |
Multi-unit delivery system
|
US5938654A
(en)
*
|
1987-06-25 |
1999-08-17 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
US5236689A
(en)
*
|
1987-06-25 |
1993-08-17 |
Alza Corporation |
Multi-unit delivery system
|
US5391381A
(en)
*
|
1987-06-25 |
1995-02-21 |
Alza Corporation |
Dispenser capable of delivering plurality of drug units
|
US5110597A
(en)
*
|
1987-06-25 |
1992-05-05 |
Alza Corporation |
Multi-unit delivery system
|
US5340590A
(en)
*
|
1987-06-25 |
1994-08-23 |
Alza Corporation |
Delivery system with bilayer osmotic engine
|
US4874388A
(en)
*
|
1987-06-25 |
1989-10-17 |
Alza Corporation |
Multi-layer delivery system
|
US4891223A
(en)
*
|
1987-09-03 |
1990-01-02 |
Air Products And Chemicals, Inc. |
Controlled release delivery coating formulation for bioactive substances
|
US4880631A
(en)
*
|
1987-09-24 |
1989-11-14 |
Merck & Co., Inc. |
Controlled porosity osmotic pump
|
US4886668A
(en)
*
|
1987-09-24 |
1989-12-12 |
Merck & Co., Inc. |
Multiparticulate controlled porosity osmotic pump
|
US4950486A
(en)
*
|
1987-10-02 |
1990-08-21 |
Alza Corporation |
Dosage form for treating cardiovascular diseases
|
US4816263A
(en)
*
|
1987-10-02 |
1989-03-28 |
Alza Corporation |
Dosage form for treating cardiovascular diseases comprising isradipine
|
US4946687A
(en)
*
|
1987-10-02 |
1990-08-07 |
Alza Corporation |
Dosage form for treating cardiovascular diseases
|
US4994273A
(en)
*
|
1987-11-02 |
1991-02-19 |
Merck & Co., Inc. |
Solubility modulated drug delivery device
|
US5030203A
(en)
*
|
1987-11-16 |
1991-07-09 |
Baxter International Inc. |
Ampule for controlled administration of beneficial agent
|
JP2590358B2
(ja)
*
|
1988-03-01 |
1997-03-12 |
正雄 五十嵐 |
子宮内膜症治療用の子宮内又は膣内投与製剤
|
US4837111A
(en)
*
|
1988-03-21 |
1989-06-06 |
Alza Corporation |
Dosage form for dispensing drug for human therapy
|
US4959218A
(en)
*
|
1988-03-25 |
1990-09-25 |
Alza Corporation |
Method for delivering somatotropin to an animal
|
US4855141A
(en)
*
|
1988-03-25 |
1989-08-08 |
Alza Corporation |
Device comprising means for protecting and dispensing fluid sensitive medicament
|
US4996060A
(en)
*
|
1988-03-25 |
1991-02-26 |
Alza Corporation |
Device comprising liner for protecting fluid sensitive medicament
|
US5019397A
(en)
*
|
1988-04-21 |
1991-05-28 |
Alza Corporation |
Aqueous emulsion for pharmaceutical dosage form
|
US4892739A
(en)
*
|
1988-04-25 |
1990-01-09 |
Ciba-Geigy Corporation |
Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
|
US4931285A
(en)
*
|
1988-04-28 |
1990-06-05 |
Alza Corporation |
Aqueous based pharmaceutical coating composition for dosage forms
|
US5160743A
(en)
*
|
1988-04-28 |
1992-11-03 |
Alza Corporation |
Annealed composition for pharmaceutically acceptable drug
|
US5006346A
(en)
*
|
1988-04-28 |
1991-04-09 |
Alza Corporation |
Delivery system
|
US5024842A
(en)
*
|
1988-04-28 |
1991-06-18 |
Alza Corporation |
Annealed coats
|
US4859470A
(en)
*
|
1988-06-02 |
1989-08-22 |
Alza Corporation |
Dosage form for delivering diltiazem
|
US4966769A
(en)
*
|
1988-06-02 |
1990-10-30 |
Alza Corporation |
Method for delivering dosage form for diltiazem
|
US5028434A
(en)
*
|
1988-07-21 |
1991-07-02 |
Alza Corporation |
Method for administering nilvadipine for treating cardiovascular symptoms
|
GB8820353D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Staniforth J N |
Controlled release tablet
|
US5612059A
(en)
*
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
US5096716A
(en)
*
|
1988-09-01 |
1992-03-17 |
Alza Corporation |
Dosage form for administering calcium antagonist nicardipine
|
US5236714A
(en)
*
|
1988-11-01 |
1993-08-17 |
Alza Corporation |
Abusable substance dosage form having reduced abuse potential
|
US5030456A
(en)
*
|
1988-11-07 |
1991-07-09 |
Alza Corporation |
Dosage form for treating cardiovascular diseases
|
US4997658A
(en)
*
|
1988-11-21 |
1991-03-05 |
Merck & Co., Inc. |
Method for enhancing the lowering of plasma cholesterol levels
|
US5376383A
(en)
*
|
1988-11-21 |
1994-12-27 |
Merck & Co., Inc. |
Method for enhancing the lowering of plasma-cholesterol levels
|
US5059423A
(en)
*
|
1988-12-13 |
1991-10-22 |
Alza Corporation |
Delivery system comprising biocompatible beneficial agent formulation
|
US5174999A
(en)
*
|
1988-12-13 |
1992-12-29 |
Alza Corporation |
Delivery system comprising fluid ingress and drug egress
|
US5135523A
(en)
*
|
1988-12-13 |
1992-08-04 |
Alza Corporation |
Delivery system for administering agent to ruminants and swine
|
US5057318A
(en)
*
|
1988-12-13 |
1991-10-15 |
Alza Corporation |
Delivery system for beneficial agent over a broad range of rates
|
US5034229A
(en)
*
|
1988-12-13 |
1991-07-23 |
Alza Corporation |
Dispenser for increasing feed conversion of hog
|
US5110596A
(en)
*
|
1988-12-13 |
1992-05-05 |
Alza Corporation |
Delivery system comprising means for delivering agent to livestock
|
US5037420A
(en)
*
|
1988-12-13 |
1991-08-06 |
Alza Corporation |
Delivery system comprising two sections for delivering somatotropin
|
US5728088A
(en)
*
|
1988-12-13 |
1998-03-17 |
Alza Corporation |
Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
|
IL92966A
(en)
*
|
1989-01-12 |
1995-07-31 |
Pfizer |
Hydrogel-operated release devices
|
US5030452A
(en)
*
|
1989-01-12 |
1991-07-09 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
US5108756A
(en)
*
|
1989-01-12 |
1992-04-28 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
US5186942A
(en)
*
|
1989-01-30 |
1993-02-16 |
Alza Corporation |
Nicardipine therapy
|
DD295760A5
(de)
*
|
1989-01-31 |
1991-11-14 |
Martin-Luther-Universitaet Halle Wittenberg,De |
Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
|
US4969872A
(en)
*
|
1989-03-08 |
1990-11-13 |
Alza Corporation |
Intravenous system for delivering a beneficial agent with delivery rate control via permeable surface area variance
|
US5019396A
(en)
*
|
1989-05-12 |
1991-05-28 |
Alza Corporation |
Delivery dispenser for treating cardiac arrhythmias
|
US5021053A
(en)
*
|
1989-07-14 |
1991-06-04 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
US5776493A
(en)
*
|
1989-07-14 |
1998-07-07 |
Alza Corporation |
Oral osmotic device for delivery of nystatin with hydrogel driving member
|
US5273752A
(en)
*
|
1989-07-18 |
1993-12-28 |
Alza Corporation |
Controlled release dispenser comprising beneficial agent
|
US5126142A
(en)
*
|
1989-07-18 |
1992-06-30 |
Alza Corporation |
Dispenser comprising ionophore
|
US5091190A
(en)
*
|
1989-09-05 |
1992-02-25 |
Alza Corporation |
Delivery system for administration blood-glucose lowering drug
|
US20020197309A1
(en)
*
|
1989-09-05 |
2002-12-26 |
Kuczynski Anthony L. |
Method for lowering blood glucose
|
US5035897A
(en)
*
|
1989-09-05 |
1991-07-30 |
Alza Corporation |
Dosage form for delivering soluble or insoluble drugs
|
US5024843A
(en)
*
|
1989-09-05 |
1991-06-18 |
Alza Corporation |
Oral hypoglycemic glipizide granulation
|
US6361795B1
(en)
|
1989-09-05 |
2002-03-26 |
Alza Corporation |
Method for lowering blood glucose
|
US5591454A
(en)
*
|
1989-09-05 |
1997-01-07 |
Alza Corporation |
Method for lowering blood glucose
|
US5112614A
(en)
*
|
1989-09-14 |
1992-05-12 |
Alza Corporation |
Implantable delivery dispenser
|
US5098714A
(en)
*
|
1989-11-16 |
1992-03-24 |
Alza Corporation |
Osmotic, oral dosage form for fertility control
|
US5200197A
(en)
*
|
1989-11-16 |
1993-04-06 |
Alza Corporation |
Contraceptive pill
|
US5474785A
(en)
*
|
1990-01-24 |
1995-12-12 |
Alza Corporation |
Delivery system comprising means for controlling internal pressure
|
US5071607A
(en)
*
|
1990-01-31 |
1991-12-10 |
Alza Corporatino |
Method and apparatus for forming a hole in a drug dispensing device
|
US5024663A
(en)
*
|
1990-02-21 |
1991-06-18 |
Alza Corporation |
Self-contained suction pump
|
US5178866A
(en)
*
|
1990-03-23 |
1993-01-12 |
Alza Corporation |
Dosage form for delivering drug to the intestine
|
US5242391A
(en)
*
|
1990-04-25 |
1993-09-07 |
Alza Corporation |
Urethral insert for treatment of erectile dysfunction
|
US5017381A
(en)
*
|
1990-05-02 |
1991-05-21 |
Alza Corporation |
Multi-unit pulsatile delivery system
|
US5190763A
(en)
*
|
1990-05-07 |
1993-03-02 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5221536A
(en)
|
1990-05-07 |
1993-06-22 |
Alza Corporation |
Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
|
US5192550A
(en)
*
|
1990-05-07 |
1993-03-09 |
Alza Corporation |
Dosage form for treating central nervous system disorders
|
US5128145A
(en)
*
|
1990-06-13 |
1992-07-07 |
Alza Corporation |
Dosage form for Parkinson's disease, spasticity and muscle spasms
|
US5057321A
(en)
*
|
1990-06-13 |
1991-10-15 |
Alza Corporation |
Dosage form comprising drug and maltodextrin
|
US5238687A
(en)
*
|
1990-07-11 |
1993-08-24 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5234692A
(en)
*
|
1990-07-11 |
1993-08-10 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5234693A
(en)
*
|
1990-07-11 |
1993-08-10 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5234694A
(en)
*
|
1990-07-11 |
1993-08-10 |
Alza Corporation |
Method for increasing feed efficiency in animals
|
US5180591A
(en)
*
|
1990-07-11 |
1993-01-19 |
Alza Corporation |
Delivery device with a protective sleeve
|
US5147654A
(en)
*
|
1990-07-23 |
1992-09-15 |
Alza Corporation |
Oral osmotic device for delivering nicotine
|
JPH0794379B2
(ja)
*
|
1990-08-07 |
1995-10-11 |
ファイザー・インコーポレーテッド |
放出製剤における界面重合膜の使用方法
|
US5104899A
(en)
*
|
1990-08-13 |
1992-04-14 |
Sepracor, Inc. |
Methods and compositions for treating depression using optically pure fluoxetine
|
US5589511A
(en)
*
|
1990-08-13 |
1996-12-31 |
Sepracor Inc. |
Method for treating migraine headaches using optically pure S(+) fluoxetine
|
US5232705A
(en)
*
|
1990-08-31 |
1993-08-03 |
Alza Corporation |
Dosage form for time-varying patterns of drug delivery
|
US5156850A
(en)
*
|
1990-08-31 |
1992-10-20 |
Alza Corporation |
Dosage form for time-varying patterns of drug delivery
|
US5246709A
(en)
*
|
1990-09-10 |
1993-09-21 |
Alza Corporation |
Antiemetic therapy
|
US5166145A
(en)
*
|
1990-09-10 |
1992-11-24 |
Alza Corporation |
Antiemetic therapy
|
DK0550641T3
(da)
*
|
1990-09-28 |
1994-08-22 |
Pfizer |
Dispenseringsanordning indeholdende et hydrofobt medium
|
US5151093A
(en)
*
|
1990-10-29 |
1992-09-29 |
Alza Corporation |
Osmotically driven syringe with programmable agent delivery
|
US5443459A
(en)
*
|
1991-01-30 |
1995-08-22 |
Alza Corporation |
Osmotic device for delayed delivery of agent
|
US5708035A
(en)
*
|
1991-02-04 |
1998-01-13 |
Sepracor Inc. |
Methods of use and compositions of R(-) fluoxetine
|
US5861166A
(en)
*
|
1991-03-12 |
1999-01-19 |
Alza Corporation |
Delivery device providing beneficial agent stability
|
US5208037A
(en)
*
|
1991-04-22 |
1993-05-04 |
Alza Corporation |
Dosage forms comprising polymers comprising different molecular weights
|
US5198229A
(en)
*
|
1991-06-05 |
1993-03-30 |
Alza Corporation |
Self-retaining gastrointestinal delivery device
|
US5227167A
(en)
*
|
1991-06-11 |
1993-07-13 |
Alza Corporation |
Long-term delivery device including hydrophobic loading dose
|
US5137727A
(en)
*
|
1991-06-12 |
1992-08-11 |
Alza Corporation |
Delivery device providing beneficial agent stability
|
US5801141A
(en)
*
|
1991-06-24 |
1998-09-01 |
American Cyanamid Company |
Implant compositions containing a biologically active protein, peptide or polypeptide
|
US5160744A
(en)
*
|
1991-06-27 |
1992-11-03 |
Alza Corporation |
Verapmil therapy
|
US5190765A
(en)
*
|
1991-06-27 |
1993-03-02 |
Alza Corporation |
Therapy delayed
|
US5252338A
(en)
*
|
1991-06-27 |
1993-10-12 |
Alza Corporation |
Therapy delayed
|
US6764697B1
(en)
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5178867A
(en)
*
|
1991-08-19 |
1993-01-12 |
Alza Corporation |
Dosage form for delivering drug in short-time period
|
US5240713A
(en)
*
|
1991-09-27 |
1993-08-31 |
Alza Corporation |
Dual rate agent delivery device
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5254349A
(en)
*
|
1991-12-06 |
1993-10-19 |
Alza Corporation |
Process for lessening irritation caused by drug
|
US5200195A
(en)
*
|
1991-12-06 |
1993-04-06 |
Alza Corporation |
Process for improving dosage form delivery kinetics
|
US5266332A
(en)
*
|
1991-12-06 |
1993-11-30 |
Alza Corporation |
Method for administering anti-Parkinson drug
|
US5200194A
(en)
*
|
1991-12-18 |
1993-04-06 |
Alza Corporation |
Oral osmotic device
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5968551A
(en)
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5223265A
(en)
*
|
1992-01-10 |
1993-06-29 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery
|
US5185158A
(en)
*
|
1992-02-27 |
1993-02-09 |
Alza Corporation |
Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
|
US5246711A
(en)
*
|
1992-02-27 |
1993-09-21 |
Alza Corporation |
Dosage form for treating dysthymia
|
US5246710A
(en)
*
|
1992-02-27 |
1993-09-21 |
Alza Corporation |
Dosage form for treating cyclothymia
|
US5688518A
(en)
*
|
1992-02-27 |
1997-11-18 |
Alza Corporation |
Antidepressive therapy
|
US5330762A
(en)
*
|
1992-02-27 |
1994-07-19 |
Alza Corporation |
Tandospiaine antidepressive therapy
|
US5858407A
(en)
*
|
1992-02-27 |
1999-01-12 |
Alza Corporation |
Method for administering tandospirone
|
US5248310A
(en)
*
|
1992-03-27 |
1993-09-28 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
US5512299A
(en)
*
|
1992-03-30 |
1996-04-30 |
Alza Corporation |
Method of treating oral inflammatory disease
|
US5869097A
(en)
|
1992-11-02 |
1999-02-09 |
Alza Corporation |
Method of therapy comprising an osmotic caplet
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
US5573776A
(en)
*
|
1992-12-02 |
1996-11-12 |
Alza Corporation |
Oral osmotic device with hydrogel driving member
|
US5358721A
(en)
*
|
1992-12-04 |
1994-10-25 |
Alza Corporation |
Antiviral therapy
|
EP0684814B1
(en)
*
|
1993-02-22 |
1998-06-17 |
Alza Corporation |
Compositions for oral delivery of active agents
|
DE69425453T2
(de)
*
|
1993-04-23 |
2001-04-12 |
Novartis Ag |
Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
|
IL109460A
(en)
|
1993-05-10 |
1998-03-10 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US6287598B1
(en)
|
1993-05-28 |
2001-09-11 |
Alza Corporation |
Method for providing sustained antiepileptic therapy
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5410054A
(en)
*
|
1993-07-20 |
1995-04-25 |
Merck Frosst Canada, Inc. |
Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US5498255A
(en)
*
|
1993-08-17 |
1996-03-12 |
Alza Corporation |
Osmotic device for protracted pulsatile delivery of agent
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
DE4342173A1
(de)
*
|
1993-12-10 |
1995-06-14 |
Lohmann Therapie Syst Lts |
Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
|
US5532003A
(en)
*
|
1994-01-18 |
1996-07-02 |
Alza Corporation |
Pentoxifylline therapy
|
US5540665A
(en)
*
|
1994-01-31 |
1996-07-30 |
Alza Corporation |
Gas driven dispensing device and gas generating engine therefor
|
US5985328A
(en)
*
|
1994-03-07 |
1999-11-16 |
Regents Of The University Of California |
Micromachined porous membranes with bulk support
|
US5985164A
(en)
*
|
1994-03-07 |
1999-11-16 |
Regents Of The University Of California |
Method for forming a filter
|
US5770076A
(en)
*
|
1994-03-07 |
1998-06-23 |
The Regents Of The University Of California |
Micromachined capsules having porous membranes and bulk supports
|
US5798042A
(en)
*
|
1994-03-07 |
1998-08-25 |
Regents Of The University Of California |
Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
US20040191314A1
(en)
*
|
1994-04-28 |
2004-09-30 |
Frank Jao |
Antiepileptic dosage form and process for protecting antiepileptic drug
|
ZA953078B
(en)
*
|
1994-04-28 |
1996-01-05 |
Alza Corp |
Effective therapy for epilepsies
|
US6077533A
(en)
*
|
1994-05-25 |
2000-06-20 |
Purdue Pharma L.P. |
Powder-layered oral dosage forms
|
US5411745A
(en)
*
|
1994-05-25 |
1995-05-02 |
Euro-Celtique, S.A. |
Powder-layered morphine sulfate formulations
|
US5460826A
(en)
*
|
1994-06-27 |
1995-10-24 |
Alza Corporation |
Morphine therapy
|
US5698224A
(en)
*
|
1994-06-27 |
1997-12-16 |
Alza Corporation |
Tacrine therapy
|
US5914131A
(en)
*
|
1994-07-07 |
1999-06-22 |
Alza Corporation |
Hydromorphone therapy
|
US5529787A
(en)
*
|
1994-07-07 |
1996-06-25 |
Alza Corporation |
Hydromorphone therapy
|
US5633011A
(en)
*
|
1994-08-04 |
1997-05-27 |
Alza Corporation |
Progesterone replacement therapy
|
DE4431653C2
(de)
*
|
1994-09-06 |
2000-01-20 |
Lohmann Therapie Syst Lts |
Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
|
US6491945B1
(en)
|
1994-09-16 |
2002-12-10 |
Alza Corporation |
Hydrocodone therapy
|
US5718700A
(en)
*
|
1994-09-20 |
1998-02-17 |
Alza Corporation |
Exit means in dosage form
|
US5614578A
(en)
*
|
1994-10-28 |
1997-03-25 |
Alza Corporation |
Injection-molded dosage form
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US5595759A
(en)
*
|
1994-11-10 |
1997-01-21 |
Alza Corporation |
Process for providing therapeutic composition
|
US5582838A
(en)
*
|
1994-12-22 |
1996-12-10 |
Merck & Co., Inc. |
Controlled release drug suspension delivery device
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US5595997A
(en)
|
1994-12-30 |
1997-01-21 |
Sepracor Inc. |
Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
|
US5651979A
(en)
*
|
1995-03-30 |
1997-07-29 |
Gel Sciences, Inc. |
Apparatus and method for delivering a biologically active compound into a biological environment
|
US5558879A
(en)
*
|
1995-04-28 |
1996-09-24 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water soluble drugs in which a passageway is formed in situ
|
US5736159A
(en)
*
|
1995-04-28 |
1998-04-07 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
|
US6262115B1
(en)
*
|
1995-05-22 |
2001-07-17 |
Alza Coporation |
Method for the management of incontinence
|
US6124355A
(en)
*
|
1995-05-22 |
2000-09-26 |
Guittard; George V. |
Oxybutynin therapy
|
US5912268A
(en)
*
|
1995-05-22 |
1999-06-15 |
Alza Corporation |
Dosage form and method for treating incontinence
|
US5674895A
(en)
*
|
1995-05-22 |
1997-10-07 |
Alza Corporation |
Dosage form comprising oxybutynin
|
US5817335A
(en)
*
|
1995-05-26 |
1998-10-06 |
Alza Corporation |
Osmotic device with high drug loading and delayed activation of drug delivery
|
US5800422A
(en)
*
|
1995-06-02 |
1998-09-01 |
Alza Corporation |
Osmotic device with delayed activation of drug delivery and complete drug release
|
US5869079A
(en)
*
|
1995-06-02 |
1999-02-09 |
Oculex Pharmaceuticals, Inc. |
Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
|
US5713852A
(en)
*
|
1995-06-07 |
1998-02-03 |
Alza Corporation |
Oral dosage and method for treating painful conditions of the oral cavity
|
US5690952A
(en)
*
|
1995-06-07 |
1997-11-25 |
Judy A. Magruder et al. |
Implantable system for delivery of fluid-sensitive agents to animals
|
US5798119A
(en)
*
|
1995-06-13 |
1998-08-25 |
S. C. Johnson & Son, Inc. |
Osmotic-delivery devices having vapor-permeable coatings
|
US6548084B2
(en)
*
|
1995-07-20 |
2003-04-15 |
Smithkline Beecham Plc |
Controlled release compositions
|
US5780058A
(en)
*
|
1995-07-21 |
1998-07-14 |
Alza Corporation |
Oral delivery of discrete units
|
US5840332A
(en)
*
|
1996-01-18 |
1998-11-24 |
Perio Products Ltd. |
Gastrointestinal drug delivery system
|
US6858589B2
(en)
|
1996-01-25 |
2005-02-22 |
Pharmacy And Therapeutic Advisory Consultancy Pty Ltd |
Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
|
ATE211906T1
(de)
*
|
1996-03-12 |
2002-02-15 |
Alza Corp |
Zusammensetzung und dosisform mit einem opioid- antagonisten
|
US6096339A
(en)
*
|
1997-04-04 |
2000-08-01 |
Alza Corporation |
Dosage form, process of making and using same
|
US5902605A
(en)
*
|
1996-04-18 |
1999-05-11 |
Alza Corporation |
Drug delivery device with minimal residual drug retention
|
WO1997048440A1
(en)
|
1996-06-18 |
1997-12-24 |
Alza Corporation |
Device for enhancing transdermal agent delivery or sampling
|
WO1998006692A1
(en)
*
|
1996-08-12 |
1998-02-19 |
Celgene Corporation |
Novel immunotherapeutic agents and their use in the reduction of cytokine levels
|
JP3291627B2
(ja)
|
1996-10-18 |
2002-06-10 |
アルザ コーポレイション |
活性物質送出装置のクロージャ・システム
|
ES2158526T3
(es)
|
1996-10-18 |
2001-09-01 |
Alza Corp |
Dispositivo de multiples recorridos de flujo para la administracion oral de unidades discretas.
|
US6024721A
(en)
|
1996-10-18 |
2000-02-15 |
Alza Corporation |
Mixing system for an active agent delivery device
|
JP4863534B2
(ja)
*
|
1996-10-25 |
2012-01-25 |
スパーナス ファーマシューティカルズ インコーポレイテッド |
可溶形態浸透用量送達システム
|
US6361796B1
(en)
|
1996-10-25 |
2002-03-26 |
Shire Laboratories, Inc. |
Soluble form osmotic dose delivery system
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
US5900421A
(en)
*
|
1997-02-11 |
1999-05-04 |
Sepracor Inc. |
Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
|
US5939426A
(en)
*
|
1997-02-28 |
1999-08-17 |
Sepracor Inc. |
Methods for treating urinary incontinence using descarboethoxyloratadine
|
US5948787A
(en)
|
1997-02-28 |
1999-09-07 |
Alza Corporation |
Compositions containing opiate analgesics
|
PT966285E
(pt)
|
1997-03-07 |
2002-12-31 |
Vernalis Res Ltd |
Utilizacao de (+)mefloquina para o tratamento da malaria
|
ATE246489T1
(de)
*
|
1997-03-31 |
2003-08-15 |
Alza Corp |
Implantierbares diffusionabgabesystem
|
EP1304105B1
(en)
*
|
1997-03-31 |
2006-07-19 |
Alza Corporation |
Diffusional implantable delivery system
|
WO1998051259A1
(en)
|
1997-05-16 |
1998-11-19 |
Alza Corporation |
Flow controller configurations for an active agent delivery device
|
US5994148A
(en)
*
|
1997-06-23 |
1999-11-30 |
The Regents Of University Of California |
Method of predicting and enhancing success of IVF/ET pregnancy
|
US6110499A
(en)
*
|
1997-07-24 |
2000-08-29 |
Alza Corporation |
Phenytoin therapy
|
US6245042B1
(en)
|
1997-08-27 |
2001-06-12 |
Science Incorporated |
Fluid delivery device with temperature controlled energy source
|
JP2001515855A
(ja)
*
|
1997-09-09 |
2001-09-25 |
アルザ・コーポレーション |
薬剤コーティング組成物と使用方法
|
US6514530B2
(en)
|
1997-09-09 |
2003-02-04 |
Alza Corporation |
Dosage form comprising means for changing drug delivery shape
|
US7060734B1
(en)
|
1997-09-09 |
2006-06-13 |
Alza Corporation |
Pharmaceutical coating composition and method of use
|
PT1017392E
(pt)
|
1997-09-25 |
2002-10-31 |
Bayer Ag |
Formulacao de medicamento com libertacao controlada do principio activo
|
US20040062799A1
(en)
*
|
1997-09-29 |
2004-04-01 |
Ayer Atul D. |
Therapeutic composition and delivery system for administering drug
|
US6607751B1
(en)
*
|
1997-10-10 |
2003-08-19 |
Intellipharamaceutics Corp. |
Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
|
US6197788B1
(en)
|
1997-11-26 |
2001-03-06 |
Vernalis Research Limited |
(−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
|
DE69805001T2
(de)
|
1997-12-05 |
2002-08-22 |
Alza Corp |
Osmotische darreichungsform mit zwei mantelschichten
|
US20060141036A1
(en)
*
|
1997-12-12 |
2006-06-29 |
Andrx Labs Llc |
HMG-CoA reductase inhibitor extended release formulation
|
US20040029962A1
(en)
*
|
1997-12-12 |
2004-02-12 |
Chih-Ming Chen |
HMG-COA reductase inhibitor extended release formulation
|
US20080219976A1
(en)
*
|
1997-12-19 |
2008-09-11 |
Naomi Balaban |
Methods and compositions for treatment and prevention of staphylococcal infections
|
US7323179B2
(en)
*
|
1997-12-19 |
2008-01-29 |
Naomi Balaban |
Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
|
JP4215188B2
(ja)
|
1997-12-22 |
2009-01-28 |
インターシア セラピューティクス,インコーポレイティド |
薬剤供給を調節するデバイスのための速度調節膜
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
US6277384B1
(en)
|
1997-12-22 |
2001-08-21 |
Euro-Celtique S.A. |
Opioid agonist/antagonist combinations
|
EP1041968B1
(en)
|
1997-12-29 |
2004-03-03 |
Alza Corporation |
Osmotic delivery system with membrane plug retention mechanism
|
PT1051217E
(pt)
|
1997-12-31 |
2003-12-31 |
Alza Corp |
Sistema de controlo osmotico de administracao de medicamento
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
WO1999038504A1
(en)
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
WO1999038503A1
(en)
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmacological uses of optically pure (+)-bupropion
|
US8524277B2
(en)
*
|
1998-03-06 |
2013-09-03 |
Alza Corporation |
Extended release dosage form
|
US6245357B1
(en)
|
1998-03-06 |
2001-06-12 |
Alza Corporation |
Extended release dosage form
|
US6099859A
(en)
|
1998-03-20 |
2000-08-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral tablet having a unitary core
|
AR018321A1
(es)
*
|
1998-03-26 |
2001-11-14 |
Alza Corp |
Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
|
PE20000354A1
(es)
|
1998-04-03 |
2000-05-20 |
Advanced Medicine Inc |
Nuevos compuestos y usos anestesicos locales
|
US6462034B1
(en)
|
1998-04-03 |
2002-10-08 |
Theravance, Inc. |
Local anesthetic compounds and uses
|
US6196993B1
(en)
|
1998-04-20 |
2001-03-06 |
Eyelab Group, Llc |
Ophthalmic insert and method for sustained release of medication to the eye
|
US20010038855A1
(en)
*
|
1998-06-05 |
2001-11-08 |
Desjardin Michael A. |
Dosage form for administering prescribed dose
|
US6420354B1
(en)
|
1998-06-08 |
2002-07-16 |
Advanced Medicine, Inc. |
Sodium channel drugs and uses
|
US6897305B2
(en)
|
1998-06-08 |
2005-05-24 |
Theravance, Inc. |
Calcium channel drugs and uses
|
JP2003522103A
(ja)
|
1998-06-15 |
2003-07-22 |
セプラコア インコーポレーテッド |
無呼吸、過食症およびその他の障害を治療するための光学的に純粋な(−)−ノルシスアプリドの使用
|
EP1089733B1
(en)
|
1998-06-15 |
2005-03-23 |
Sepracor Inc. |
Use of optically pure (+)-norcisapride for treating irritable bowel syndrome
|
US6369039B1
(en)
*
|
1998-06-30 |
2002-04-09 |
Scimed Life Sytems, Inc. |
High efficiency local drug delivery
|
US7890176B2
(en)
*
|
1998-07-06 |
2011-02-15 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating chronic pelvic pain
|
TW407058B
(en)
|
1998-07-17 |
2000-10-01 |
Dev Center Biotechnology |
Oral cisapride dosage forms with an extended duration
|
RU2224523C2
(ru)
|
1998-07-24 |
2004-02-27 |
Сео Хонг Ю |
Водный раствор, содержащий желчную кислоту, и способ его получения
|
US7303768B2
(en)
|
1998-07-24 |
2007-12-04 |
Seo Hong Yoo |
Preparation of aqueous clear solution dosage forms with bile acids
|
US20050158408A1
(en)
*
|
1998-07-24 |
2005-07-21 |
Yoo Seo H. |
Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
|
US7772220B2
(en)
*
|
2004-10-15 |
2010-08-10 |
Seo Hong Yoo |
Methods and compositions for reducing toxicity of a pharmaceutical compound
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
US6974838B2
(en)
*
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
US6476078B2
(en)
*
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
US6099862A
(en)
*
|
1998-08-31 |
2000-08-08 |
Andrx Corporation |
Oral dosage form for the controlled release of a biguanide and sulfonylurea
|
US6703050B1
(en)
*
|
1998-09-04 |
2004-03-09 |
The Regents Of The University Of Michigan |
Methods and compositions for the prevention or treatment of cancer
|
US6551613B1
(en)
*
|
1998-09-08 |
2003-04-22 |
Alza Corporation |
Dosage form comprising therapeutic formulation
|
IL141914A0
(en)
*
|
1998-09-09 |
2002-03-10 |
Alza Corp |
Dosage form comprising liquid formulation
|
US6174547B1
(en)
*
|
1999-07-14 |
2001-01-16 |
Alza Corporation |
Dosage form comprising liquid formulation
|
US7906143B1
(en)
|
1998-10-05 |
2011-03-15 |
Intellipharmaceutics Corp |
Controlled release pharmaceutical delivery device and process for preparation thereof
|
US7101909B2
(en)
*
|
1998-10-12 |
2006-09-05 |
Theravance, Inc. |
Calcium channel drugs and uses
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
GB9822854D0
(en)
|
1998-10-21 |
1998-12-16 |
Reckitt & Colmann Prod Ltd |
Improvements in or relating to organic compositions
|
US6706282B1
(en)
|
1998-11-02 |
2004-03-16 |
Evangeline Cruz |
Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
|
CN1325301A
(zh)
*
|
1998-11-02 |
2001-12-05 |
阿尔扎有限公司 |
活性物质的控制释放
|
US6342533B1
(en)
|
1998-12-01 |
2002-01-29 |
Sepracor, Inc. |
Derivatives of (−)-venlafaxine and methods of preparing and using the same
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6342249B1
(en)
|
1998-12-23 |
2002-01-29 |
Alza Corporation |
Controlled release liquid active agent formulation dosage forms
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6855820B2
(en)
*
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6638727B1
(en)
*
|
1999-01-26 |
2003-10-28 |
Cytyc Health Corporation |
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
|
DE19906974C2
(de)
*
|
1999-02-19 |
2003-10-09 |
Lohmann Therapie Syst Lts |
Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
|
AU779696B2
(en)
*
|
1999-03-01 |
2005-02-10 |
Sepracor, Inc. |
Methods for treating apnea and apnea disorders using optically pure R(+)ondansetron
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6342496B1
(en)
*
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6362202B1
(en)
|
1999-03-02 |
2002-03-26 |
Sepracor Inc. |
Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
|
US6353005B1
(en)
|
1999-03-02 |
2002-03-05 |
Sepracor, Inc. |
Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
|
US6835194B2
(en)
*
|
1999-03-18 |
2004-12-28 |
Durect Corporation |
Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
|
US6541021B1
(en)
*
|
1999-03-18 |
2003-04-01 |
Durect Corporation |
Devices and methods for pain management
|
US6428818B1
(en)
|
1999-03-30 |
2002-08-06 |
Purdue Research Foundation |
Tea catechin formulations and processes for making same
|
US6410052B1
(en)
|
1999-03-30 |
2002-06-25 |
Purdue Research Foundation |
Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
|
EP1905757A1
(en)
*
|
1999-04-06 |
2008-04-02 |
Sepracor Inc. |
Derivatives of Venlafaxine and methods of preparing and using the same
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
DE60040979D1
(de)
|
1999-05-07 |
2009-01-15 |
Wockhardt Ltd |
(s)-benzochinolizincarbonsäuren und ihre verwendung als antibakterielle mittel
|
US6479498B1
(en)
|
1999-06-04 |
2002-11-12 |
Theravance, Inc. |
Sodium channel drugs and uses
|
US6403567B1
(en)
*
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
US6214807B1
(en)
*
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
USRE47351E1
(en)
|
1999-06-22 |
2019-04-16 |
Gilead Sciences, Inc. |
2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
|
US6100274A
(en)
*
|
1999-07-07 |
2000-08-08 |
Schering Corporation |
8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
DE60026146T2
(de)
*
|
1999-09-03 |
2006-08-17 |
Apbi Holdings, Llc |
Verwendung von Dapoxetin, A selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Disfunktion
|
US6491683B1
(en)
|
1999-09-07 |
2002-12-10 |
Alza Corporation |
Osmotic dosage form composed of an extruded polymer tube form
|
US6387403B1
(en)
|
1999-09-15 |
2002-05-14 |
Alza Corporation |
Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
US6878749B2
(en)
*
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
AR028299A1
(es)
|
1999-09-17 |
2003-05-07 |
Novartis Ag |
Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
|
US6638263B1
(en)
|
1999-10-12 |
2003-10-28 |
Durect Corporation |
Regulation of drug delivery through flow diversion
|
US6331313B1
(en)
|
1999-10-22 |
2001-12-18 |
Oculex Pharmaceticals, Inc. |
Controlled-release biocompatible ocular drug delivery implant devices and methods
|
US6114346A
(en)
*
|
1999-10-22 |
2000-09-05 |
Schering Corporation |
Treating sleep disorders using desloratadine
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
MXPA02004293A
(es)
|
1999-10-29 |
2002-10-31 |
Euro Celtique Sa |
Formulaciones de hidrocodona de liberacion controlada..
|
ATE292453T1
(de)
*
|
1999-12-09 |
2005-04-15 |
Alza Corp |
Antivirale arznei
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
AU2276801A
(en)
|
1999-12-20 |
2001-07-03 |
Schering Corporation |
Extended release oral dosage composition
|
WO2001045668A2
(en)
*
|
1999-12-20 |
2001-06-28 |
Schering Corporation |
Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
|
US6491949B2
(en)
|
2000-01-14 |
2002-12-10 |
Osmotica Corp. |
Osmotic device within an osmotic device
|
US7700341B2
(en)
*
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
US6432446B2
(en)
|
2000-02-03 |
2002-08-13 |
Bridge Pharma, Inc. |
Non-arrhythmogenic metabolite of oxybutynin
|
US7405223B2
(en)
|
2000-02-03 |
2008-07-29 |
Schering Corporation |
Treating allergic and inflammatory conditions
|
BR0108080A
(pt)
*
|
2000-02-04 |
2006-02-07 |
Seo Hong Yoo |
Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
|
EP1935421A1
(en)
|
2000-02-08 |
2008-06-25 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
PT1255547E
(pt)
|
2000-02-08 |
2008-11-24 |
Euro Celtique Sa |
Composições de libertação controlada contendo agonistas e antagonistas opióides
|
US6464688B1
(en)
|
2000-02-15 |
2002-10-15 |
Microsolutions, Inc. |
Osmotic pump delivery system with flexible drug compartment
|
US6616652B1
(en)
|
2000-02-15 |
2003-09-09 |
Microsolutions, Inc. |
Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter
|
US6471688B1
(en)
|
2000-02-15 |
2002-10-29 |
Microsolutions, Inc. |
Osmotic pump drug delivery systems and methods
|
US6528511B2
(en)
|
2000-02-18 |
2003-03-04 |
Cv Therapeutics, Inc. |
Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
|
AU2001238665A1
(en)
*
|
2000-02-23 |
2001-09-03 |
Cv Therapeutics, Inc. |
Method of identifying partial agonists of the a2a receptor
|
US6582441B1
(en)
|
2000-02-24 |
2003-06-24 |
Advanced Bionics Corporation |
Surgical insertion tool
|
US7074803B2
(en)
*
|
2001-03-02 |
2006-07-11 |
Durect Corporation |
Opioid formulations
|
US6569152B2
(en)
*
|
2000-03-21 |
2003-05-27 |
Farrington Pharmaceuticals, Llc |
Sustained release delivery systems for solutes
|
EP1272189A4
(en)
*
|
2000-03-31 |
2004-01-14 |
Celgene Corp |
INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY
|
AU2001257359A1
(en)
|
2000-04-27 |
2001-11-07 |
Verion Inc. |
Zero order release and temperature-controlled microcapsules and process for the preparation thereof
|
US7259152B2
(en)
|
2000-06-07 |
2007-08-21 |
Alfa Wasserman, Inc. |
Methods and compositions using sulodexide for the treatment of diabetic nephropathy
|
US6726918B1
(en)
|
2000-07-05 |
2004-04-27 |
Oculex Pharmaceuticals, Inc. |
Methods for treating inflammation-mediated conditions of the eye
|
US7449454B2
(en)
*
|
2000-08-30 |
2008-11-11 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
US6638924B2
(en)
|
2000-08-30 |
2003-10-28 |
Pharmacyclics, Inc. |
Metallotexaphyrin derivatives
|
US20040115236A1
(en)
*
|
2000-10-06 |
2004-06-17 |
Chan Tai Wah |
Devices and methods for management of inflammation
|
CN100518827C
(zh)
|
2000-10-30 |
2009-07-29 |
欧罗赛铁克股份有限公司 |
控释氢可酮制剂
|
US20060034922A1
(en)
*
|
2000-11-03 |
2006-02-16 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
US20070208087A1
(en)
|
2001-11-02 |
2007-09-06 |
Sanders Virginia J |
Compounds, compositions and methods for the treatment of inflammatory diseases
|
US6790459B1
(en)
*
|
2000-11-03 |
2004-09-14 |
Andrx Labs, Llc |
Methods for treating diabetes via administration of controlled release metformin
|
WO2002036100A1
(en)
|
2000-11-03 |
2002-05-10 |
Andrx Corporation |
Controlled release metformin compositions
|
US6866866B1
(en)
*
|
2000-11-03 |
2005-03-15 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
CA2429411A1
(en)
*
|
2000-11-17 |
2002-05-23 |
Pharmacyclics, Inc. |
Texaphyrin coordination compounds and uses thereof
|
US20030195706A1
(en)
*
|
2000-11-20 |
2003-10-16 |
Michael Korenberg |
Method for classifying genetic data
|
US20050070883A1
(en)
*
|
2000-11-29 |
2005-03-31 |
Brown James E |
Devices and methods for controlled delivery from a drug delivery device
|
ES2250504T3
(es)
*
|
2000-11-29 |
2006-04-16 |
Allergan Inc. |
Prevencion del rechazo de injerto en el ojo.
|
NZ526683A
(en)
*
|
2000-11-30 |
2008-03-28 |
Childrens Medical Center |
Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
|
WO2002045695A2
(en)
|
2000-12-05 |
2002-06-13 |
Alexander Macgregor |
Hydrostatic delivery system for controlled delivery of agent
|
JP2004521878A
(ja)
|
2000-12-07 |
2004-07-22 |
スィーヴィー セラピューティクス インコーポレイテッド |
Abca−1を上昇させる化合物
|
US20030167524A1
(en)
*
|
2000-12-19 |
2003-09-04 |
Rooijen Gijs Van |
Methods for the production of multimeric protein complexes, and related compositions
|
US7493172B2
(en)
*
|
2001-01-30 |
2009-02-17 |
Boston Scientific Neuromodulation Corp. |
Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
|
US20060064140A1
(en)
*
|
2001-01-30 |
2006-03-23 |
Whitehurst Todd K |
Methods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder
|
US20050143789A1
(en)
*
|
2001-01-30 |
2005-06-30 |
Whitehurst Todd K. |
Methods and systems for stimulating a peripheral nerve to treat chronic pain
|
IN190699B
(el)
|
2001-02-02 |
2003-08-16 |
Sun Pharmaceutical Ind Ltd |
|
US6673838B2
(en)
*
|
2001-02-12 |
2004-01-06 |
Wyeth |
Succinate salt of O-desmethyl-venlafaxine
|
US7125703B2
(en)
|
2001-03-13 |
2006-10-24 |
Dendreon Corporation |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
EP1383884A4
(en)
|
2001-03-22 |
2004-12-15 |
Dendreon Corp |
SERINE PROTEASE CVSP14 CODING NUCLEIC ACID MOLECULES, THE CODED POLYPEPTIDES AND METHODS THEREOF
|
WO2002077267A2
(en)
|
2001-03-27 |
2002-10-03 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
|
WO2002083631A1
(en)
*
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
US6632217B2
(en)
*
|
2001-04-19 |
2003-10-14 |
Microsolutions, Inc. |
Implantable osmotic pump
|
US6964966B2
(en)
*
|
2001-04-25 |
2005-11-15 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
US6878713B2
(en)
|
2001-04-25 |
2005-04-12 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
KR20040080940A
(ko)
|
2001-05-14 |
2004-09-20 |
덴드레온 코포레이션 |
트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
|
US7232924B2
(en)
*
|
2001-06-11 |
2007-06-19 |
Xenoport, Inc. |
Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
|
KR20040016882A
(ko)
|
2001-06-11 |
2004-02-25 |
제노포트 인코포레이티드 |
감소된 독성을 가진 gaba 유사체 프로드러그의 구강투여용 투여 형태물
|
US8048917B2
(en)
*
|
2005-04-06 |
2011-11-01 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US7420002B2
(en)
*
|
2001-06-11 |
2008-09-02 |
Xenoport |
Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US7186855B2
(en)
|
2001-06-11 |
2007-03-06 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
US20040180087A1
(en)
*
|
2001-06-21 |
2004-09-16 |
Boyong Li |
Stable controlled release pharmaceutical compositions containing pravastatin
|
AUPR602401A0
(en)
*
|
2001-06-29 |
2001-07-26 |
Smart Drug Systems Inc |
Sustained release delivery system
|
US7034059B2
(en)
*
|
2001-07-02 |
2006-04-25 |
Sepracor Inc. |
Methods of using norfluoxetine
|
AU2002346065A1
(en)
*
|
2001-07-05 |
2003-01-21 |
Marantech Holding, Llc |
Methods of using electron active compounds for managing conditions afflicting mammals
|
CA2452872A1
(en)
|
2001-07-06 |
2003-01-16 |
Endo Pharmaceuticals, Inc. |
Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
|
ES2292775T3
(es)
|
2001-07-06 |
2008-03-16 |
Penwest Pharmaceuticals Co. |
Formulaciones de liberacion prolongada de oximorfona.
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
US7713946B2
(en)
*
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
US7157440B2
(en)
*
|
2001-07-13 |
2007-01-02 |
Cv Therapeutics, Inc. |
Partial and full agonists of A1 adenosine receptors
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
PL367427A1
(en)
|
2001-08-06 |
2005-02-21 |
Euro-Celtique S.A. |
Opioid agonist formulations with releasable and sequestered antagonist
|
EP1283025A1
(de)
*
|
2001-08-10 |
2003-02-12 |
Stöckert Instrumente GmbH |
Ballonokklusionsvorrichtung
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
EP1429746B1
(en)
*
|
2001-09-28 |
2008-08-13 |
McNEIL-PPC, INC. |
Dosage forms having an inner core and outer shell
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
US20070184104A1
(en)
*
|
2001-10-25 |
2007-08-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
CN100467469C
(zh)
|
2001-11-09 |
2009-03-11 |
Cv医药有限公司 |
A2b腺苷受体拮抗剂
|
AU2002357004A1
(en)
*
|
2001-11-20 |
2003-06-10 |
Dendreon San Diego Llc |
Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
|
US7157493B2
(en)
*
|
2001-11-28 |
2007-01-02 |
Nashai Biotech, Llc |
Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof
|
JP2005516001A
(ja)
|
2001-12-05 |
2005-06-02 |
ベイラー カレッジ オブ メディスン |
交感神経活動状態の調節による骨形成の制御のための方法及び組成物
|
AU2002357935A1
(en)
*
|
2001-12-18 |
2003-06-30 |
Alza Corporation |
Dosage form for providing time-varying patterns of drug delivery
|
AU2002359793B2
(en)
*
|
2001-12-19 |
2007-06-14 |
Alza Corporation |
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
|
NZ533062A
(en)
*
|
2001-12-19 |
2006-03-31 |
Alza Corp |
Formulation and dosage form for the controlled delivery of therapeutic agents
|
US20040009953A1
(en)
*
|
2002-01-10 |
2004-01-15 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
US20030181416A1
(en)
*
|
2002-01-10 |
2003-09-25 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
US20030161882A1
(en)
*
|
2002-02-01 |
2003-08-28 |
Waterman Kenneth C. |
Osmotic delivery system
|
ES2345044T3
(es)
|
2002-02-01 |
2010-09-14 |
Euro-Celtique S.A. |
2-piperazin-piridinas utiles para tratar el dolor.
|
WO2003063868A1
(en)
|
2002-02-01 |
2003-08-07 |
Pfizer Products Inc. |
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
|
US20030175346A1
(en)
*
|
2002-02-01 |
2003-09-18 |
Anne Billotte |
Osmotic delivery system
|
US8685427B2
(en)
|
2002-07-31 |
2014-04-01 |
Boston Scientific Scimed, Inc. |
Controlled drug delivery
|
US8133501B2
(en)
|
2002-02-08 |
2012-03-13 |
Boston Scientific Scimed, Inc. |
Implantable or insertable medical devices for controlled drug delivery
|
WO2003074474A2
(en)
|
2002-03-01 |
2003-09-12 |
University Of South Florida |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
US7446107B2
(en)
*
|
2002-02-15 |
2008-11-04 |
Transform Pharmaceuticals, Inc. |
Crystalline forms of conazoles and methods of making and using the same
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
WO2003077902A1
(en)
*
|
2002-02-19 |
2003-09-25 |
Xenoport, Inc. |
Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
|
EP2412716A1
(en)
*
|
2002-02-19 |
2012-02-01 |
Cv Therapeutics, Inc. |
Partial and full agonists of A1 adenosine receptors
|
KR101191254B1
(ko)
*
|
2002-03-11 |
2012-10-16 |
알콘, 인코퍼레이티드 |
이식 가능한 약물 전달 시스템
|
NZ534757A
(en)
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
DE60322371D1
(de)
*
|
2002-03-29 |
2008-09-04 |
Alza Corp |
Volumensparende arzneiform zur kontrollierten freisetzung
|
US20080109040A1
(en)
*
|
2002-04-04 |
2008-05-08 |
Luiz Belardinelli |
Method of treating arrhythmias
|
US20030220344A1
(en)
*
|
2002-04-04 |
2003-11-27 |
Luiz Belardinelli |
Method of treating arrhythmias
|
MXPA04009713A
(es)
|
2002-04-05 |
2005-01-11 |
Euro Celtique Sa |
Preparacion farmaceutica que contiene oxicodona y naloxona.
|
US20040005358A1
(en)
*
|
2002-04-23 |
2004-01-08 |
Slugg Peter H. |
Modified-release vasopeptidase inhibitor formulation, combinations and method
|
AU2003234216A1
(en)
*
|
2002-04-29 |
2003-11-17 |
Alza Corporation |
Methods and dosage forms for controlled delivery of oxycodone
|
US20050106249A1
(en)
*
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
US7470267B2
(en)
*
|
2002-05-01 |
2008-12-30 |
Microlin, Llc |
Fluid delivery device having an electrochemical pump with an anionic exchange membrane and associated method
|
US20060116663A1
(en)
*
|
2002-05-01 |
2006-06-01 |
Joshi Ashok V |
Electro-osmotic fluid delivery device and method
|
US7458965B2
(en)
*
|
2002-05-01 |
2008-12-02 |
Microlin, Llc |
Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
|
US7896867B2
(en)
*
|
2002-05-01 |
2011-03-01 |
Microlin, Llc |
Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
|
US7205413B2
(en)
*
|
2002-05-03 |
2007-04-17 |
Transform Pharmaceuticals, Inc. |
Solvates and polymorphs of ritonavir and methods of making and using the same
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
CN103393681B
(zh)
|
2002-05-17 |
2017-04-12 |
细胞基因公司 |
用于治疗和控制多发性骨髓瘤的方法及组合物
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
AU2003243180A1
(en)
*
|
2002-05-17 |
2003-12-12 |
Xenoport, Inc. |
Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
|
NZ570777A
(en)
|
2002-05-17 |
2009-04-30 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
CA2486712C
(en)
*
|
2002-05-21 |
2012-01-03 |
Cv Therapeutics, Inc. |
Method of treating diabetes
|
US8822473B2
(en)
*
|
2002-05-21 |
2014-09-02 |
Gilead Sciences, Inc. |
Method of treating diabetes
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
AU2003241537A1
(en)
*
|
2002-05-23 |
2003-12-12 |
Andrx Corporation |
Biguanide formulations
|
US7151961B1
(en)
*
|
2002-05-24 |
2006-12-19 |
Advanced Bionics Corporation |
Treatment of movement disorders by brain stimulation
|
ES2473581T3
(es)
|
2002-05-31 |
2014-07-07 |
Proteotech Inc. |
Compuestos, composiciones y métodos para el tratamiento de amiloidosis y sinucleinopat�as tales como la enfermedad de Alzheimer, la diabetes de tipo 2 y la enfermedad de Parkinson
|
US8829198B2
(en)
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
JP2005528423A
(ja)
*
|
2002-05-31 |
2005-09-22 |
アルザ・コーポレーシヨン |
オキシコドンの変動性投薬用量の浸透圧的送達のための剤形および組成物
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
EP1511490A4
(en)
*
|
2002-05-31 |
2009-03-11 |
Transform Pharmaceuticals Inc |
NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
US6995168B2
(en)
|
2002-05-31 |
2006-02-07 |
Euro-Celtique S.A. |
Triazaspiro compounds useful for treating or preventing pain
|
US6900203B2
(en)
|
2002-06-19 |
2005-05-31 |
Polium Technologies, Inc. |
Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
|
CN100360117C
(zh)
|
2002-06-21 |
2008-01-09 |
转化医药公司 |
具有提高的溶出度的药物组合物
|
AR039744A1
(es)
*
|
2002-06-26 |
2005-03-09 |
Alza Corp |
Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
|
CA2490412A1
(en)
*
|
2002-06-28 |
2004-01-08 |
Alza Corporation |
Oral dosage from comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition
|
TWI326214B
(en)
*
|
2002-07-17 |
2010-06-21 |
Avanir Pharmaceuticals Inc |
Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
|
CN1688303A
(zh)
|
2002-07-23 |
2005-10-26 |
密歇根大学董事会 |
用于抗血管发生疗法的四硫代钼酸四丙铵及相关化合物
|
US7189865B2
(en)
*
|
2002-07-23 |
2007-03-13 |
Attenuon, Llc |
Thiomolybdate analogues and uses thereof
|
CA2493458A1
(en)
|
2002-07-24 |
2004-01-29 |
Ptc Therapeutics, Inc. |
Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
|
US20050226926A1
(en)
|
2002-07-25 |
2005-10-13 |
Pfizer Inc |
Sustained-release tablet composition of pramipexole
|
MY142204A
(en)
*
|
2002-07-25 |
2010-10-29 |
Pharmacia Corp |
Pramipexole once-daily dosage form
|
US20050020915A1
(en)
*
|
2002-07-29 |
2005-01-27 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging methods and compositions
|
AU2003259264A1
(en)
*
|
2002-07-29 |
2004-02-16 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging using a2a receptor agonists
|
US8470801B2
(en)
|
2002-07-29 |
2013-06-25 |
Gilead Sciences, Inc. |
Myocardial perfusion imaging methods and compositions
|
NZ537543A
(en)
*
|
2002-07-29 |
2007-08-31 |
Alza Corp |
Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
US7254449B2
(en)
*
|
2002-07-31 |
2007-08-07 |
Advanced Bionics Corp |
Systems and methods for providing power to one or more implantable devices
|
US8920826B2
(en)
|
2002-07-31 |
2014-12-30 |
Boston Scientific Scimed, Inc. |
Medical imaging reference devices
|
SI1542658T1
(sl)
|
2002-08-15 |
2011-04-29 |
Euro Celtique Sa |
Farmacevtski sestavki, ki obsegajo opioidni analgetik
|
AU2003267756A1
(en)
|
2002-09-03 |
2004-03-29 |
Circ Pharma Research And Development Limited |
Pravastatin pharmaceutical formulations and methods of their use
|
EP1545551A4
(en)
|
2002-09-06 |
2008-10-22 |
Durect Corp |
DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
|
US20060009739A1
(en)
*
|
2002-09-06 |
2006-01-12 |
Durect Corporation |
Implantable flow regulator with failsafe mode and reserve drug supply
|
DK1551372T3
(en)
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
|
US20050051922A1
(en)
*
|
2002-09-20 |
2005-03-10 |
Avinash Nangia |
Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
|
US9060941B2
(en)
*
|
2002-09-20 |
2015-06-23 |
Actavis, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US20050048119A1
(en)
*
|
2002-09-20 |
2005-03-03 |
Avinash Nangia |
Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
|
US7785627B2
(en)
*
|
2002-09-20 |
2010-08-31 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
US7959946B2
(en)
|
2002-09-20 |
2011-06-14 |
Watson Pharmaceuticals, Inc. |
Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
|
KR101363679B1
(ko)
|
2002-09-20 |
2014-02-14 |
안드렉스 랩스 엘엘씨 |
약제학적 정제
|
WO2004029059A1
(en)
|
2002-09-25 |
2004-04-08 |
Euro-Celtique S.A. |
N-substituted hydromorphones and the use thereof
|
GB0222522D0
(en)
|
2002-09-27 |
2002-11-06 |
Controlled Therapeutics Sct |
Water-swellable polymers
|
CA2500091A1
(en)
*
|
2002-09-27 |
2004-04-08 |
Bioenvision, Inc. |
Methods and compositions for the treatment of lupus using clofarabine
|
US20060100167A1
(en)
*
|
2002-09-27 |
2006-05-11 |
Wood Christopher B |
Methods and compositions for the treatment of autoimmune disorders using clofarabine
|
JP2006505620A
(ja)
*
|
2002-10-07 |
2006-02-16 |
レイディオアールエックス インコーポレイテッド |
X−ニトロ化合物、それらの医薬組成物及びそれらの使用
|
EP1554270A2
(en)
*
|
2002-10-11 |
2005-07-20 |
Proteotech, Inc. |
Isolation, purification and synthesis of procyanidin b2 and uses thereof
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
NZ539534A
(en)
*
|
2002-10-15 |
2008-06-30 |
Celgene Corp |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
TW200418527A
(en)
*
|
2002-10-31 |
2004-10-01 |
Alza Corp |
Dosage form providing ascending release of liquid formulation
|
US20040142040A1
(en)
*
|
2002-10-31 |
2004-07-22 |
Dong Liang C. |
Formulation and dosage form providing increased bioavailability of hydrophobic drugs
|
US7265096B2
(en)
*
|
2002-11-04 |
2007-09-04 |
Xenoport, Inc. |
Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
AU2003290652B2
(en)
|
2002-11-06 |
2008-06-19 |
Celgene Corporation |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
KR20050072790A
(ko)
*
|
2002-11-06 |
2005-07-12 |
셀진 코포레이션 |
골수증식 질환의 치료 및 관리를 위한 선택적 시토킨 억제약물의 사용 방법 및 이를 포함하는 조성물
|
BR0316259A
(pt)
*
|
2002-11-18 |
2005-10-04 |
Celgene Corp |
Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
|
US7202259B2
(en)
*
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
MXPA05005161A
(es)
*
|
2002-11-18 |
2005-07-22 |
Celgene Corp |
Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
|
NZ540363A
(en)
*
|
2002-11-25 |
2007-11-30 |
Attenuon Llc |
Peptides which target tumor and endothelial cells, compositions and uses thereof
|
US20040102476A1
(en)
*
|
2002-11-25 |
2004-05-27 |
Chan Tai Wah |
High concentration formulations of opioids and opioid derivatives
|
US7101912B2
(en)
|
2002-12-06 |
2006-09-05 |
Xenoport, Inc. |
Carbidopa prodrugs and derivatives, and compositions and uses thereof
|
US20040111071A1
(en)
*
|
2002-12-09 |
2004-06-10 |
Jeffrey Lewis Powers |
Portable device for dispensing hand treatments
|
US8286834B2
(en)
*
|
2002-12-09 |
2012-10-16 |
Jeffrey Lewis Powers |
Skin treatment dispenser and method of manufacture
|
US7060727B2
(en)
*
|
2002-12-11 |
2006-06-13 |
Xenoport, Inc. |
Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
|
AU2003297909A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Xenoport, Inc. |
Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
|
AU2003299659A1
(en)
|
2002-12-13 |
2004-07-09 |
Durect Corporation |
Oral drug delivery system comprising high viscosity liquid carrier materials
|
EP2298874A1
(en)
|
2002-12-16 |
2011-03-23 |
Halozyme, Inc. |
Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
|
US7259186B2
(en)
*
|
2002-12-17 |
2007-08-21 |
Abbott Laboratories |
Salts of fenofibric acid and pharmaceutical formulations thereof
|
CN100473378C
(zh)
*
|
2002-12-17 |
2009-04-01 |
阿伯特有限及两合公司 |
包含非诺贝酸、其生理可接受的盐或衍生物的制剂
|
US20080051411A1
(en)
*
|
2002-12-17 |
2008-02-28 |
Cink Russell D |
Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
|
US20070077301A1
(en)
*
|
2002-12-23 |
2007-04-05 |
Meyer Glenn A |
Venlafaxine osmotic device formulation
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
EP2339328A3
(en)
|
2002-12-30 |
2011-07-13 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions of celecoxib
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
JP2006522016A
(ja)
*
|
2003-01-14 |
2006-09-28 |
アルザ・コーポレーシヨン |
改変された粘度の層を用いる方法および投薬形態物
|
KR20050092424A
(ko)
|
2003-01-17 |
2005-09-21 |
씨브이 쎄러퓨틱스, 인코포레이티드 |
심혈관 질환의 치료에 유용한 치환된 헤테로고리 화합물
|
ZA200504940B
(en)
*
|
2003-01-28 |
2006-09-27 |
Xenoport Inc |
Amino acid derived prodrugs of propofol, compositions and uses thereof
|
WO2004071497A1
(en)
*
|
2003-02-11 |
2004-08-26 |
Alza Corporation |
Methods and dosage forms with modified layer geometry
|
US7629362B2
(en)
|
2003-02-13 |
2009-12-08 |
Banyu Pharmaceutical Co., Ltd. |
2-pyridine carboxamide derivatives
|
ATE550022T1
(de)
|
2003-02-28 |
2012-04-15 |
Mcneil Ppc Inc |
Pharmazeutische mischkristalle von celecoxib- nicotinamid
|
DE602004024041D1
(de)
|
2003-03-05 |
2009-12-24 |
Halozyme Inc |
Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
AU2004227995B2
(en)
*
|
2003-03-31 |
2010-06-03 |
Xenoport, Inc. |
Treating or preventing hot flashes using prodrugs of GABA analogs
|
ES2926542T3
(es)
|
2003-04-11 |
2022-10-26 |
Ptc Therapeutics Inc |
Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para supresión de mutaciones finalizadoras y el tratamiento de enfermedades
|
US20040214893A1
(en)
*
|
2003-04-11 |
2004-10-28 |
Matthew Peterson |
Gabapentin compositions
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
US20070083240A1
(en)
*
|
2003-05-08 |
2007-04-12 |
Peterson David K L |
Methods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator
|
WO2005016241A2
(en)
|
2003-05-16 |
2005-02-24 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
US8029822B2
(en)
*
|
2003-05-22 |
2011-10-04 |
Osmotica Kereskedelmi és Seolgáltató KFT |
Rupturing controlled release device having a preformed passageway
|
WO2005000786A1
(en)
*
|
2003-05-23 |
2005-01-06 |
Transform Pharmaceuticals, Inc. |
Sertraline compositions
|
CA2522888C
(en)
*
|
2003-05-23 |
2012-07-17 |
Bridge Pharma, Inc. |
Smooth muscle spasmolytic agents
|
WO2004110364A2
(en)
*
|
2003-05-27 |
2004-12-23 |
Attenuon L.L.C. |
Thiotungstate analogues and uses thereof
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
US20090227647A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Thomas Lake |
Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
|
US7438903B2
(en)
*
|
2003-06-06 |
2008-10-21 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
MY142655A
(en)
*
|
2003-06-12 |
2010-12-15 |
Euro Celtique Sa |
Therapeutic agents useful for treating pain
|
EP1643946A2
(en)
*
|
2003-06-20 |
2006-04-12 |
Viral Genomix, Inc. |
Compositions for and methods for treating hiv
|
US7145125B2
(en)
|
2003-06-23 |
2006-12-05 |
Advanced Optical Technologies, Llc |
Integrating chamber cone light using LED sources
|
CA2529984C
(en)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
PT1641775E
(pt)
*
|
2003-07-03 |
2009-04-23 |
Euro Celtique Sa |
Derivados de 2-piridina-alcino úteis para o tratamento da dor
|
WO2005004882A1
(en)
*
|
2003-07-09 |
2005-01-20 |
Monash University |
Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
|
DE602004030689D1
(de)
*
|
2003-07-23 |
2011-02-03 |
Synta Pharmaceuticals Corp |
Verbindungen gegen entzündungen und immun-relevante verwendungen
|
EA009480B1
(ru)
*
|
2003-07-24 |
2008-02-28 |
Еуро-Селтик С. А. |
Гетероарил-тетрагидропиридины и их применение для лечения или профилактики боли
|
PL1867644T3
(pl)
|
2003-07-24 |
2009-10-30 |
Euro Celtique Sa |
Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
|
US20050020692A1
(en)
*
|
2003-07-24 |
2005-01-27 |
Ciofalo Vincent B. |
Treatment of heaves
|
GEP20094676B
(en)
|
2003-07-24 |
2009-05-10 |
Euro Celtique Sa |
Piperidine compounds and pharmaceutical compositions containing them
|
US20090317476A1
(en)
*
|
2003-07-31 |
2009-12-24 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
|
US20050026882A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
|
AU2004261277A1
(en)
*
|
2003-07-31 |
2005-02-10 |
Alza Corporation |
Permeation-Resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation
|
DE602004025244D1
(de)
|
2003-08-01 |
2010-03-11 |
Euro Celtique Sa |
Zur behandlung von schmerzen geeignete therapeutische mittel
|
WO2005016306A2
(en)
*
|
2003-08-06 |
2005-02-24 |
Alza Corporation |
Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
|
GB0318824D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Glaxo Group Ltd |
Novel composition
|
EP2354120A1
(en)
|
2003-08-20 |
2011-08-10 |
XenoPort, Inc. |
Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
|
BRPI0413756A
(pt)
*
|
2003-08-20 |
2006-10-31 |
Xenoport Inc |
composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica
|
CA2536061A1
(en)
*
|
2003-08-22 |
2005-03-17 |
Edward J. Ellis |
Polymeric systems for controlled drug therapy
|
WO2005020957A2
(en)
*
|
2003-08-22 |
2005-03-10 |
Alza Corporation |
Stepwise delivery of topiramate over prolonged period of time
|
GB0320020D0
(en)
|
2003-08-27 |
2003-10-01 |
Mw Encap Ltd |
Improved formulation for providing an enteric coating material
|
AU2004268661A1
(en)
*
|
2003-09-02 |
2005-03-10 |
Alza Corporation |
Novel drug compositions and dosage forms of topiramate
|
CA2536902A1
(en)
*
|
2003-09-03 |
2005-03-10 |
Agi Therapeutics Limited |
Proton pump inhibitor formulations, and methods of preparing and using such formulations
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
CA2537066C
(en)
*
|
2003-09-04 |
2011-05-24 |
Wockhardt Limited |
Benzoquinolizine-2-carboxylic acid arginine salt tetrahydrate
|
WO2005023204A2
(en)
*
|
2003-09-09 |
2005-03-17 |
Xenoport, Inc. |
Aromatic prodrugs of propofol, compositions and uses thereof
|
WO2005025562A1
(en)
|
2003-09-11 |
2005-03-24 |
Xenoport, Inc. |
Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
|
SG146643A1
(en)
*
|
2003-09-17 |
2008-10-30 |
Xenoport Inc |
Treating or preventing restless legs syndrome using prodrugs of gaba analogs
|
WO2005027853A2
(en)
*
|
2003-09-19 |
2005-03-31 |
University Of Louisville Research Foundation Inc |
Method for treating snoring and sleep apnea with leukotriene antagonists
|
CN1856489A
(zh)
*
|
2003-09-22 |
2006-11-01 |
欧洲凯尔特公司 |
用于治疗疼痛的苯甲酰胺化合物
|
DE602004017481D1
(de)
*
|
2003-09-22 |
2008-12-11 |
Euro Celtique Sa |
Zur behandlung von schmerzen geeignete therapeutische mittel
|
EP1663229B1
(en)
|
2003-09-25 |
2010-04-14 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
MXPA06003451A
(es)
*
|
2003-09-26 |
2006-08-31 |
Johnson & Johnson |
Formas de dosificacion osmotica para suministro controlado de alprazolam.
|
EP1667653A1
(en)
*
|
2003-09-26 |
2006-06-14 |
Alza Corporation |
Dosage form for controlled release of an active agent formulation
|
US20050158382A1
(en)
*
|
2003-09-26 |
2005-07-21 |
Evangeline Cruz |
Controlled release formulations of opioid and nonopioid analgesics
|
WO2005030182A1
(en)
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Controlled release formulations exhibiting an ascending rate of release
|
WO2005030164A2
(en)
*
|
2003-09-26 |
2005-04-07 |
Alza Corporation |
Improved controlled release dosage form including a banded engine
|
EP1708684A2
(en)
|
2003-09-26 |
2006-10-11 |
Alza Corporation |
Drug coating providing high drug loading and methods for providing the same
|
NZ586198A
(en)
|
2003-09-26 |
2011-12-22 |
Alza Corp |
Oros push-stick sustained release dosage forms for controlled delivery of active agents
|
DK1677767T3
(da)
*
|
2003-10-14 |
2011-10-24 |
Xenoport Inc |
Krystallinsk form af gamma-aminobutyrsyre-analog
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US7407973B2
(en)
*
|
2003-10-24 |
2008-08-05 |
Intermune, Inc. |
Use of pirfenidone in therapeutic regimens
|
KR20060109922A
(ko)
*
|
2003-10-31 |
2006-10-23 |
알자 코포레이션 |
가바펜틴 및 프리가발린의 개선된 흡수를 위한 조성물 및제형
|
US20050118246A1
(en)
*
|
2003-10-31 |
2005-06-02 |
Wong Patrick S. |
Dosage forms and layered deposition processes for fabricating dosage forms
|
US20050095288A1
(en)
*
|
2003-11-03 |
2005-05-05 |
Andrx Labs, Llc |
Decongestant and expectorant tablets
|
US20050113410A1
(en)
*
|
2003-11-03 |
2005-05-26 |
Mark Tawa |
Pharmaceutical salts of zafirlukast
|
US8987322B2
(en)
|
2003-11-04 |
2015-03-24 |
Circ Pharma Research And Development Limited |
Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
|
OA13284A
(en)
*
|
2003-11-06 |
2007-01-31 |
Corporation Celgene |
Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
EP1684713A1
(en)
*
|
2003-11-14 |
2006-08-02 |
ALZA Corporation |
Controlled release of topirimate in liquid dosage forms
|
US7470435B2
(en)
*
|
2003-11-17 |
2008-12-30 |
Andrx Pharmaceuticals, Llc |
Extended release venlafaxine formulation
|
JP2007511618A
(ja)
|
2003-11-19 |
2007-05-10 |
シグナル ファーマシューティカルズ,エルエルシー |
インダゾール化合物およびタンパク質キナーゼ阻害剤としてのその使用方法
|
US7829552B2
(en)
|
2003-11-19 |
2010-11-09 |
Metabasis Therapeutics, Inc. |
Phosphorus-containing thyromimetics
|
EP1686967A4
(en)
*
|
2003-11-25 |
2012-08-08 |
Smithkline Beecham Cork Ltd |
CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
|
EP1691789B1
(en)
*
|
2003-11-25 |
2017-12-20 |
SmithKline Beecham (Cork) Limited |
Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
|
JP5122821B2
(ja)
*
|
2003-11-28 |
2013-01-16 |
イーストマン ケミカル カンパニー |
セルロースインターポリマー及び酸化方法
|
AU2004305563C1
(en)
|
2003-12-11 |
2011-07-07 |
Sunovion Pharmaceuticals Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
US20050129764A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Vergez Juan A. |
Osmotic device containing licofelone
|
US7769461B2
(en)
*
|
2003-12-19 |
2010-08-03 |
Boston Scientific Neuromodulation Corporation |
Skull-mounted electrical stimulation system and method for treating patients
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
WO2005063206A1
(en)
*
|
2003-12-23 |
2005-07-14 |
Alza Corporation |
Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
|
EP1701708A2
(en)
*
|
2003-12-29 |
2006-09-20 |
Alza Corporation |
Novel drug compositions and dosage forms of topiramate
|
KR20060105872A
(ko)
*
|
2003-12-29 |
2006-10-11 |
반유 세이야꾸 가부시끼가이샤 |
신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체
|
US20050175696A1
(en)
*
|
2003-12-29 |
2005-08-11 |
David Edgren |
Drug granule coatings that impart smear resistance during mechanical compression
|
AU2004312082A1
(en)
*
|
2003-12-29 |
2005-07-21 |
Alza Corporation, Inc. |
Novel drug compositions and dosage forms
|
RS50958B
(sr)
*
|
2003-12-30 |
2010-10-31 |
Euro-Celtique S.A. |
Piperazini korisni za lečenje bola
|
US8138204B2
(en)
*
|
2004-01-07 |
2012-03-20 |
Aryx Therapeutics, Inc. |
Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
WO2005068461A1
(en)
|
2004-01-07 |
2005-07-28 |
Aryx Therapeutics |
Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
US8524736B2
(en)
|
2004-01-07 |
2013-09-03 |
Armetheon, Inc. |
Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
US7976520B2
(en)
*
|
2004-01-12 |
2011-07-12 |
Nulens Ltd. |
Eye wall anchored fixtures
|
WO2005072701A1
(en)
|
2004-01-20 |
2005-08-11 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
EP2292213A1
(en)
|
2004-02-06 |
2011-03-09 |
Cephalon, Inc. |
Compositions comprising a polymorphic form of armodafinil
|
CA2556220A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Athpharma Limited |
Chronotherapeutic compositions and methods of their use
|
US20080058411A1
(en)
|
2004-02-18 |
2008-03-06 |
Gpc Biotech Ag |
Methods For Treating Resistant Or Refractory Tumors
|
EP1729784A1
(en)
*
|
2004-02-23 |
2006-12-13 |
Attenuon, LLC |
Formulations of thiomolybdate or thiotungstate compounds and uses thereof
|
US20050196448A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Hai Yong Huang |
Polymeric compositions and dosage forms comprising the same
|
US20050196447A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196446A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US20050196442A1
(en)
*
|
2004-03-05 |
2005-09-08 |
Huang Hai Y. |
Polymeric compositions and dosage forms comprising the same
|
US7612071B2
(en)
|
2004-03-12 |
2009-11-03 |
Syntrix Biosystems, Inc. |
Compositions and methods employing aminopterin
|
US7928132B2
(en)
*
|
2004-08-06 |
2011-04-19 |
Ohio University |
Methods for the amelioration of episodes of acute or chronic ulcerative colitis
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050209295A1
(en)
*
|
2004-03-16 |
2005-09-22 |
Kohn Leonard D |
Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
|
US20100004304A1
(en)
*
|
2004-03-16 |
2010-01-07 |
Kohn Leonard D |
Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
|
CN1956718A
(zh)
|
2004-03-22 |
2007-05-02 |
细胞基因公司 |
用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
|
WO2005092065A2
(en)
*
|
2004-03-25 |
2005-10-06 |
Transform Pharmaceuticals, Inc. |
Novel tricyclic compounds and related methods of treatment
|
TWI365880B
(en)
|
2004-03-30 |
2012-06-11 |
Euro Celtique Sa |
Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
|
CN100522960C
(zh)
*
|
2004-04-08 |
2009-08-05 |
惠氏公司 |
作为黄体酮受体调节剂的硫代酰胺衍生物
|
CN1972686A
(zh)
*
|
2004-04-14 |
2007-05-30 |
细胞基因公司 |
选择性细胞因子抑制药在髓发育不良综合征中的用途
|
CN1968695A
(zh)
*
|
2004-04-14 |
2007-05-23 |
细胞基因公司 |
含有用于治疗和控制骨髓发育不良综合征的免疫调节化合物的组合物和使用方法
|
JP2007533760A
(ja)
*
|
2004-04-23 |
2007-11-22 |
セルジーン・コーポレーション |
肺高血圧症を治療し管理するための、pde4モジュレーターの使用方法及びpde4モジュレーターを含む組成物
|
MXPA06012403A
(es)
*
|
2004-04-27 |
2007-01-17 |
Wyeth Corp |
Purificacion de moduladores de receptor progesterona.
|
US20050244500A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
US20050244469A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Extended therapeutic effect ocular implant treatments
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
US8425929B2
(en)
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
US8147865B2
(en)
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
WO2005107708A1
(en)
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase inhibitors implants
|
US7803366B2
(en)
*
|
2004-05-07 |
2010-09-28 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
US20060185357A1
(en)
*
|
2004-05-07 |
2006-08-24 |
Kovacevich Ian D |
Independently drawing and tensioning lines with bi-directional rotary device having two spools
|
AU2005245896A1
(en)
*
|
2004-05-14 |
2005-12-01 |
Receptor Biologix, Inc. |
Cell surface receptor isoforms and methods of identifying and using the same
|
EP1749000A4
(en)
*
|
2004-05-25 |
2009-12-30 |
Metabolex Inc |
BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
|
WO2005115383A2
(en)
*
|
2004-05-25 |
2005-12-08 |
Metabolex, Inc. |
Substituted triazoles as modulators of ppar and methods of their preparation
|
US20060009425A1
(en)
*
|
2004-05-28 |
2006-01-12 |
Leticia Delgado-Herrera |
Oral formulations of paricalcitol
|
JP2008501024A
(ja)
|
2004-05-28 |
2008-01-17 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
混合コクリスタルおよびそれを含んでなる製薬学的組成物
|
US8481501B2
(en)
*
|
2004-05-28 |
2013-07-09 |
Human Biomolecular Research Institute |
Synthesis of metabolically stable analgesics, pain medications and other agents
|
US20050267555A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Marnfeldt Goran N |
Engagement tool for implantable medical devices
|
WO2005120584A2
(en)
*
|
2004-06-03 |
2005-12-22 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled arylsulfonyl compounds and uses thereof
|
WO2005121070A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Xenoport, Inc. |
Levodopa prodrugs, and compositions and uses thereof
|
JP4781352B2
(ja)
*
|
2004-06-04 |
2011-09-28 |
ゼノポート,インコーポレーテッド |
レボドパプロドラッグおよびその組成物ならびにその使用
|
EP1604667A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
SI1765292T1
(en)
|
2004-06-12 |
2018-04-30 |
Collegium Pharmaceutical, Inc. |
Formulations of medicines to discourage abuse
|
US7713550B2
(en)
*
|
2004-06-15 |
2010-05-11 |
Andrx Corporation |
Controlled release sodium valproate formulation
|
US20050276848A1
(en)
*
|
2004-06-15 |
2005-12-15 |
Nilobon Podhipleux |
Sustained release neutralized divalproex sodium
|
WO2006007448A2
(en)
*
|
2004-06-17 |
2006-01-19 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical co-crystal compositions and related methods of use
|
CA2579756C
(en)
*
|
2004-06-19 |
2013-04-30 |
Human Biomolecular Research Institute |
Modulators of central nervous system neurotransmitters
|
US20050287185A1
(en)
*
|
2004-06-23 |
2005-12-29 |
David Wong |
Extended release oxybutynin formulation
|
WO2006007323A2
(en)
*
|
2004-06-28 |
2006-01-19 |
Alza Corporation |
Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
|
CA2571554A1
(en)
*
|
2004-06-28 |
2006-01-19 |
Alza Corporation |
A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
|
US20050287214A1
(en)
*
|
2004-06-28 |
2005-12-29 |
Ayer Atul D |
Squeeze controlled oral dosage form
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US20080027513A1
(en)
*
|
2004-07-09 |
2008-01-31 |
Advanced Bionics Corporation |
Systems And Methods For Using A Butterfly Coil To Communicate With Or Transfer Power To An Implantable Medical Device
|
US7241807B2
(en)
*
|
2004-07-12 |
2007-07-10 |
Xenoport, Inc. |
Prodrugs of propofol, compositions and uses thereof
|
DK1781596T3
(da)
*
|
2004-07-12 |
2009-01-19 |
Xenoport Inc |
Aminosyreafledte profarmaka af propofolsammensætninger og anvendelser deraf
|
US20060128676A1
(en)
*
|
2004-07-13 |
2006-06-15 |
Pharmacofore, Inc. |
Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
|
WO2006012536A2
(en)
|
2004-07-22 |
2006-02-02 |
Ritter Andrew J |
Methods and compositions for treating lactose intolerance
|
GB0417401D0
(en)
|
2004-08-05 |
2004-09-08 |
Controlled Therapeutics Sct |
Stabilised prostaglandin composition
|
SG155189A1
(en)
*
|
2004-08-06 |
2009-09-30 |
Transform Pharmaceuticals Inc |
Novel fenofibrate formulations and related methods of treatment
|
KR20070038553A
(ko)
*
|
2004-08-06 |
2007-04-10 |
트렌스폼 파마수티컬스 인코퍼레이티드 |
신규한 스타틴 약제학적 조성물 및 관련된 치료방법
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
MX2007001850A
(es)
*
|
2004-08-13 |
2007-03-28 |
Boehringer Ingelheim Int |
Formulacion de pildora de liberacion prolongada que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para fabricarlo y uso del mismo.
|
EP1781260B2
(en)
*
|
2004-08-13 |
2014-04-02 |
Boehringer Ingelheim International GmbH |
Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
|
US8452407B2
(en)
*
|
2004-08-16 |
2013-05-28 |
Boston Scientific Neuromodulation Corporation |
Methods for treating gastrointestinal disorders
|
CA2577583A1
(en)
*
|
2004-08-19 |
2006-03-02 |
Alza Corporation |
Controlled release nanoparticle active agent formulation dosage forms and methods
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US8268791B2
(en)
|
2004-08-25 |
2012-09-18 |
Aegis Therapeutics, Llc. |
Alkylglycoside compositions for drug administration
|
WO2006025882A2
(en)
|
2004-08-25 |
2006-03-09 |
The Uab Research Foundation |
Absorption enhancers for drug administration
|
ATE458489T1
(de)
*
|
2004-08-30 |
2010-03-15 |
Seo Hong Yoo |
Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
|
CA2579569C
(en)
|
2004-09-08 |
2016-07-05 |
Spinal Modulation Inc. |
Neurostimulation methods and systems
|
US9205261B2
(en)
|
2004-09-08 |
2015-12-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Neurostimulation methods and systems
|
US20120277839A1
(en)
|
2004-09-08 |
2012-11-01 |
Kramer Jeffery M |
Selective stimulation to modulate the sympathetic nervous system
|
NZ584773A
(en)
|
2004-09-17 |
2012-07-27 |
Whitehead Biomedical Inst |
Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
|
US7709518B2
(en)
*
|
2004-09-21 |
2010-05-04 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
US8541026B2
(en)
*
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
NZ589657A
(en)
|
2004-10-15 |
2012-06-29 |
Gilead Palo Alto Inc |
Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
|
ATE506955T1
(de)
|
2004-10-15 |
2011-05-15 |
Seo Hong Yoo |
Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
|
CN101076343A
(zh)
*
|
2004-10-20 |
2007-11-21 |
Cv医药有限公司 |
A2a腺苷受体激动剂的应用
|
WO2006046112A2
(en)
*
|
2004-10-25 |
2006-05-04 |
Ranbaxy Laboratories Limited |
Ketolide derivatives as antibacterial agents
|
AU2005302523A1
(en)
*
|
2004-10-28 |
2006-05-11 |
Celgene Corporation |
Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
|
WO2006050165A2
(en)
*
|
2004-11-01 |
2006-05-11 |
Seo Hong Yoo |
Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
|
WO2006049304A1
(ja)
|
2004-11-02 |
2006-05-11 |
Banyu Pharmaceutical Co., Ltd |
アリールオキシ置換ベンズイミダゾール誘導体
|
WO2006050471A2
(en)
*
|
2004-11-03 |
2006-05-11 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
|
WO2006050472A2
(en)
*
|
2004-11-03 |
2006-05-11 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
|
EP1811986B1
(en)
*
|
2004-11-04 |
2014-03-26 |
XenoPort, Inc. |
Gabapentin prodrug sustained release oral dosage forms
|
US9358393B1
(en)
|
2004-11-09 |
2016-06-07 |
Andres M. Lozano |
Stimulation methods and systems for treating an auditory dysfunction
|
WO2006053184A2
(en)
*
|
2004-11-10 |
2006-05-18 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating or preventing a vascular disease
|
ES2399241T3
(es)
|
2004-11-18 |
2013-03-26 |
Synta Pharmaceuticals Corporation |
Compuestos de triazol que modulan la actividad de HSP90
|
EP1828174A1
(en)
*
|
2004-11-19 |
2007-09-05 |
Ranbaxy Laboratories Limited |
Azabicyclic muscarinic receptor antagonists
|
AR053986A1
(es)
|
2004-12-03 |
2007-05-30 |
Osmotica Pharmaceutical Argent |
Dispositivo osmotico que contiene amantadina y una sal osmotica
|
US7483746B2
(en)
*
|
2004-12-06 |
2009-01-27 |
Boston Scientific Neuromodulation Corp. |
Stimulation of the stomach in response to sensed parameters to treat obesity
|
WO2006065792A2
(en)
*
|
2004-12-13 |
2006-06-22 |
Indevus Pharmaceuticals, Inc. |
Treatment of interstitial cystitis using cannabinoid analogs
|
WO2006065793A2
(en)
|
2004-12-13 |
2006-06-22 |
Indevus Pharmaceuticals, Inc. |
TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
|
WO2006066074A2
(en)
|
2004-12-16 |
2006-06-22 |
The Regents Of The University Of California |
Lung-targeted drugs
|
TWI407956B
(zh)
|
2004-12-17 |
2013-09-11 |
Anadys Pharmaceuticals Inc |
3,5-二取代和3,5,7-三取代-3H-唑并及3H-噻唑并〔4,5-d〕嘧啶-2-酮化合物及其前藥
|
US9327069B2
(en)
|
2004-12-21 |
2016-05-03 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating a medical condition by promoting neural remodeling within the brain
|
US20060161217A1
(en)
*
|
2004-12-21 |
2006-07-20 |
Jaax Kristen N |
Methods and systems for treating obesity
|
US20070038264A1
(en)
*
|
2004-12-21 |
2007-02-15 |
Jaax Kristen N |
Methods and systems for treating autism
|
US9095713B2
(en)
*
|
2004-12-21 |
2015-08-04 |
Allison M. Foster |
Methods and systems for treating autism by decreasing neural activity within the brain
|
US9352145B2
(en)
*
|
2004-12-22 |
2016-05-31 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating a psychotic disorder
|
US8515541B1
(en)
|
2004-12-22 |
2013-08-20 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating post-stroke disorders
|
DE602004021404D1
(de)
|
2004-12-23 |
2009-07-16 |
Gpc Biotech Ag |
Quadratsäurederivate mit antiproliferativer Wirkung
|
EP1844000B1
(en)
*
|
2004-12-23 |
2010-01-27 |
Xenoport, Inc. |
Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
|
US20060160783A1
(en)
*
|
2004-12-30 |
2006-07-20 |
Transform Pharmaceuticals, Inc. |
Novel omeprazole forms and related methods
|
AU2006211646B2
(en)
*
|
2005-01-07 |
2012-09-20 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
AU2006208045B2
(en)
|
2005-01-25 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
US20060165798A1
(en)
*
|
2005-01-27 |
2006-07-27 |
Edgren David E |
Oral osmotic dosage form having a high flux membrane
|
EP2319499A1
(en)
*
|
2005-01-28 |
2011-05-11 |
Euro-Celtique S.A. |
Alcohol resistant dosage forms
|
JP2006224318A
(ja)
*
|
2005-02-15 |
2006-08-31 |
Brother Ind Ltd |
インクジェット記録装置
|
EP1690540A1
(en)
|
2005-02-15 |
2006-08-16 |
Neuro3D |
Composition comprising ocaperidone
|
US20060185665A1
(en)
*
|
2005-02-22 |
2006-08-24 |
Bachinski Thomas J |
Sauna fireplace
|
US20060194724A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Whitehurst Todd K |
Methods and systems for nerve regeneration
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
US7312217B2
(en)
|
2005-03-11 |
2007-12-25 |
Syntrix Biosystems, Inc. |
Aminopterin dosage forms and methods for inflammatory disorders
|
US7920915B2
(en)
*
|
2005-11-16 |
2011-04-05 |
Boston Scientific Neuromodulation Corporation |
Implantable stimulator
|
US20060206165A1
(en)
*
|
2005-03-14 |
2006-09-14 |
Jaax Kristen N |
Occipital nerve stimulation to treat headaches and other conditions
|
US7848803B1
(en)
|
2005-03-14 |
2010-12-07 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for facilitating stimulation of one or more stimulation sites
|
US7853321B2
(en)
*
|
2005-03-14 |
2010-12-14 |
Boston Scientific Neuromodulation Corporation |
Stimulation of a stimulation site within the neck or head
|
US8423155B1
(en)
|
2005-03-14 |
2013-04-16 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for facilitating stimulation of one or more stimulation sites
|
WO2006102426A2
(en)
|
2005-03-21 |
2006-09-28 |
Metabolex, Inc. |
Methods for avoiding edema in the treatment of metabolic, inflammatory, and cardiovascular disorders
|
US8222257B2
(en)
|
2005-04-01 |
2012-07-17 |
The Regents Of The University Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
US20080152714A1
(en)
*
|
2005-04-08 |
2008-06-26 |
Yi Gao |
Pharmaceutical Formulations
|
CA2604078C
(en)
|
2005-04-08 |
2013-07-23 |
Abbott Laboratories |
Enteric pharmaceutical formulations of choline salt of fenofibric acid
|
AR056968A1
(es)
|
2005-04-11 |
2007-11-07 |
Xenon Pharmaceuticals Inc |
Compuestos espiro-oxindol y composiciones farmacéuticas
|
AR053710A1
(es)
*
|
2005-04-11 |
2007-05-16 |
Xenon Pharmaceuticals Inc |
Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
|
US20060229261A1
(en)
*
|
2005-04-12 |
2006-10-12 |
John Devane |
Acarbose methods and formulations for treating chronic constipation
|
WO2006109156A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Ranbaxy Laboratories Limited |
Oxazolidinone derivatives as antimicrobials
|
US20060233882A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Sowden Harry S |
Osmotic dosage form
|
CN101232868A
(zh)
*
|
2005-04-19 |
2008-07-30 |
阿尔扎公司 |
曲马多和加巴喷丁的控释递药剂型
|
AR053713A1
(es)
*
|
2005-04-20 |
2007-05-16 |
Xenon Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos como agentes terapeuticos
|
US8071559B2
(en)
|
2005-05-02 |
2011-12-06 |
Cold Spring Harbor Laboratory |
Compositions and methods for cancer diagnosis and treatment
|
US20070087406A1
(en)
*
|
2005-05-04 |
2007-04-19 |
Pei Jin |
Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
|
US20070041944A1
(en)
*
|
2005-05-05 |
2007-02-22 |
The Trustees Of Columbia University In The City Of New York |
Treating tumors by ENH dislocation of ID proteins
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
EP2301937A1
(en)
*
|
2005-06-16 |
2011-03-30 |
Cv Therapeutics, Inc. |
Prodrugs of A2b adenosine receptor antagonists
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
ATE469880T1
(de)
|
2005-06-20 |
2010-06-15 |
Xenoport Inc |
Acyloxyalkylcarbamat-prodrugs von tranexansäure und anwendung
|
US20070054868A1
(en)
*
|
2005-06-20 |
2007-03-08 |
The Trustees Of Columbia University In The City Of New York |
Synergistic polyphenol compounds, compositions thereof, and uses thereof
|
EP1896002A4
(en)
|
2005-06-27 |
2009-11-25 |
Biovail Lab Int Srl |
BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
|
WO2007002867A1
(en)
*
|
2005-06-28 |
2007-01-04 |
Cv Therapeutics, Inc. |
Abca1 elevating compounds
|
WO2007002872A2
(en)
*
|
2005-06-29 |
2007-01-04 |
Alza Corporation |
Semi-permeable compositions providing reduced drying time for osmotic dosage forms
|
US8348930B2
(en)
*
|
2005-07-01 |
2013-01-08 |
Microlin, Llc |
Fluid delivery device with a diffusion membrane and electrochemical pump
|
MX2008000249A
(es)
*
|
2005-07-06 |
2008-03-18 |
Sepracor Inc |
Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
|
US20070009573A1
(en)
*
|
2005-07-07 |
2007-01-11 |
L N K International |
Method of forming immediate release dosage form
|
TWI279234B
(en)
*
|
2005-07-12 |
2007-04-21 |
Anchen Pharmaceuticals Taiwan |
Method for controlling lag time of in-situ passageway formation in osmotic delivery system
|
US20070025869A1
(en)
*
|
2005-07-15 |
2007-02-01 |
Gordon John H |
Fluid Delivery Device
|
US20070021734A1
(en)
*
|
2005-07-15 |
2007-01-25 |
Sai Bhavaraju |
Bioelectro-osmotic engine fluid delivery device
|
US20070023291A1
(en)
*
|
2005-07-15 |
2007-02-01 |
Sai Bhavaraju |
Metal Trap
|
EP1907357A1
(en)
|
2005-07-22 |
2008-04-09 |
Amgen Inc. |
Aniline sulfonamide derivatives and their uses
|
US20070031496A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Edgren David E |
Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
|
US7507842B2
(en)
*
|
2005-08-12 |
2009-03-24 |
Radiorx, Inc. |
Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
|
US20070135380A1
(en)
|
2005-08-12 |
2007-06-14 |
Radiorx, Inc. |
O-nitro compounds, pharmaceutical compositions thereof and uses thereof
|
EP1928450A2
(en)
*
|
2005-08-26 |
2008-06-11 |
Xenoport, Inc. |
Treating premature ejaculation using gabapentin and pregabalin prodrugs
|
US20080274180A1
(en)
*
|
2005-08-30 |
2008-11-06 |
Nicholas Piramal India Limited |
Extended Release Pharmaceutical Composition of Metformin and a Process for Producing It
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
CA2620379C
(en)
*
|
2005-08-31 |
2015-02-24 |
Aryx Therapeutics, Inc. |
Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
|
JP5578785B2
(ja)
|
2005-08-31 |
2014-08-27 |
セルジーン コーポレイション |
イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
US7684858B2
(en)
*
|
2005-09-21 |
2010-03-23 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for placing an implanted stimulator for stimulating tissue
|
US20070072838A1
(en)
|
2005-09-26 |
2007-03-29 |
Pharmacyclics, Inc. |
High-purity texaphyrin metal complexes
|
US20070078119A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Pharmacyclics, Inc. |
Storage system for texaphyrin pharmaceutical formulations
|
AU2006295645B2
(en)
*
|
2005-09-30 |
2011-09-29 |
Msd K.K. |
2-heteroaryl-substituted indole derivative
|
US20070190137A1
(en)
*
|
2005-10-07 |
2007-08-16 |
Reyes Iran |
Osmotic dosage form with controlled release and fast release aspects
|
CA2625783A1
(en)
*
|
2005-10-13 |
2007-04-26 |
Elfatih Elzein |
A1 adenosine receptor agonists
|
US20070092585A1
(en)
*
|
2005-10-14 |
2007-04-26 |
Skinner Michael K |
Cancer chemotherapy compositions comprising PI3K pathways modulators and triptolide
|
PL116330U1
(en)
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
EP1960382A1
(en)
|
2005-11-03 |
2008-08-27 |
ChemBridge Research Laboratories, Inc. |
Heterocyclic compounds as tyrosine kinase modulators
|
CA2628031C
(en)
|
2005-11-10 |
2013-03-05 |
Circ Pharma Research And Development Limited |
Once-daily administration of central nervous system drugs
|
EP1954714A2
(en)
*
|
2005-11-10 |
2008-08-13 |
Receptor Biologix, Inc. |
Hepatocyte growth factor intron fusion proteins
|
CA2629775A1
(en)
*
|
2005-11-14 |
2007-05-24 |
Enterprise Partners Venture Capital |
Stem cell factor therapy for tissue injury
|
PT1951718E
(pt)
|
2005-11-21 |
2012-05-21 |
Purdue Pharma Lp |
Compostos de 4-oxadiazolil-piperidina e as suas utilizações
|
US7729758B2
(en)
|
2005-11-30 |
2010-06-01 |
Boston Scientific Neuromodulation Corporation |
Magnetically coupled microstimulators
|
US7563821B2
(en)
*
|
2005-12-05 |
2009-07-21 |
Xenoport, Inc. |
Levodopa prodrug mesylate, compositions thereof, and uses thereof
|
US7982066B2
(en)
*
|
2005-12-09 |
2011-07-19 |
Novalife, Inc. |
High protein supplement
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
US20090176882A1
(en)
*
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
US7610100B2
(en)
*
|
2005-12-30 |
2009-10-27 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating osteoarthritis
|
US20070190127A1
(en)
|
2005-12-30 |
2007-08-16 |
Mingdong Zhou |
Extended release of neuregulin for improved cardiac function
|
US7835803B1
(en)
|
2006-01-17 |
2010-11-16 |
Boston Scientific Neuromodulation Corporation |
Lead assemblies with one or more switching networks
|
AU2007208225B2
(en)
*
|
2006-01-25 |
2013-05-02 |
Synta Pharmaceuticals Corp. |
Thiazole and thiadiazole compounds for inflammation and immune-related uses
|
TW200806292A
(en)
|
2006-01-25 |
2008-02-01 |
Synta Pharmaceuticals Corp |
Vinyl-phenyl derivatives for inflammation and immune-related uses
|
CA2639927A1
(en)
|
2006-01-25 |
2007-08-02 |
Synta Pharmaceuticals Corp. |
Substituted biaryl compounds for inflammation and immune-related uses
|
EP1813276A1
(en)
*
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Tamper resistant dosage forms
|
DK1984338T3
(da)
|
2006-01-31 |
2013-04-22 |
Synta Pharmaceuticals Corp |
Pyridylphenylforbindelser til inflammations- og immunrelaterede anvendelser
|
EP2581381A3
(en)
|
2006-02-03 |
2013-10-30 |
Gilead Sciences, Inc. |
Process for preparing an A2A-adenosine receptor agonist and its polymorphs
|
WO2007092329A2
(en)
*
|
2006-02-03 |
2007-08-16 |
Avanir Pharmaceuticals |
Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
|
WO2007090883A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Boehringer Ingelheim International Gmbh |
Extended release formulation
|
US20090041844A1
(en)
*
|
2006-02-10 |
2009-02-12 |
Boehringer Ingelheim International Gmbh |
Modified Release Formulation
|
US20070196487A1
(en)
*
|
2006-02-16 |
2007-08-23 |
Geerke Johan H |
Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
US7518017B2
(en)
|
2006-02-17 |
2009-04-14 |
Idexx Laboratories |
Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
|
US20070201024A1
(en)
*
|
2006-02-28 |
2007-08-30 |
Geerke Johan H |
Method and apparatus for semi-permeable membrane detection on osmotic tablets incorating near-infrared spectroscopy
|
US7795262B2
(en)
|
2006-03-10 |
2010-09-14 |
Neurogen Corporation |
Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
|
MX2008011844A
(es)
*
|
2006-03-13 |
2008-10-02 |
Encysive Pharmaceuticals Inc |
Formulaciones de sitaxsentano de sodio.
|
CN101443314B
(zh)
*
|
2006-03-13 |
2014-04-09 |
杏林制药株式会社 |
作为gsk-3抑制剂的氨基喹诺酮类
|
JP2009530284A
(ja)
*
|
2006-03-13 |
2009-08-27 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
拡張期心不全を治療するための方法と組成物
|
US8175710B2
(en)
*
|
2006-03-14 |
2012-05-08 |
Boston Scientific Neuromodulation Corporation |
Stimulator system with electrode array and the method of making the same
|
US20070219174A1
(en)
*
|
2006-03-15 |
2007-09-20 |
Pharmacyclics, Inc. |
Methods of treating cancer using hypofractionated radiation and texaphyrins
|
EP2007373A4
(en)
*
|
2006-03-29 |
2012-12-19 |
Foldrx Pharmaceuticals Inc |
INHIBITION OF ALPHA SYNUCLEINE TOXICITY
|
US9561188B2
(en)
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
JP5349290B2
(ja)
*
|
2006-04-03 |
2013-11-20 |
オディディ,イサ |
薬物送達組成物およびそれを含む医薬品、ならびにその製造方法
|
WO2007125455A1
(en)
*
|
2006-04-28 |
2007-11-08 |
Koninklijke Philips Electronics N. V. |
Osmotic pump with at least one chargeable material
|
US9011930B2
(en)
*
|
2006-05-01 |
2015-04-21 |
Zycal Bioceuticals Healthcare Company, Inc. |
Nutritional supplement and use thereof
|
US10960077B2
(en)
*
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
EP2027087A2
(en)
|
2006-05-18 |
2009-02-25 |
MannKind Corporation |
Intracellular kinase inhibitors
|
US8058260B2
(en)
*
|
2006-05-22 |
2011-11-15 |
Xenoport, Inc. |
2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
|
AU2007267510B2
(en)
|
2006-05-26 |
2013-01-31 |
Signature Therapeutics, Inc. |
Controlled release of phenolic opioids
|
ATE476418T1
(de)
*
|
2006-06-08 |
2010-08-15 |
Amgen Inc |
Benzamidderivate und assoziierte verwendungen
|
TW200808695A
(en)
*
|
2006-06-08 |
2008-02-16 |
Amgen Inc |
Benzamide derivatives and uses related thereto
|
AU2007257683A1
(en)
*
|
2006-06-12 |
2007-12-21 |
Symphogen A/S |
Pan-cell surface receptor- specific therapeutics
|
WO2007149438A2
(en)
|
2006-06-19 |
2007-12-27 |
Alpharma, Inc. |
Pharmaceutical compositions
|
EP2038286B1
(en)
|
2006-06-22 |
2017-03-08 |
Anadys Pharmaceuticals, Inc. |
Pyrro[1,2-b]pyridazinone compounds
|
ATE496924T1
(de)
|
2006-06-22 |
2011-02-15 |
Anadys Pharmaceuticals Inc |
Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
EP2068850A1
(en)
*
|
2006-06-22 |
2009-06-17 |
Cv Therapeutics, Inc. |
Use of a2a adenosine receptor agonists in the treatment of ischemia
|
US20070298073A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US20080085915A1
(en)
*
|
2006-06-23 |
2008-04-10 |
Cyrus Becker |
Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
|
US8802128B2
(en)
|
2006-06-23 |
2014-08-12 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
US8401654B1
(en)
|
2006-06-30 |
2013-03-19 |
Boston Scientific Neuromodulation Corporation |
Methods and systems for treating one or more effects of deafferentation
|
US8504163B1
(en)
|
2006-06-30 |
2013-08-06 |
Boston Scientific Neuromodulation Corporation |
Cranially mounted stimulation systems and methods
|
SG175602A1
(en)
|
2006-07-05 |
2011-11-28 |
Catalyst Biosciences Inc |
Protease screening methods and proteases identified thereby
|
GB0613333D0
(en)
|
2006-07-05 |
2006-08-16 |
Controlled Therapeutics Sct |
Hydrophilic polyurethane compositions
|
GB0613638D0
(en)
|
2006-07-08 |
2006-08-16 |
Controlled Therapeutics Sct |
Polyurethane elastomers
|
AU2007272970C1
(en)
|
2006-07-11 |
2013-01-10 |
Roy C. Levitt |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
DE602007012881D1
(en)
|
2006-07-18 |
2011-04-14 |
Anadys Pharmaceuticals Inc |
Carbonat- und carbamat-prodrugs von thiazolo ä4,5-dü-pyrimidinen
|
AU2007275034A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophilic abuse deterrent delivery system
|
EP2046769A2
(en)
|
2006-07-27 |
2009-04-15 |
Cv Therapeutics, Inc. |
Aldh-2 inhibitors in the treatment of addiction
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
CA2659037A1
(en)
*
|
2006-08-04 |
2008-03-13 |
Agi Therapeutics Research Limited |
Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
US9114133B2
(en)
|
2006-08-25 |
2015-08-25 |
U.S. Dept. Of Veterans Affairs |
Method of improving diastolic dysfunction
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
NZ575061A
(en)
|
2006-08-30 |
2011-10-28 |
Celgene Corp |
5-substituted isoindoline compounds
|
US20090081120A1
(en)
*
|
2006-09-01 |
2009-03-26 |
Cv Therapeutics, Inc. |
Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
|
WO2008028140A1
(en)
*
|
2006-09-01 |
2008-03-06 |
Cv Therapeutics, Inc. |
Methods and compositions for increasing patient tolerability during myocardial imaging methods
|
EP2066329B1
(en)
|
2006-09-15 |
2017-09-06 |
Reviva Pharmaceuticals, Inc. |
Synthesis, methods of using, and compositions of cyclobutylmethylamines
|
WO2008033572A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
|
US7879846B2
(en)
|
2006-09-21 |
2011-02-01 |
Kyorin Pharmaceutical Co.., Ltd. |
Serine hydrolase inhibitors
|
US8779154B2
(en)
|
2006-09-26 |
2014-07-15 |
Qinglin Che |
Fused ring compounds for inflammation and immune-related uses
|
HUE026827T2
(en)
|
2006-09-26 |
2016-07-28 |
Celgene Corp |
5-substituted quinazolinone derivatives as anticancer agents
|
US7445528B1
(en)
|
2006-09-29 |
2008-11-04 |
Boston Scientific Neuromodulation Corporation |
Connector assemblies
|
JP2011502101A
(ja)
*
|
2006-09-29 |
2011-01-20 |
ギリアード・パロ・アルト・インコーポレイテッド |
肺疾患の病歴を有する患者における心筋画像化法
|
RU2009112397A
(ru)
*
|
2006-10-05 |
2010-10-10 |
Си Ви ТЕРАПЬЮТИКС, ИНК (US) |
Бициклические азотсодержащие гетероциклические соединения для применения в качестве ингибиторов стеароил соа десатуразы
|
US7893066B2
(en)
*
|
2006-10-05 |
2011-02-22 |
Gilead Palo Alto, Inc. |
Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
|
AR063028A1
(es)
|
2006-10-06 |
2008-12-23 |
Banyu Pharma Co Ltd |
Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
|
EP2813144A1
(en)
|
2006-10-09 |
2014-12-17 |
Charleston Laboratories, Inc. |
Analgesic compositions comprising an antihistamine
|
TW200833695A
(en)
*
|
2006-10-12 |
2008-08-16 |
Xenon Pharmaceuticals Inc |
Use of spiro-oxindole compounds as therapeutic agents
|
CL2007002953A1
(es)
*
|
2006-10-12 |
2008-02-01 |
Xenon Pharmaceuticals Inc |
Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
|
CN101522685A
(zh)
*
|
2006-10-12 |
2009-09-02 |
泽农医药公司 |
三环螺-吲哚酮衍生物及其作为治疗剂的用途
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
GB0620685D0
(en)
|
2006-10-18 |
2006-11-29 |
Controlled Therapeutics Sct |
Bioresorbable polymers
|
DE602007013440D1
(de)
|
2006-10-19 |
2011-05-05 |
Auspex Pharmaceuticals Inc |
Substituierte indole
|
PL2076268T3
(pl)
|
2006-10-19 |
2013-06-28 |
Genzyme Corp |
Roskowityna do leczenia pewnych chorób torbielowatych
|
US7347746B1
(en)
|
2006-10-27 |
2008-03-25 |
Boston Scientific Neuromodulation Corporation |
Receptacle connector assembly
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
CA2669695C
(en)
|
2006-11-13 |
2012-10-30 |
Synta Pharmaceuticals Corp. |
Tetrahydropyridinyl compounds for inflammation and immune-related uses
|
EA018036B1
(ru)
|
2006-11-27 |
2013-05-30 |
Х. Лундбекк А/С |
Гетероариламидные производные
|
JP5405120B2
(ja)
|
2006-12-01 |
2014-02-05 |
Msd株式会社 |
新規フェニル−イソキサゾール−3−オール誘導体
|
JP2010511628A
(ja)
|
2006-12-01 |
2010-04-15 |
ギリアード・パロ・アルト・インコーポレイテッド |
A2aアデノシン受容体アンタゴニスト
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
WO2008070809A2
(en)
|
2006-12-06 |
2008-06-12 |
Spinal Modulation, Inc. |
Implantable flexible circuit leads and methods of use
|
JP5414531B2
(ja)
|
2006-12-06 |
2014-02-12 |
スパイナル・モデュレーション・インコーポレイテッド |
送達装置、ならびに複数の脊髄レベルにある神経組織を刺激するためのシステムおよび方法
|
WO2008070806A2
(en)
*
|
2006-12-06 |
2008-06-12 |
Spinal Modulation, Inc. |
Hard tissue anchors and delivery devices
|
US9427570B2
(en)
*
|
2006-12-06 |
2016-08-30 |
St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) |
Expandable stimulation leads and methods of use
|
CA2672044A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Xenoport, Inc. |
Use of prodrugs of gaba analogs for treating diseases
|
AU2007333586A1
(en)
*
|
2006-12-11 |
2008-06-19 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
|
WO2008073928A1
(en)
|
2006-12-12 |
2008-06-19 |
Gilead Colorado, Inc. |
Composition for treating a pulmonary hypertension
|
GB0624880D0
(en)
*
|
2006-12-14 |
2007-01-24 |
Johnson Matthey Plc |
Improved method for making analgesics
|
US20080147186A1
(en)
*
|
2006-12-14 |
2008-06-19 |
Joshi Ashok V |
Electrochemical Implant For Delivering Beneficial Agents
|
US7709527B2
(en)
|
2006-12-21 |
2010-05-04 |
Xenoport, Inc. |
Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
|
US7829592B2
(en)
*
|
2006-12-21 |
2010-11-09 |
Xenoport, Inc. |
Catechol protected levodopa diester prodrugs, compositions, and methods of use
|
WO2008079371A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of c3a receptor and methods of use thereof
|
US7932421B2
(en)
*
|
2006-12-26 |
2011-04-26 |
Amgen Inc. |
N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
CA2674039A1
(en)
*
|
2006-12-28 |
2008-07-17 |
Astellas Pharma Inc. |
Sustained release formulation for tacrolimus
|
CA2673653A1
(en)
*
|
2007-01-03 |
2008-07-17 |
Cv Therapeutics, Inc. |
Myocardial perfusion imaging
|
RS51474B
(en)
|
2007-01-16 |
2011-04-30 |
Purdue Pharma L.P. |
HETEROCYCLICALLY SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS
|
WO2008089260A2
(en)
*
|
2007-01-16 |
2008-07-24 |
Victory Pharma, Inc. |
Combined administration of benzonatate and guaifenesin
|
EP2111253B1
(en)
*
|
2007-01-29 |
2018-05-02 |
Spinal Modulation, Inc. |
Sutureless lead retention features
|
US7999107B2
(en)
|
2007-01-31 |
2011-08-16 |
Merck Sharp & Dohme Corp. |
Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
|
CA2894112C
(en)
|
2007-02-09 |
2020-09-15 |
Metabasis Therapeutics, Inc. |
Novel antagonists of the glucagon receptor
|
US8524749B2
(en)
*
|
2007-02-09 |
2013-09-03 |
Alza Corporation |
Controlled release compositions of tizanidine
|
CN101663263A
(zh)
|
2007-02-21 |
2010-03-03 |
塞普拉柯公司 |
包含(-)-o-去甲基文拉法辛的固体形式及其用途
|
AU2008219622A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
CL2008000666A1
(es)
*
|
2007-03-07 |
2008-06-13 |
Xenon Pharmaceuticals Inc |
Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
|
WO2008112495A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Wyeth |
Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
|
EP2137150A1
(en)
*
|
2007-03-12 |
2009-12-30 |
Biolipox AB |
Piperidinones useful in the treatment of inflammation
|
US20070172525A1
(en)
*
|
2007-03-15 |
2007-07-26 |
Ramesh Sesha |
Anti-diabetic combinations
|
EP3103790B1
(en)
|
2007-03-15 |
2018-05-09 |
Auspex Pharmaceuticals, Inc. |
Substituted phenethylamine with serotoninergic and/or norepinephrinergic activity
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
ES2400964T3
(es)
|
2007-04-04 |
2013-04-15 |
Sigmoid Pharma Limited |
Composiciones famacéuticas de ciclosporina
|
CA2681560A1
(en)
*
|
2007-04-09 |
2008-10-16 |
Cv Therapeutics, Inc. |
Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
|
US20090105283A1
(en)
*
|
2007-04-11 |
2009-04-23 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
US20080255161A1
(en)
*
|
2007-04-11 |
2008-10-16 |
Dmitry Koltun |
3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
|
WO2008132707A1
(en)
|
2007-04-26 |
2008-11-06 |
Sigmoid Pharma Limited |
Manufacture of multiple minicapsules
|
CA2833209C
(en)
|
2007-04-27 |
2016-06-28 |
Purdue Pharma L.P. |
Piperidine and piperazine compounds as trpv1 antagonists
|
US8389549B2
(en)
*
|
2007-04-27 |
2013-03-05 |
Purdue Pharma L.P. |
Substituted pyridines useful for treating pain
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
EP2162135A4
(en)
*
|
2007-05-21 |
2012-02-22 |
Reviva Pharmaceuticals Inc |
COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
|
EP2019101A1
(en)
*
|
2007-07-26 |
2009-01-28 |
GPC Biotech AG |
Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
|
JP5420534B2
(ja)
|
2007-05-31 |
2014-02-19 |
サノビオン ファーマシューティカルズ インク |
モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
|
AU2008287542C1
(en)
|
2007-06-01 |
2015-01-22 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
CA2688547A1
(en)
*
|
2007-06-05 |
2008-12-11 |
Xenon Pharmaceuticals, Inc. |
Aromatic and heteroaromatic compounds useful in treating iron disorders
|
WO2009011988A2
(en)
*
|
2007-06-05 |
2009-01-22 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
|
US20080306076A1
(en)
*
|
2007-06-08 |
2008-12-11 |
Senomyx, Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
US7928111B2
(en)
*
|
2007-06-08 |
2011-04-19 |
Senomyx, Inc. |
Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
|
US8633186B2
(en)
|
2007-06-08 |
2014-01-21 |
Senomyx Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
US9603848B2
(en)
*
|
2007-06-08 |
2017-03-28 |
Senomyx, Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
EP2520561B1
(en)
|
2007-06-08 |
2016-02-10 |
MannKind Corporation |
IRE-1A Inhibitors
|
US20090012103A1
(en)
*
|
2007-07-05 |
2009-01-08 |
Matthew Abelman |
Substituted heterocyclic compounds
|
AU2008275752A1
(en)
*
|
2007-07-06 |
2009-01-15 |
Nuon Therapeutics, Inc. |
Treatment of neuropathic pain
|
US8247423B2
(en)
*
|
2007-07-12 |
2012-08-21 |
Tragara Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
|
WO2009012263A2
(en)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
CN101754962B
(zh)
|
2007-07-19 |
2013-12-25 |
赛马拜制药公司 |
作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
|
EP2185514A4
(en)
|
2007-08-01 |
2011-05-18 |
Synta Pharmaceuticals Corp |
VINYL-ARYL DERIVATIVES FOR INFLAMMATORY AND IMMUNE DISORDERS
|
WO2009017818A1
(en)
|
2007-08-01 |
2009-02-05 |
Synta Pharmaceuticals Corp. |
Heterocycle-aryl compounds for inflammation and immune-related uses
|
US7893045B2
(en)
*
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
SI2194783T1
(sl)
|
2007-08-10 |
2017-12-29 |
Vm Discovery, Inc. |
Sestavki in metode za modulatorje apoptose
|
CN106279283A
(zh)
|
2007-08-13 |
2017-01-04 |
症变治疗公司 |
新颖的葡糖激酶活化剂
|
WO2009027852A2
(en)
*
|
2007-08-28 |
2009-03-05 |
Agi Therapeutics, P.L.C. |
Methods and compositions for treating gastrointestinal conditions
|
BRPI0815327A2
(pt)
*
|
2007-08-31 |
2015-12-15 |
Purdue Pharma Lp |
"compostos de piperidina do tipo quinoxalina substituída e os usos destes"
|
US20090082315A1
(en)
*
|
2007-09-05 |
2009-03-26 |
Raif Tawakol |
Compositions and Methods for Controlling Cholesterol Levels
|
AU2008299903B2
(en)
*
|
2007-09-11 |
2013-08-29 |
Kyorin Pharmaceutical Co., Ltd |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
KR101597841B1
(ko)
|
2007-09-12 |
2016-02-26 |
교린 세이야꾸 가부시키 가이샤 |
Gsk-3 억제제로서의 스피로시클릭 아미노퀴놀론
|
CZ300468B6
(cs)
*
|
2007-09-20 |
2009-05-27 |
Zentiva, A. S |
Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy
|
MY157495A
(en)
|
2007-09-26 |
2016-06-15 |
Celgene Corp |
6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
|
AR068540A1
(es)
*
|
2007-09-28 |
2009-11-18 |
Merck & Co Inc |
Metodos de produccion de un derivado de pirazol-3-il-benzamida.
|
US20090087484A1
(en)
*
|
2007-09-28 |
2009-04-02 |
Alza Corporation |
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
WO2009052184A2
(en)
*
|
2007-10-16 |
2009-04-23 |
Receptor Biologix, Inc. |
Compositions comprising optimized her1 and her3 multimers and methods of use thereof
|
WO2009052454A2
(en)
|
2007-10-19 |
2009-04-23 |
University Of California |
Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
|
ES2493593T3
(es)
|
2007-11-12 |
2014-09-12 |
Msd K.K. |
Derivado de heteroariloxi quinazolina
|
CN102065852B
(zh)
|
2007-11-23 |
2015-06-17 |
格吕伦塔尔有限公司 |
他喷他多组合物
|
JP2011506318A
(ja)
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
経口医薬製剤
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20090162417A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Cook Incorporated |
Drug eluting ocular conformer
|
JPWO2009081782A1
(ja)
|
2007-12-25 |
2011-05-06 |
萬有製薬株式会社 |
N−ピラゾール−2−ピリジンカルボキサミド誘導体
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
ES2620672T3
(es)
|
2008-01-09 |
2017-06-29 |
Charleston Laboratories, Inc. |
Comprimidos de doble capa que comprenden oxicodona y prometazina
|
US9226907B2
(en)
|
2008-02-01 |
2016-01-05 |
Abbvie Inc. |
Extended release hydrocodone acetaminophen and related methods and uses thereof
|
JP2011511802A
(ja)
*
|
2008-02-07 |
2011-04-14 |
ギリアード・パロ・アルト・インコーポレイテッド |
Abca−1を上昇させる化合物およびかかる化合物の使用方法
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
US20090214665A1
(en)
*
|
2008-02-26 |
2009-08-27 |
Lai Felix S |
Controlled Release Muscarinic Receptor Antagonist Formulation
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
PL2268623T3
(pl)
*
|
2008-03-17 |
2015-10-30 |
Ambit Biosciences Corp |
Pochodne chinazoliny jako modulatory kinazy RAF oraz sposoby ich zastosowania
|
US8822500B2
(en)
|
2008-03-19 |
2014-09-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
US9249147B2
(en)
|
2008-03-19 |
2016-02-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
JP5628145B2
(ja)
|
2008-03-19 |
2014-11-19 |
ケムブリッジ・コーポレーション |
新規チロシンキナーゼ阻害剤
|
EP2687213B1
(en)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
KR20150038547A
(ko)
|
2008-03-27 |
2015-04-08 |
셀진 코포레이션 |
(+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온을 포함하는 고체 형태, 이의 조성물, 및 이의 용도
|
DK2280704T3
(en)
*
|
2008-03-31 |
2015-06-29 |
Cymabay Therapeutics Inc |
Oxymethylenarylforbindelser and uses thereof
|
WO2009145982A1
(en)
|
2008-04-01 |
2009-12-03 |
Antipodean Pharmaceuticals, Inc. |
Compositions and methods for skin care
|
MX2010010949A
(es)
*
|
2008-04-04 |
2011-02-22 |
Gilead Sciences Inc |
Derivados de triazolopiridinona para utilizarse como inhibidores de desaturasa de estearoilo coa.
|
NZ601248A
(en)
|
2008-04-14 |
2014-06-27 |
Halozyme Inc |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
EP2303327A2
(en)
*
|
2008-05-20 |
2011-04-06 |
Cerenis Therapeutics S.A. |
Niacin and nsaid for combination therapy
|
WO2009154993A1
(en)
*
|
2008-05-27 |
2009-12-23 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using piperazine based antipsychotic agents
|
AU2009255183A1
(en)
|
2008-06-02 |
2009-12-10 |
Msd K.K. |
Novel isoxazole derivative
|
US8894602B2
(en)
|
2010-09-17 |
2014-11-25 |
Johnson & Johnson Vision Care, Inc. |
Punctal plugs with directional release
|
ES2732453T3
(es)
|
2008-07-01 |
2019-11-22 |
Curemark Llc |
Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
RU2500678C2
(ru)
|
2008-07-21 |
2013-12-10 |
Пэдью Фарма Л.П. |
Замещенные хиноксалинового типа мостиковые пиперидиновые соединения и их применение
|
US8173637B2
(en)
*
|
2008-07-24 |
2012-05-08 |
Handa Pharmaceuticals, Llc |
Stabilized atypical antipsychotic formulation
|
SI2326651T1
(sl)
|
2008-07-30 |
2014-03-31 |
Purdue Pharma L.P. |
Buprenorfinski analogi
|
CN102170797B
(zh)
|
2008-07-31 |
2014-02-19 |
西诺米克斯公司 |
包含甜味增强剂的组合物和它们的制备方法
|
WO2010014666A2
(en)
|
2008-07-31 |
2010-02-04 |
Senomyx, Inc. |
Processes and intermediates for making sweet taste enhancers
|
US8907103B2
(en)
|
2008-08-13 |
2014-12-09 |
Metabasis Therapeutics, Inc. |
Glucagon antagonists
|
EP2348863A4
(en)
|
2008-09-04 |
2012-03-07 |
Anacor Pharmaceuticals Inc |
BORN SMALL MOLECULES
|
US20100190752A1
(en)
|
2008-09-05 |
2010-07-29 |
Gruenenthal Gmbh |
Pharmaceutical Combination
|
WO2010037122A1
(en)
*
|
2008-09-29 |
2010-04-01 |
Gilead Palo Alto, Inc. |
Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
|
EP2350064A1
(en)
*
|
2008-10-01 |
2011-08-03 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
EP3025727A1
(en)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Methods of treating liver disease
|
ES2589915T3
(es)
|
2008-10-08 |
2016-11-17 |
Xgene Pharmaceutical Inc |
Conjugados de GABA y métodos de utilización de los mismos
|
TWI480272B
(zh)
|
2008-10-09 |
2015-04-11 |
Anadys Pharmaceuticals Inc |
藉由5,6-二氫-1h-吡啶-2-酮與一或多種其他抗病毒化合物的組合物抑制c型肝炎病毒的方法
|
CN106243100B
(zh)
|
2008-10-10 |
2019-04-09 |
Vm生物医药公司 |
治疗酒精使用障碍,疼痛和其他疾病的药物组合与方法
|
WO2010045374A1
(en)
*
|
2008-10-15 |
2010-04-22 |
Gilead Palo Alto, Inc. |
3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
|
RU2011119626A
(ru)
|
2008-10-17 |
2012-11-27 |
Ксенон Фармасьютикалз Инк. |
Спирооксиндольные соединения и их применение в качестве терапевтичеких средств
|
US8101647B2
(en)
*
|
2008-10-17 |
2012-01-24 |
Xenon Pharmaceuticals Inc. |
Spiro-oxindole compounds and their use as therapeutic agents
|
WO2010047775A2
(en)
*
|
2008-10-20 |
2010-04-29 |
Xenoport, Inc. |
Methods of synthesizing a levodopa ester prodrug
|
US8399513B2
(en)
*
|
2008-10-20 |
2013-03-19 |
Xenoport, Inc. |
Levodopa prodrug mesylate hydrate
|
EP2350016A2
(en)
|
2008-10-21 |
2011-08-03 |
Metabolex Inc. |
Aryl gpr120 receptor agonists and uses thereof
|
CN102264228A
(zh)
|
2008-10-22 |
2011-11-30 |
默沙东公司 |
用于抗糖尿病药的新的环状苯并咪唑衍生物
|
US8703962B2
(en)
*
|
2008-10-24 |
2014-04-22 |
Purdue Pharma L.P. |
Monocyclic compounds and their use as TRPV1 ligands
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
US8546388B2
(en)
*
|
2008-10-24 |
2013-10-01 |
Purdue Pharma L.P. |
Heterocyclic TRPV1 receptor ligands
|
CN102202729B
(zh)
|
2008-10-27 |
2014-11-05 |
脊髓调制公司 |
选择性刺激系统和用于医疗状况的信号参数
|
RU2527952C2
(ru)
|
2008-10-29 |
2014-09-10 |
Селджин Корпорейшн |
Изоиндолиновые соединения для применения при лечении рака
|
PE20142368A1
(es)
|
2008-10-30 |
2015-02-04 |
Gruenenthal Chemie |
Formas de dosificacion del tapentadol novedosas y potentes
|
WO2010056527A2
(en)
|
2008-10-30 |
2010-05-20 |
Gilead Palo Alto, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
US20100113514A1
(en)
|
2008-10-30 |
2010-05-06 |
Gilead Palo Alto, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
JP2012506912A
(ja)
|
2008-11-04 |
2012-03-22 |
ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション |
アテローム硬化症、メタボリックシンドロームおよびそれらの症状を予防および処置するためのd−タガトースベースの組成物および方法
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
EP2376495A4
(en)
|
2008-12-08 |
2012-10-31 |
Vm Pharma Llc |
COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
|
CA2746181C
(en)
|
2008-12-09 |
2016-03-15 |
Halozyme, Inc. |
Extended soluble ph20 polypeptides and uses thereof
|
US8592608B2
(en)
|
2008-12-16 |
2013-11-26 |
Sunovion Pharmaceuticals Inc. |
Triple reuptake inhibitors and methods of their use
|
EP2376633A1
(en)
|
2008-12-17 |
2011-10-19 |
AVI BioPharma, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
AR074760A1
(es)
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
CA2747805A1
(en)
|
2008-12-22 |
2010-07-01 |
Sloan-Kettering Institute For Cancer Research |
Methods for treating or preventing cancer and neurodegenerative diseases
|
JP2012513471A
(ja)
|
2008-12-22 |
2012-06-14 |
スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ |
アルツハイマー病および癌の治療のためのクマリン系化合物
|
WO2010078307A1
(en)
|
2008-12-29 |
2010-07-08 |
Xenon Pharmaceuticals Inc. |
Spiro-oxindole-derivatives as sodium channel blockers
|
EP2376524B1
(en)
|
2008-12-31 |
2017-03-15 |
Cypralis Limited |
Derivatives of cyclosporin a
|
WO2010080835A1
(en)
|
2009-01-06 |
2010-07-15 |
Curemark Llc |
Compositions and methods for the treatment or the prevention oral infections by e. coli
|
AU2010203709B2
(en)
|
2009-01-06 |
2014-05-22 |
Galenagen, Llc |
Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
US8389021B2
(en)
|
2009-02-03 |
2013-03-05 |
Microbion Corporation |
Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
|
WO2010091268A1
(en)
|
2009-02-09 |
2010-08-12 |
Sepracor Inc. |
Pyrrolidine triple reuptake inhibitors
|
WO2010093588A1
(en)
|
2009-02-10 |
2010-08-19 |
Celgene Corporation |
Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
|
EP2396312A1
(en)
|
2009-02-11 |
2011-12-21 |
Celgene Corporation |
Isotopologues of lenalidomide
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
RU2011137419A
(ru)
|
2009-02-11 |
2013-03-20 |
Суновион Фармасьютикалз Инк. |
Обратные агонисты и антагонисты гистамина н3 и способы их применения
|
US8409606B2
(en)
|
2009-02-12 |
2013-04-02 |
Incept, Llc |
Drug delivery through hydrogel plugs
|
EP2398800A4
(en)
|
2009-02-23 |
2012-07-25 |
Msd Kk |
Pyrimidin-4 (3H) -ONE DERIVATIVES
|
CA2752800C
(en)
|
2009-02-24 |
2017-12-05 |
Ritter Pharmaceuticals, Inc. |
Prebiotic formulations and methods of use
|
US8785160B2
(en)
|
2009-02-24 |
2014-07-22 |
Ritter Pharmaceuticals, Inc. |
Prebiotic formulations and methods of use
|
AU2010217772B2
(en)
*
|
2009-02-26 |
2014-10-23 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
|
US20120065221A1
(en)
|
2009-02-26 |
2012-03-15 |
Theraquest Biosciences, Inc. |
Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
|
CN102395576A
(zh)
*
|
2009-02-27 |
2012-03-28 |
埃姆比特生物科学公司 |
调控jak激酶的喹唑啉衍生物和其使用方法
|
EP2403860B1
(en)
|
2009-03-04 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
|
WO2010102262A1
(en)
|
2009-03-06 |
2010-09-10 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
|
MY152279A
(en)
|
2009-03-10 |
2014-09-15 |
Euro Celtique Sa |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
MX2011009414A
(es)
*
|
2009-03-11 |
2011-10-19 |
Kyorin Seiyaku Kk |
7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
|
JP5580834B2
(ja)
|
2009-03-11 |
2014-08-27 |
Msd株式会社 |
新規イソインドリン−1−オン誘導体
|
MX2011009413A
(es)
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
US8975247B2
(en)
|
2009-03-18 |
2015-03-10 |
The Board Of Trustees Of The Leland Stanford Junion University |
Methods and compositions of treating a flaviviridae family viral infection
|
CN102438698B
(zh)
|
2009-03-24 |
2014-09-10 |
脊髓调制公司 |
使用针对感觉异常的刺激亚阈值的疼痛治疗
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
AU2010229468A1
(en)
|
2009-03-27 |
2011-10-13 |
Vetdc, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
EP2421524B1
(en)
|
2009-04-20 |
2018-08-08 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
DK2421829T3
(en)
|
2009-04-22 |
2016-01-04 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted aryl sulfonamide CCR3 antagonists
|
EP2502921B1
(en)
|
2009-04-22 |
2015-05-20 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamide CCR3 antagonists
|
KR101687144B1
(ko)
|
2009-04-22 |
2016-12-15 |
액시킨 파마수티컬스 인코포레이티드 |
2,5-이치환된 아릴설폰아마이드 ccr3 길항제
|
WO2010127452A1
(en)
|
2009-05-04 |
2010-11-11 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
5-oxo-ete receptor antagonist compounds
|
MX2011012140A
(es)
*
|
2009-05-14 |
2012-02-28 |
Gilead Sciences Inc |
Ranolazina para el tratamiento de problemas del snc.
|
US9259569B2
(en)
|
2009-05-15 |
2016-02-16 |
Daniel M. Brounstein |
Methods, systems and devices for neuromodulating spinal anatomy
|
CN102470106B
(zh)
|
2009-05-18 |
2015-09-23 |
希格默伊德药业有限公司 |
包含油滴的组合物
|
CN102448472A
(zh)
|
2009-05-25 |
2012-05-09 |
国立大学法人东京工业大学 |
包含与中枢神经细胞的增殖和分化相关的核因子的药物组合物
|
WO2010139111A1
(en)
|
2009-06-02 |
2010-12-09 |
Dow Global Technologies Inc. |
Sustained release dosage form
|
KR20120035183A
(ko)
|
2009-06-10 |
2012-04-13 |
선오비온 파마슈티컬스 인코포레이티드 |
히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
ES2769357T3
(es)
|
2009-06-16 |
2020-06-25 |
Pfizer |
Formas farmacéuticas de apixaban
|
AR077252A1
(es)
|
2009-06-29 |
2011-08-10 |
Xenon Pharmaceuticals Inc |
Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
CA2987503C
(en)
|
2009-07-07 |
2019-02-26 |
Mei Pharma, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
WO2011006012A1
(en)
|
2009-07-08 |
2011-01-13 |
Charleston Laboratories Inc. |
Pharmaceutical compositions
|
AU2010270605B2
(en)
|
2009-07-08 |
2014-07-31 |
Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals |
Sodium thiosulfate-containing pharmaceutical compositions
|
TWI625121B
(zh)
|
2009-07-13 |
2018-06-01 |
基利科學股份有限公司 |
調節細胞凋亡信號之激酶的抑制劑
|
WO2011009961A1
(en)
|
2009-07-24 |
2011-01-27 |
Virologik Gmbh |
Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
|
ME02847B
(me)
|
2009-07-27 |
2018-01-20 |
Gilead Sciences Inc |
Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
US20130017188A1
(en)
|
2009-07-31 |
2013-01-17 |
The Brigham And Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
IN2012DN00781A
(el)
|
2009-08-12 |
2015-06-26 |
Sigmoid Pharma Ltd |
|
US20110039799A1
(en)
|
2009-08-14 |
2011-02-17 |
Gilead Palo Alto, Inc. |
A1 adenosine receptor agonist polymorphs
|
EP2467137A1
(en)
|
2009-08-19 |
2012-06-27 |
Ambit Biosciences Corporation |
Biaryl compounds and methods of use thereof
|
WO2011028234A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Xenoport, Inc. |
Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
|
SG178964A1
(en)
|
2009-09-04 |
2012-04-27 |
United Paragon Associates Inc |
Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
|
JP2013504580A
(ja)
|
2009-09-11 |
2013-02-07 |
スノヴィオン ファーマシューティカルズ インコーポレイテッド |
ヒスタミンh3インバースアゴニストおよびアンタゴニストとその使用方法
|
CA2775840C
(en)
|
2009-10-01 |
2018-02-06 |
Metabolex, Inc. |
Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
WO2011042482A1
(en)
|
2009-10-06 |
2011-04-14 |
Green Molecular |
Polyphenols for use in the treatment of cancer
|
US8282970B2
(en)
*
|
2009-10-07 |
2012-10-09 |
Jiahgsu Dehe Bio-Tech Co., Ltd |
Theaflavin compositions, related processes and methods of use
|
US20110082198A1
(en)
*
|
2009-10-07 |
2011-04-07 |
Jiangsu Dehe Bio-Tech Co., Ltd. |
Theaflavin compositions, production, and methods to control physiological disorders in mammals
|
EP2488531B1
(en)
*
|
2009-10-14 |
2014-03-26 |
Xenon Pharmaceuticals Inc. |
Synthetic methods for spiro-oxindole compounds
|
WO2011047173A2
(en)
*
|
2009-10-14 |
2011-04-21 |
Xenon Pharmaceuticals Inc. |
Pharmaceutical compositions for oral administration
|
EA022119B1
(ru)
|
2009-10-19 |
2015-11-30 |
Синта Фармасьютиклз Корп. |
Комбинированная терапия раковых заболеваний с помощью соединений - ингибиторов hsp90
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
WO2011056985A2
(en)
|
2009-11-04 |
2011-05-12 |
Gilead Sciences, Inc. |
Substituted heterocyclic compounds
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
NZ601747A
(en)
|
2009-11-09 |
2014-08-29 |
Xenoport Inc |
Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
|
MX361709B
(es)
|
2009-11-09 |
2018-12-07 |
Allergan Inc |
Composiciones y metodos para estimular el crecimiento del cabello.
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
JP2013511536A
(ja)
|
2009-11-19 |
2013-04-04 |
セルジーン コーポレイション |
サルコイドーシスを処置する方法
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
KR101855471B1
(ko)
|
2009-12-04 |
2018-05-09 |
선오비온 파마슈티컬스 인코포레이티드 |
다환형 화합물 및 이의 사용 방법
|
RU2016104396A
(ru)
|
2009-12-04 |
2018-11-23 |
Суновион Фармасьютикалз Инк. |
Лекарственные формы, соли и полиморфы транснорсертралина и их применения
|
WO2011070364A1
(en)
|
2009-12-09 |
2011-06-16 |
Scynexis, Inc. |
Novel cyclic peptides
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
CN102822175A
(zh)
|
2009-12-18 |
2012-12-12 |
埃迪尼克斯医药公司 |
5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
|
TWI508726B
(zh)
|
2009-12-21 |
2015-11-21 |
Gilead Sciences Inc |
治療心房纖維性顫動之方法
|
CA2783616A1
(en)
|
2009-12-22 |
2011-06-30 |
Celgene Corporation |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
CA2785978A1
(en)
|
2009-12-30 |
2011-07-07 |
Scynexis, Inc. |
Cyclosporine analogues
|
EP3536333B1
(en)
|
2010-01-04 |
2022-08-03 |
Mapi Pharma Limited |
Depot system comprising glatiramer acetate
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
CA2786266A1
(en)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
|
WO2011089166A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
|
WO2011091164A1
(en)
*
|
2010-01-22 |
2011-07-28 |
Xenoport, Inc. |
Oral dosage forms having a high loading of a tranexamic acid prodrug
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
EP2531197B1
(en)
|
2010-02-05 |
2017-05-17 |
Tragara Pharmaceuticals, Inc. |
Solid state forms of macrocyclic kinase inhibitors
|
US8471041B2
(en)
*
|
2010-02-09 |
2013-06-25 |
Alliant Techsystems Inc. |
Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
|
PT3202460T
(pt)
|
2010-02-11 |
2019-08-05 |
Celgene Corp |
Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização
|
WO2011106273A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2011106729A2
(en)
|
2010-02-26 |
2011-09-01 |
Xenon Pharmaceuticals Inc. |
Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
|
ES2542404T3
(es)
|
2010-03-02 |
2015-08-05 |
Axikin Pharmaceuticals, Inc. |
Antagonistas de CCR3 de tipo arilsulfonamida enriquecidos isotópicamente
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
KR101717809B1
(ko)
|
2010-03-11 |
2017-03-17 |
질레드 코네티컷 인코포레이티드 |
이미다조피리딘 syk 억제제
|
KR20130038838A
(ko)
*
|
2010-03-12 |
2013-04-18 |
셀진 코포레이션 |
레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
|
JP5818873B2
(ja)
|
2010-03-17 |
2015-11-18 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
アリールスルホンアミドccr3アンタゴニスト
|
PL2554168T3
(pl)
|
2010-03-29 |
2018-05-30 |
Astellas Pharma Inc. |
Kompozycja farmaceutyczna do kontrolowanego uwalniania
|
CA2795350C
(en)
|
2010-04-05 |
2016-02-09 |
Mannkind Corporation |
Ire-1.alpha. inhibitors
|
CA2794096A1
(en)
|
2010-04-07 |
2011-10-13 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
EP2556082B1
(en)
|
2010-04-08 |
2017-02-22 |
Emory University |
Substituted androst-4-ene diones
|
WO2011133521A2
(en)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
WO2011140360A1
(en)
|
2010-05-05 |
2011-11-10 |
The Trustees Of Columbia University In The City Of New York |
Radiolabeled compounds and uses thereof
|
EP2568904B1
(en)
|
2010-05-10 |
2019-10-02 |
Spinal Modulation Inc. |
Device for reducing migration
|
WO2011146803A1
(en)
|
2010-05-20 |
2011-11-24 |
Synta Pharmaceuticals Corp. |
Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
|
WO2011149824A1
(en)
|
2010-05-24 |
2011-12-01 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
|
NZ603789A
(en)
|
2010-05-26 |
2015-03-27 |
Sunovion Pharmaceuticals Inc |
Heteroaryl compounds and methods of use thereof
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
CN102918031A
(zh)
|
2010-05-28 |
2013-02-06 |
通用电气健康护理有限公司 |
放射标记的化合物及其方法
|
AU2011261501B2
(en)
|
2010-06-01 |
2016-01-21 |
Biotheryx, Inc. |
Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
|
CA2801001A1
(en)
|
2010-06-01 |
2011-12-08 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
|
CN103108868B
(zh)
|
2010-06-07 |
2015-11-25 |
诺沃梅迪科斯有限公司 |
呋喃基化合物及其用途
|
US8299117B2
(en)
|
2010-06-16 |
2012-10-30 |
Metabolex Inc. |
GPR120 receptor agonists and uses thereof
|
TW201215392A
(en)
|
2010-06-16 |
2012-04-16 |
Gilead Sciences Inc |
Use of ranolazine for treating pulmonary hypertension
|
JP5746334B2
(ja)
|
2010-06-16 |
2015-07-08 |
シマベイ セラピューティクス, インコーポレーテッド |
Gpr120受容体作動薬及びその使用
|
CN103037843A
(zh)
|
2010-06-23 |
2013-04-10 |
麦它波莱克斯股份有限公司 |
5-乙基-2-{4-[4-(4-四唑-1-基-苯氧甲基)-噻唑-2-基]-哌啶-1-基}-嘧啶的组合物
|
CN103237548A
(zh)
|
2010-06-30 |
2013-08-07 |
吉利德科学股份有限公司 |
A2b腺苷受体拮抗剂用于治疗肺高血压的应用
|
CA2802288C
(en)
|
2010-07-02 |
2018-08-21 |
Gilead Sciences, Inc. |
Triazolopyridinone compounds as ion channel modulators
|
WO2012003501A2
(en)
|
2010-07-02 |
2012-01-05 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
|
PL2588475T3
(pl)
|
2010-07-02 |
2015-10-30 |
Gilead Sciences Inc |
Inhibitory kinazy regulującej sygnał apoptozy
|
WO2012003968A1
(en)
|
2010-07-06 |
2012-01-12 |
Grünenthal GmbH |
Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
|
US20120015031A1
(en)
|
2010-07-14 |
2012-01-19 |
Grunenthal Gmbh |
Novel gastro-retentive dosage forms
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
US8906943B2
(en)
|
2010-08-05 |
2014-12-09 |
John R. Cashman |
Synthetic compounds and methods to decrease nicotine self-administration
|
WO2012021837A2
(en)
|
2010-08-12 |
2012-02-16 |
Senomyx, Inc. |
Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
|
DK2608782T3
(en)
|
2010-08-24 |
2016-09-05 |
Algiax Pharmaceuticals Gmbh |
New use of leflunomide malononitrilamider
|
EP2611369A2
(en)
|
2010-08-30 |
2013-07-10 |
Sinusys Corporation |
Devices for dilating a paranasal sinus opening and for treating sinusitis
|
EP2611809A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
WO2012030948A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
EP2611502A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
WO2012030913A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
EP2663553B1
(en)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
WO2012030910A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
CA2809983A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
EP2611812A1
(en)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridine and thienopyrimidine compounds and methods of use thereof
|
WO2012030914A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Boisciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
US8821457B2
(en)
|
2010-09-08 |
2014-09-02 |
Johnson & Johnson Vision Care, Inc. |
Punctal plug containing drug formulation
|
AU2011302344B2
(en)
|
2010-09-13 |
2015-01-15 |
Synta Pharmaceuticals Corp. |
HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
|
WO2012050922A2
(en)
|
2010-09-28 |
2012-04-19 |
Depomed, Inc. |
Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
|
WO2012050907A2
(en)
|
2010-09-28 |
2012-04-19 |
The Regents Of The University Of California |
Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
CN103298786B
(zh)
|
2010-10-11 |
2016-01-20 |
埃克希金医药品有限公司 |
芳基磺酰胺盐ccr3拮抗剂
|
EP2627349B1
(en)
|
2010-10-15 |
2016-02-03 |
The Trustees of Columbia University in the City of New York |
Obesity-related genes and their proteins and uses thereof
|
EP3106163A1
(en)
|
2010-10-15 |
2016-12-21 |
Gilead Sciences, Inc. |
Compositions and methods of treating pulmonary hypertension
|
WO2012054535A2
(en)
|
2010-10-18 |
2012-04-26 |
Cerenis Therapeutics Sa |
Compounds, compositions and methods useful for cholesterol mobilisation
|
KR20140114736A
(ko)
|
2010-10-19 |
2014-09-29 |
엘셀릭스 테라퓨틱스 인코포레이티드 |
화학감각 수용체 리간드-기반 요법
|
PL2632451T3
(pl)
|
2010-10-29 |
2018-04-30 |
Algiax Pharmaceuticals Gmbh |
Zastosowanie malononitryloamidów w bólu neuropatycznym
|
US20130289071A1
(en)
|
2010-11-09 |
2013-10-31 |
Synta Pharmaceuticals Corp. |
Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses
|
CA2817577A1
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2012068531A2
(en)
|
2010-11-18 |
2012-05-24 |
The General Hospital Corporation |
Novel compositions and uses of anti-hypertension agents for cancer therapy
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
JP2014500275A
(ja)
|
2010-12-06 |
2014-01-09 |
フォリカ,インコーポレイテッド |
禿頭症を治療するため、および毛髪の成長を促進するための方法
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
WO2012078757A2
(en)
|
2010-12-08 |
2012-06-14 |
Synta Pharmaceuticals Corp. |
Combination breast cancer therapy with hsp90 inhibitory compounds
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US20120157938A1
(en)
|
2010-12-16 |
2012-06-21 |
Tokarski Jason M |
Punctal plug with drug core retention features
|
EP2651400B2
(en)
|
2010-12-16 |
2023-01-18 |
Amgen (Europe) GmbH |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
JP5872585B2
(ja)
|
2010-12-22 |
2016-03-01 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
リン置換キノキサリンタイプピペリジン化合物とその使用
|
EA032906B1
(ru)
|
2010-12-22 |
2019-08-30 |
Пэдью Фарма Л.П. |
Твердая лекарственная форма с контролируемым высвобождением и способы ее получения и применения
|
KR101458334B1
(ko)
|
2010-12-23 |
2014-11-04 |
퍼듀 퍼머 엘피 |
탬퍼 저항성 고체 경구 투여 형태
|
HUE051738T2
(hu)
|
2011-01-07 |
2021-03-29 |
Anji Pharma Us Llc |
Kemoszenzoros receptorligandum-alapú terápiák
|
WO2013103384A1
(en)
|
2012-01-06 |
2013-07-11 |
Elcelyx Therapeutics, Inc. |
Biguanide compositions and methods of treating metabolic disorders
|
EP2663292B9
(en)
|
2011-01-10 |
2017-11-08 |
Celgene Corporation |
Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
|
ES2673114T3
(es)
|
2011-01-10 |
2018-06-19 |
Celgene Corporation |
Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas
|
UA115767C2
(uk)
|
2011-01-10 |
2017-12-26 |
Інфініті Фармасьютікалз, Інк. |
Способи отримання ізохінолінонів і тверді форми ізохінолінонів
|
US8765760B2
(en)
|
2011-01-11 |
2014-07-01 |
Sunovion Pharmaceuticals, Inc. |
[1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
|
WO2012096919A1
(en)
|
2011-01-11 |
2012-07-19 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
ES2555927T3
(es)
|
2011-01-20 |
2016-01-11 |
Bionevia Pharmaceuticals Inc. |
Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
|
JP2014503597A
(ja)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
シチジンアナログの医薬組成物及びその使用方法
|
EP2670426B1
(en)
|
2011-01-31 |
2017-05-10 |
The General Hospital Corporation |
Multimodal trail molecules and uses in cellular therapies
|
AU2012212150B2
(en)
|
2011-02-02 |
2016-09-29 |
Spinal Modulation, Inc |
Devices, systems and methods for the targeted treatment of movement disorders
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
EP2678013A1
(en)
|
2011-02-23 |
2014-01-01 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with radiotherapy
|
EP2678014A2
(en)
|
2011-02-24 |
2014-01-01 |
Synta Pharmaceuticals Corp. |
Prostate cancer therapy with hsp90 inhibitory compounds
|
CA2826649C
(en)
|
2011-02-25 |
2016-07-26 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
US20140045908A1
(en)
|
2011-02-25 |
2014-02-13 |
Synta Pharmaceuticals Corp. |
Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
|
US9795792B2
(en)
|
2011-02-25 |
2017-10-24 |
Medtronic, Inc. |
Emergency mode switching for non-pacing modes
|
WO2012121988A2
(en)
|
2011-03-07 |
2012-09-13 |
Celgene Corporation |
Methods for treating diseases using isoindoline compounds
|
CA2829570C
(en)
|
2011-03-11 |
2019-05-07 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
BR112013023277A2
(pt)
|
2011-03-11 |
2017-06-27 |
Celgene Corp |
métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona
|
US20140057978A1
(en)
|
2011-03-17 |
2014-02-27 |
Algiax Pharmaceuticals Gmbh |
Novel use of benzofuranylsulfonates
|
EP2685983B1
(en)
|
2011-03-17 |
2016-05-18 |
Algiax Pharmaceuticals GmbH |
Novel use of imidazotriazinones
|
WO2012129237A2
(en)
|
2011-03-20 |
2012-09-27 |
Trustees Of Boston University |
Therapeutic agent for emphysema and copd
|
WO2012135299A1
(en)
|
2011-03-28 |
2012-10-04 |
Deuteria Pharmaceuticals Inc |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
EP2691389A1
(en)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
EP2691388A1
(en)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
CA2831582C
(en)
|
2011-03-28 |
2019-01-08 |
Mei Pharma, Inc. |
(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120321590A1
(en)
|
2011-04-06 |
2012-12-20 |
Anadys Pharmaceuticals, Inc. |
Bridged polycyclic compounds
|
AR085942A1
(es)
|
2011-04-07 |
2013-11-06 |
Gilead Sciences Inc |
Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
|
DK2701733T3
(da)
|
2011-04-21 |
2019-05-27 |
Curemark Llc |
Forbindelser til behandling af neuropsykiatriske forstyrrelser
|
ES2601892T3
(es)
|
2011-04-21 |
2017-02-16 |
Mapi Pharma Limited |
Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
|
JP6022548B2
(ja)
|
2011-04-28 |
2016-11-09 |
セルジーン コーポレイション |
Pde4阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物
|
CN103688176A
(zh)
|
2011-04-29 |
2014-03-26 |
细胞基因公司 |
利用cereblon作为预报因子治疗癌和炎性疾病的方法
|
EP2704701B1
(en)
|
2011-05-03 |
2018-01-03 |
PRCL Research Inc. |
Compounds for inflammation and immune-related uses
|
WO2012151474A2
(en)
|
2011-05-04 |
2012-11-08 |
Trustees Of Boston University |
Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
|
US9301874B2
(en)
|
2011-05-06 |
2016-04-05 |
Johnson & Johnson Vision Care, Inc. |
Punctal plugs for controlled release of therapeutic agents
|
NZ617987A
(en)
|
2011-05-10 |
2016-02-26 |
Gilead Sciences Inc |
Fused heterocyclic compounds as sodium channel modulators
|
EP2714038A1
(en)
|
2011-05-24 |
2014-04-09 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
|
MY183704A
(en)
|
2011-06-07 |
2021-03-09 |
Anadys Pharmaceuticals Inc |
[1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
|
RU2011122942A
(ru)
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
AR086709A1
(es)
|
2011-06-22 |
2014-01-15 |
Purdue Pharma Lp |
Antagonistas trpv1 que incluyen sustituyentes dihidroxi y sus usos
|
WO2012177678A2
(en)
|
2011-06-22 |
2012-12-27 |
Celgene Corporation |
Isotopologues of pomalidomide
|
WO2012175698A1
(en)
|
2011-06-23 |
2012-12-27 |
Université Libre de Bruxelles |
Therapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease
|
US8604035B2
(en)
|
2011-06-23 |
2013-12-10 |
Map Pharmaceuticals, Inc. |
Fluoroergoline analogs
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
TWI567061B
(zh)
|
2011-07-01 |
2017-01-21 |
吉李德科學股份有限公司 |
用於治療成癮之化合物
|
NO3175985T3
(el)
|
2011-07-01 |
2018-04-28 |
|
|
TWI478908B
(zh)
|
2011-07-01 |
2015-04-01 |
Gilead Sciences Inc |
作為離子通道調節劑之稠合雜環化合物
|
CA2840986A1
(en)
|
2011-07-07 |
2013-01-10 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
DE102011051653A1
(de)
*
|
2011-07-07 |
2013-01-10 |
Lts Lohmann Therapie-Systeme Ag |
Quellfähige Manteltablette
|
US10702485B2
(en)
|
2011-07-09 |
2020-07-07 |
Syntrix Biosystems Inc. |
Compositions and methods for overcoming resistance to tramadol
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9056877B2
(en)
|
2011-07-19 |
2015-06-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
GB201112987D0
(en)
|
2011-07-28 |
2011-09-14 |
Ge Healthcare Ltd |
Novel compound
|
US9394293B2
(en)
|
2011-08-10 |
2016-07-19 |
Purdue Pharma L.P. |
TRPV1 antagonists including dihydroxy substituent and uses thereof
|
WO2013022872A1
(en)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Gene methylation biomarkers and methods of use thereof
|
CN103930126A
(zh)
|
2011-08-12 |
2014-07-16 |
Bsrc亚历山大.弗莱明 |
Tnf超家族三聚化的抑制剂
|
US20140296176A1
(en)
|
2011-08-19 |
2014-10-02 |
Synta Pharmaceuticals Corp. |
Combination cancer therapy with an hsp90 inhibitor and an antimetabolite
|
DK2959899T3
(en)
|
2011-08-23 |
2017-05-01 |
Cornerstone Therapeutics Inc |
Use of zileuton for the treatment of nasal polyps in patients with cystic fibrosis
|
US8664247B2
(en)
|
2011-08-26 |
2014-03-04 |
Radiorx, Inc. |
Acyclic organonitro compounds for use in treating cancer
|
PE20141371A1
(es)
|
2011-08-29 |
2014-10-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
AR087700A1
(es)
|
2011-08-30 |
2014-04-09 |
Gilead Sciences Inc |
Inhibidores de aldh-2 en el tratamiento de adicciones
|
US9944675B2
(en)
|
2011-09-01 |
2018-04-17 |
University Of Southern California |
Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
|
WO2013039920A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013039855A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
WO2013043925A1
(en)
|
2011-09-21 |
2013-03-28 |
Gilead Sciences, Inc. |
Sodium channel blockers reduce glucagon secretion
|
MX2014003467A
(es)
|
2011-09-23 |
2014-07-30 |
Celgene Corp |
Romidepsina y 5-azacitidina para el tratamiento de linfoma.
|
JP2014526564A
(ja)
|
2011-09-26 |
2014-10-06 |
セルジーン コーポレイション |
化学療法抵抗性癌の併用療法
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
US9610370B2
(en)
|
2011-10-07 |
2017-04-04 |
University Of Virginia Patent Foundation |
Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
|
US20140308260A1
(en)
|
2011-10-07 |
2014-10-16 |
Radiorx, Inc. |
Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
|
CA2850723C
(en)
|
2011-10-07 |
2019-07-09 |
Radiorx, Inc. |
Organonitro thioether compounds and medical uses thereof
|
EP2766041B1
(en)
|
2011-10-12 |
2018-12-05 |
Children's Medical Center Corporation |
Combinatorial compositions and methods of treating hemoglobinopathies
|
MY167575A
(en)
|
2011-10-14 |
2018-09-20 |
Ambit Biosciences Corp |
Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
|
TW201331221A
(zh)
|
2011-10-14 |
2013-08-01 |
Idenix Pharmaceuticals Inc |
嘌呤核苷酸化合物類之經取代的3’,5’-環磷酸酯及用於治療病毒感染之醫藥組成物
|
WO2013064983A1
(en)
|
2011-10-31 |
2013-05-10 |
Xenon Pharmaceuticals Inc. |
Benzenesulfonamide compounds and their use as therapeutic agents
|
US9125884B2
(en)
|
2011-11-01 |
2015-09-08 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
TWI615155B
(zh)
*
|
2011-11-01 |
2018-02-21 |
拜耳股份有限公司 |
滲透活性的陰道遞送系統
|
WO2013067165A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with platinum-containing agents
|
JP2014532712A
(ja)
|
2011-11-02 |
2014-12-08 |
シンタ ファーマシューティカルズ コーポレーション |
トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法
|
US9243037B2
(en)
|
2011-11-10 |
2016-01-26 |
Trustees Of Boston College |
Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
|
CA2854188A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
US9290488B2
(en)
|
2011-12-01 |
2016-03-22 |
Purdue Pharma L.P. |
Azetidine-substituted quinoxalines as opioid receptor like-1 modulators
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013085902A1
(en)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Combination therapy methods for treating an inflammatory breast cancer
|
WO2013086133A1
(en)
|
2011-12-06 |
2013-06-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
JP5946921B2
(ja)
|
2011-12-08 |
2016-07-06 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
四級化ブプレノルフィン類似体
|
SG11201403434YA
(en)
|
2011-12-19 |
2014-09-26 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
EP2793583A4
(en)
|
2011-12-21 |
2015-08-12 |
Map Pharmaceuticals Inc |
NOVEL NEUROMODULATORY CONNECTIONS
|
US8859780B2
(en)
|
2011-12-28 |
2014-10-14 |
Allergan, Inc. |
Benzimidazole derivatives as selective blockers of persistent sodium current
|
US8969583B2
(en)
|
2011-12-28 |
2015-03-03 |
Allergan, Inc. |
3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
|
WO2013101926A1
(en)
|
2011-12-28 |
2013-07-04 |
Allergan, Inc. |
Benzimidazole derivatives as selective blockers of persistent sodium current
|
ES2749620T3
(es)
|
2011-12-30 |
2020-03-23 |
Halozyme Inc |
Variantes de polipéptidos de PH20, formulaciones y usos de los mismos
|
ES2726807T3
(es)
|
2011-12-30 |
2019-10-09 |
Reviva Pharmaceuticals Inc |
Composiciones, síntesis y métodos de uso de derivados de 1-[1-fenil-ciclobutil]isobutilamina
|
PL2800578T3
(pl)
|
2012-01-05 |
2019-05-31 |
Boston Medical Center Corp |
Przekazywanie sygnału przez Slit-Robo do diagnostyki i leczenia choroby nerek
|
BR112014016810A8
(pt)
|
2012-01-06 |
2017-07-04 |
Elcelyx Therapeutics Inc |
composições e métodos para tratamento de distúrbios metabólicos
|
CA2862670A1
(en)
|
2012-01-27 |
2013-08-01 |
Gilead Sciences, Inc. |
Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
|
WO2013119895A1
(en)
|
2012-02-08 |
2013-08-15 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
JP6185490B2
(ja)
|
2012-02-21 |
2017-08-23 |
セルジーン コーポレイション |
3−(4−ニトロ−1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオンの固体形態
|
CA2807716C
(en)
|
2012-02-29 |
2019-06-11 |
Johnson & Johnson Vision Care, Inc. |
Punctal plug with energized containment array
|
CA2862297A1
(en)
|
2012-02-29 |
2013-09-06 |
SinuSys Corporation |
Devices and methods for dilating a paranasal sinus opening and for treating sinusitis
|
US9611253B2
(en)
|
2012-02-29 |
2017-04-04 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
WO2013133708A1
(en)
|
2012-03-07 |
2013-09-12 |
Stichting Vu-Vumc |
Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
|
CA2867467A1
(en)
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
ES2779698T3
(es)
|
2012-03-19 |
2020-08-18 |
Brigham & Womens Hospital Inc |
Factor 11 de diferenciación del crecimiento (GDF) para el tratamiento de afecciones cardiovasculares relacionadas con la edad
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US20140350087A9
(en)
|
2012-03-22 |
2014-11-27 |
Halozyme, Inc. |
Oncovector Nucleic Acid Molecules and Methods of Use
|
EP2830616A1
(en)
|
2012-03-27 |
2015-02-04 |
Incuron LLC |
Curaxins for use in treating breast cancer and method for identifying patients likely to respond
|
WO2013148857A1
(en)
|
2012-03-28 |
2013-10-03 |
Synta Pharmaceuticals Corp. |
Triazole derivatives as hsp90 inhibitors
|
CN108686203A
(zh)
|
2012-04-04 |
2018-10-23 |
哈洛齐梅公司 |
使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
|
CA2868323A1
(en)
|
2012-04-04 |
2013-10-10 |
Synta Pharmaceuticals Corp. |
Novel triazole compounds that modulate hsp90 activity
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
AR092820A1
(es)
|
2012-04-17 |
2015-05-06 |
Purdue Pharma Lp |
Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
|
WO2013158928A2
(en)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Chemosensory receptor ligand-based therapies
|
CA2911041C
(en)
|
2012-05-01 |
2020-12-15 |
Shelley Romayne BOYD |
Methods for treating and diagnosing blinding eye diseases
|
US20150099721A1
(en)
|
2012-05-10 |
2015-04-09 |
Synta Pharmaceuticals Corp. |
Treating cancer with hsp90 inhibitory compounds
|
AR091027A1
(es)
|
2012-05-11 |
2014-12-30 |
Purdue Pharma Lp |
Analogos de benzomorfano y el usos de estos
|
US9074972B2
(en)
|
2012-05-16 |
2015-07-07 |
Dionex Corporation |
Surrogate addition device and a method of analyte concentration
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
AU2013266393B2
(en)
|
2012-05-22 |
2017-09-28 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
WO2013187965A1
(en)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
EP2861256B1
(en)
|
2012-06-15 |
2019-10-23 |
The Brigham and Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
CA3136093A1
(en)
|
2012-06-29 |
2014-01-03 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
AR091739A1
(es)
|
2012-07-11 |
2015-02-25 |
Elcelyx Therapeutics Inc |
Composiciones y metodos para reducir el riesgo cardiometabolico
|
WO2014014427A1
(en)
|
2012-07-16 |
2014-01-23 |
Mahmut Bilgic |
Modified release pharmaceutical tablet formulations
|
BR112015000944A2
(pt)
|
2012-07-16 |
2019-10-15 |
Rhodes Tech |
processo para síntese melhorada de opioide
|
EA029925B1
(ru)
|
2012-07-16 |
2018-05-31 |
Родс Текнолоджис |
Способ усовершенствованного синтеза опиоидов
|
US9085561B2
(en)
|
2012-07-30 |
2015-07-21 |
Purdue Pharma L.P. |
Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
|
EP3698809A1
(en)
|
2012-07-31 |
2020-08-26 |
The Brigham & Women's Hospital, Inc. |
Modulation of the immune response using agents binding tim-3 and ceacam-1
|
PE20191204A1
(es)
|
2012-08-06 |
2019-09-10 |
Firmenich Incorporated |
Modificador del sabor dulce
|
JP6250671B2
(ja)
|
2012-08-09 |
2017-12-20 |
セルジーン コーポレイション |
免疫関連及び炎症性疾患の治療
|
IN2015DN00885A
(el)
|
2012-08-09 |
2015-06-12 |
Celgene Corp |
|
TWI723266B
(zh)
|
2012-08-09 |
2021-04-01 |
美商西建公司 |
利用3-(4-((4-(嗎啉基甲基)苄基)氧基)-1-氧異吲哚啉-2-基)六氫吡啶-2,6-二酮治療癌症之方法
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
US8841340B2
(en)
|
2012-08-17 |
2014-09-23 |
Gilead Sciences, Inc. |
Solid forms of an antiviral compound
|
WO2014030053A1
(en)
|
2012-08-20 |
2014-02-27 |
Rhodes Technologies |
Systems and methods for increasing stability of dronabinol compositions
|
US9382243B2
(en)
|
2012-08-22 |
2016-07-05 |
Merck Sharp & Dohme Corp. |
Azabenzimidazole tetrahydropyran derivatives
|
US9315514B2
(en)
|
2012-08-27 |
2016-04-19 |
Rhodes Technologies |
1,3-dioxanomorphides and 1,3-dioxanocodides
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
US9750705B2
(en)
|
2012-08-31 |
2017-09-05 |
The Regents Of The University Of California |
Agents useful for treating obesity, diabetes and related disorders
|
CN104781240A
(zh)
|
2012-09-07 |
2015-07-15 |
埃克希金医药品有限公司 |
同位素富集的芳基磺酰胺ccr3拮抗剂
|
CN104797256A
(zh)
|
2012-09-10 |
2015-07-22 |
细胞基因公司 |
用于治疗局部晚期乳腺癌的方法
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
GEP201706723B
(en)
|
2012-10-08 |
2017-08-25 |
Idenix Pharmaceuticals Llk |
2'-chloro nucleoside analogs for hcv infection
|
BR112015008118A2
(pt)
|
2012-10-12 |
2017-12-05 |
Brigham & Womens Hospital Inc |
reforço da resposta imune
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
WO2014066239A1
(en)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
2',4'-bridged nucleosides for hcv infection
|
HUE040126T2
(hu)
|
2012-11-01 |
2019-02-28 |
Infinity Pharmaceuticals Inc |
Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával
|
CA2890177A1
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
US20150290171A1
(en)
|
2012-11-09 |
2015-10-15 |
Celgene Corporation |
Methods for the treatment of bone loss
|
US10138207B2
(en)
|
2012-11-09 |
2018-11-27 |
Purdue Pharma, L.P. |
Benzomorphan analogs and the use thereof
|
US20160151321A1
(en)
|
2012-11-13 |
2016-06-02 |
Dinesh C. Patel |
Methods for the treatment of sialorrhea
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
US9670230B2
(en)
|
2012-11-29 |
2017-06-06 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
EP2925718B1
(en)
|
2012-11-30 |
2018-08-01 |
Novomedix, LLC |
Substituted biaryl sulfonamides and the use thereof
|
AR094641A1
(es)
|
2012-12-07 |
2015-08-19 |
Purdue Pharma Lp |
Análogos de buprenorfina
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
JP6141444B2
(ja)
|
2012-12-14 |
2017-06-07 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
スピロ環式モルフィナンおよびこれらの使用
|
US8980906B2
(en)
|
2012-12-14 |
2015-03-17 |
Purdue Pharma L.P. |
Pyridonemorphinan analogs and biological activity on opioid receptors
|
JP6163210B2
(ja)
|
2012-12-14 |
2017-07-12 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
窒素含有モルフィナン誘導体およびその使用
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
ES2685568T3
(es)
|
2012-12-21 |
2018-10-10 |
Gilead Calistoga Llc |
Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa
|
PT2941426T
(pt)
|
2012-12-21 |
2018-07-18 |
Gilead Calistoga Llc |
Quinazolinonas aminoalquis de pirimidina substituída como inibidores de fosfatidilinositol 3-quinase
|
WO2014100354A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
UY35212A
(es)
|
2012-12-21 |
2014-06-30 |
Gilead Sciences Inc |
Inhibidores de la quinasa que regula la señal de la apoptosis
|
US9040533B2
(en)
|
2012-12-27 |
2015-05-26 |
Purdue Pharma L.P. |
Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
|
US9951038B2
(en)
|
2012-12-27 |
2018-04-24 |
Purdue Pharma L.P. |
Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
|
US9090618B2
(en)
|
2012-12-27 |
2015-07-28 |
Purdue Pharma L.P. |
Substituted benzimidazole-type piperidine compounds and uses thereof
|
US9963458B2
(en)
|
2012-12-27 |
2018-05-08 |
Purdue Pharma L.P. |
Indole and indoline-type piperidine compounds and uses thereof
|
WO2014102590A1
(en)
|
2012-12-27 |
2014-07-03 |
Purdue Pharma L.P. |
Substituted piperidin-4-amino-type compounds and uses thereof
|
EP2941430B1
(en)
|
2012-12-28 |
2017-04-26 |
Purdue Pharma LP |
7,8-cyclicmorphinan analogs
|
ES2653265T3
(es)
|
2012-12-28 |
2018-02-06 |
Purdue Pharma Lp |
Morfinanos sustituidos y el uso de éstos
|
JP6359560B2
(ja)
|
2012-12-31 |
2018-07-18 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
複素環式化合物及びその使用方法
|
US20140193498A1
(en)
|
2013-01-05 |
2014-07-10 |
Elcelyx Therapeutics, Inc. |
Compositions and Methods for Treating Metabolic Disorders
|
WO2014107745A1
(en)
|
2013-01-07 |
2014-07-10 |
Halozyme, Inc. |
Metal sensitive mutants of matrix metalloproteases and uses thereof
|
WO2014110127A1
(en)
|
2013-01-08 |
2014-07-17 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
US9617607B2
(en)
|
2013-01-08 |
2017-04-11 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
US8999393B1
(en)
|
2013-01-09 |
2015-04-07 |
Edgemont Pharmaceuticals Llc |
Sustained release formulations of lorazepam
|
MX2015008757A
(es)
|
2013-01-09 |
2016-02-05 |
Edgemont Pharmaceuticals Llc |
Formulaciones de lorazepam de liberacion controlada.
|
CA2897665A1
(en)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamins c and k for treating polycystic diseases
|
AU2014205043B2
(en)
|
2013-01-14 |
2018-10-04 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
WO2014116573A1
(en)
|
2013-01-22 |
2014-07-31 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
CA2899455C
(en)
|
2013-01-30 |
2021-06-08 |
Pharmorx Therapeutics, Inc. |
Treatments for depression and other diseases with a low dose agent
|
JP6182620B2
(ja)
|
2013-01-31 |
2017-08-16 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
ベンゾモルファン類似体およびその使用
|
CN105120846B
(zh)
|
2013-02-05 |
2019-10-18 |
普渡制药公司 |
抗篡改的药物制剂
|
BR112015019546A2
(pt)
|
2013-02-15 |
2017-07-18 |
Allergan Inc |
implante de distribuição de drogas prolongado
|
JO3155B1
(ar)
|
2013-02-19 |
2017-09-20 |
Senomyx Inc |
معدِّل نكهة حلوة
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
WO2014134419A1
(en)
|
2013-03-01 |
2014-09-04 |
Gilead Sciences, Inc. |
Use of ikach blockers for the treatment of cardiac diseases
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
CN105050624A
(zh)
|
2013-03-14 |
2015-11-11 |
细胞基因公司 |
利用阿普斯特来治疗银屑病关节炎的方法
|
CA2904444A1
(en)
|
2013-03-15 |
2014-09-18 |
The Regents Of The University Of California |
Dual reactivity potent kunitz inhibitor of fibrinolysis
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
CA2905131A1
(en)
|
2013-03-15 |
2014-09-18 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
US8969358B2
(en)
|
2013-03-15 |
2015-03-03 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
BR112015023705A8
(pt)
|
2013-03-15 |
2020-03-17 |
Univ California |
compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
JP6041823B2
(ja)
|
2013-03-16 |
2016-12-14 |
ファイザー・インク |
トファシチニブの経口持続放出剤形
|
TWI530499B
(zh)
|
2013-03-28 |
2016-04-21 |
吉李德科學股份有限公司 |
作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
BR112015025252A2
(pt)
|
2013-04-02 |
2017-07-18 |
Celgene Corp |
métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
|
JP2016518357A
(ja)
|
2013-04-08 |
2016-06-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
骨格筋幹細胞を若返らせる方法および組成物
|
BR112015027631A2
(pt)
|
2013-04-30 |
2017-08-22 |
Abbvie Inc |
Métodos para melhorar perfis de lipídeo usando atrasentana
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
US9687263B2
(en)
|
2013-05-30 |
2017-06-27 |
SinuSys Corporation |
Devices and methods for inserting a sinus dilator
|
BR112015029969A2
(pt)
|
2013-05-30 |
2017-07-25 |
Infinity Pharmaceuticals Inc |
tratamento de câncer usando moduladores de isoformas quinase pi3
|
EP3003297A4
(en)
|
2013-06-05 |
2017-04-19 |
Synchroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
EP3004396B1
(en)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Compositions for the treatment of cancer
|
US20160220640A1
(en)
|
2013-06-11 |
2016-08-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for increasing neurogenesis and angiogenesis
|
CN105705152B
(zh)
|
2013-06-14 |
2021-07-09 |
阿卡玛拉疗法有限公司 |
基于脂质的铂化合物和纳米粒子
|
SI3008053T1
(en)
|
2013-06-14 |
2018-06-29 |
Gilead Calistoga Llc |
PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
US20160120861A1
(en)
|
2013-06-28 |
2016-05-05 |
Purdue Pharma L.P. |
Compositions and Methods for Treating an Arrhythmia with an Opioid Antagonist
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
WO2015009534A2
(en)
|
2013-07-16 |
2015-01-22 |
Allergan, Inc. |
Hcn inhibitors affecting ganglion cell function and visual function
|
UA116567C2
(uk)
|
2013-07-23 |
2018-04-10 |
Євро-Селтік С.А. |
Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
|
AU2014296184B2
(en)
|
2013-07-31 |
2017-04-27 |
Gilead Sciences, Inc. |
Syk inhibitors
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
WO2015015146A1
(en)
|
2013-08-02 |
2015-02-05 |
Johnson Matthey Public Limited Company |
Process for the preparation of oxymorphone
|
WO2015027146A1
(en)
|
2013-08-22 |
2015-02-26 |
The General Hospital Corporation |
Inhibitors of human 12/15-lipoxygenase
|
EP3038625A4
(en)
|
2013-08-29 |
2017-08-23 |
Trustees of Boston University |
Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
|
EP3039021A1
(en)
|
2013-08-30 |
2016-07-06 |
Ambit Biosciences Corporation |
Biaryl acetamide compounds and methods of use thereof
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
US20160213659A1
(en)
|
2013-09-24 |
2016-07-28 |
George Sylvestre |
Treatment of burn pain by trpv1 modulators
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EA201690713A1
(ru)
|
2013-10-04 |
2016-08-31 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения и их применения
|
CN105899679A
(zh)
|
2013-10-21 |
2016-08-24 |
通用医疗公司 |
与循环肿瘤细胞簇有关的方法以及癌症的治疗
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
US9750757B2
(en)
|
2013-10-29 |
2017-09-05 |
Thomas Jefferson University |
Methods of prevention or treatment for pathologic thrombosis or inflammation
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
GB201319792D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
WO2015081073A2
(en)
|
2013-11-26 |
2015-06-04 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
JP6262363B2
(ja)
|
2013-11-26 |
2018-01-17 |
ギリアード サイエンシーズ, インコーポレイテッド |
ブロモドメイン阻害剤としてのキノリン誘導体
|
EP3074411A2
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
Nucleotides for the treatment of liver cancer
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
KR20180002888A
(ko)
|
2013-12-04 |
2018-01-08 |
길리애드 사이언시즈, 인코포레이티드 |
암을 치료하는 방법
|
AU2014362307A1
(en)
|
2013-12-11 |
2016-06-30 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
MX2016008077A
(es)
|
2013-12-19 |
2016-10-12 |
Gilead Sciences Inc |
Compuestos heterociclicos fusionados como moduladores del canal ionico.
|
WO2015095527A1
(en)
|
2013-12-20 |
2015-06-25 |
The General Hosptial Corporation |
Methods and assays relating to circulating tumor cells
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
UY35898A
(es)
|
2013-12-23 |
2015-07-31 |
Gilead Sciences Inc |
?compuestos inhibidores de syk y composiciones que los comprenden?.
|
WO2015097547A1
(en)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
10-substituted morphinan hydantoins
|
US9340542B2
(en)
|
2013-12-26 |
2016-05-17 |
Purdue Pharma L.P. |
Propellane-based compounds and the use thereof
|
EP3087078B1
(en)
|
2013-12-26 |
2019-05-15 |
Purdue Pharma LP |
7-beta-alkyl analogs of orvinols
|
US9862726B2
(en)
|
2013-12-26 |
2018-01-09 |
Purdue Pharma L.P. |
Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
|
WO2015099863A1
(en)
|
2013-12-27 |
2015-07-02 |
Purdue Pharma L.P. |
6-substituted and 7-substituted morphinan analogs and the use thereof
|
EP3089978B1
(en)
|
2013-12-30 |
2018-08-29 |
Purdue Pharma L.P. |
Pyridone-sulfone morphinan analogs as opioid receptor ligands
|
EP3094328B1
(en)
|
2014-01-15 |
2020-08-19 |
Poxel SA |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
CN106029669B
(zh)
|
2014-01-15 |
2018-04-13 |
罗德科技公司 |
改进的羟二氢吗啡酮合成的方法
|
AU2015207733A1
(en)
|
2014-01-15 |
2016-07-14 |
Rhodes Technologies |
Process for improved oxycodone synthesis
|
WO2015112568A1
(en)
|
2014-01-24 |
2015-07-30 |
Celgene Corporation |
Methods for the treatment of obesity using apremilast
|
ES2874533T3
(es)
|
2014-02-05 |
2021-11-05 |
VM Oncology LLC |
Composiciones de compuestos y usos de los mismos
|
EP3114122A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
EP3116507B1
(en)
|
2014-03-10 |
2021-05-26 |
Kadmon Corporation, LLC |
Compounds for oral treatment of brain tumors
|
EP3119744B1
(en)
|
2014-03-18 |
2019-03-06 |
Algiax Pharmaceuticals GmbH |
2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
|
DK3119397T3
(da)
|
2014-03-19 |
2022-03-28 |
Infinity Pharmaceuticals Inc |
Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
|
US11369588B2
(en)
|
2014-03-20 |
2022-06-28 |
The Trustees Of Princeton University |
NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
|
AU2015231215B2
(en)
|
2014-03-20 |
2019-07-18 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
|
PT3119762T
(pt)
|
2014-03-20 |
2021-08-31 |
Capella Therapeutics Inc |
Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
|
US9062063B1
(en)
|
2014-03-21 |
2015-06-23 |
Johnson Matthey Public Limited Company |
Forms of oxymorphone hydrochloride
|
US20170107300A1
(en)
|
2014-03-21 |
2017-04-20 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
US20150283149A1
(en)
|
2014-04-02 |
2015-10-08 |
Gilead Sciences, Inc. |
Methods of treating patients having implantable cardiac devices
|
WO2015153345A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
EP3125905A4
(en)
|
2014-04-04 |
2017-11-08 |
Ritter Pharmaceuticals, Inc. |
Methods and compositions for microbiome alteration
|
AU2015243437B2
(en)
|
2014-04-09 |
2019-08-29 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxins useful for the treatment of pain
|
WO2015155281A1
(en)
|
2014-04-11 |
2015-10-15 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical combinations of dabigatran and proton pump inhibitors
|
WO2015155307A1
(en)
|
2014-04-11 |
2015-10-15 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
US20170045528A1
(en)
|
2014-04-25 |
2017-02-16 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
EP3134041A1
(en)
|
2014-04-25 |
2017-03-01 |
Johnson & Johnson Vision Care Inc. |
Method and ophthalmic device with active agent release system
|
EP3804745A1
(en)
|
2014-04-25 |
2021-04-14 |
The Brigham and Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
BR112016026560A2
(pt)
|
2014-05-12 |
2017-08-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma complicação de uma doença hepática crônica, método para tratar hipertensão portal, método para inibir uma cascata de sinalização de tnf-a e de a-fas; composição farmacêutica, kit, método de tratamento, método para tratar uma afecção
|
WO2015175773A1
(en)
|
2014-05-15 |
2015-11-19 |
Celgene Corporation |
Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
US20170087129A1
(en)
|
2014-05-16 |
2017-03-30 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
CN106573872B
(zh)
|
2014-05-19 |
2021-07-20 |
东北大学 |
5-羟色胺受体靶向化合物和方法
|
EP3145500A1
(en)
|
2014-05-23 |
2017-03-29 |
Sigmoid Pharma Limited |
Celecoxib formulations useful for treating colorectal cancer
|
WO2015181624A2
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals, Inc |
Nucleoside derivatives for the treatment of cancer
|
AU2015270925A1
(en)
|
2014-06-02 |
2016-12-22 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
US10076504B2
(en)
|
2014-06-12 |
2018-09-18 |
Ligand Pharmaceuticals, Inc. |
Glucagon antagonists
|
EP3154962B1
(en)
|
2014-06-13 |
2019-08-07 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
CA2952012A1
(en)
|
2014-06-13 |
2015-12-17 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
US20150359810A1
(en)
|
2014-06-17 |
2015-12-17 |
Celgene Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
WO2015195474A1
(en)
|
2014-06-18 |
2015-12-23 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
EA034691B1
(ru)
|
2014-06-19 |
2020-03-06 |
Ариад Фармасьютикалз, Инк. |
Гетероарильные соединения для ингибирования киназ
|
EP3157520B1
(en)
|
2014-06-23 |
2019-09-04 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
WO2015200795A1
(en)
|
2014-06-27 |
2015-12-30 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
BR112016028641A2
(pt)
|
2014-07-14 |
2017-08-22 |
Gilead Sciences Inc |
?método para tratar câncer?
|
CA2910865C
(en)
|
2014-07-15 |
2016-11-29 |
Isa Odidi |
Compositions and methods for reducing overdose
|
CN106794233B
(zh)
|
2014-08-01 |
2021-11-12 |
布里格姆及妇女医院股份有限公司 |
与肺动脉高压的治疗有关的组合物和方法
|
WO2016025686A1
(en)
|
2014-08-15 |
2016-02-18 |
Celgene Corporation |
Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
|
EA201790439A1
(ru)
|
2014-08-22 |
2017-07-31 |
Селджин Корпорейшн |
Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
|
ES2727137T3
(es)
|
2014-08-28 |
2019-10-14 |
Halozyme Inc |
Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
|
WO2016033472A1
(en)
|
2014-08-29 |
2016-03-03 |
Children's Medical Center Corporation |
Methods and compositions for the treatment of cancer
|
WO2016040860A1
(en)
|
2014-09-12 |
2016-03-17 |
Tobira Therapeutics, Inc. |
Cenicriviroc combination therapy for the treatment of fibrosis
|
EP3193872A4
(en)
|
2014-09-14 |
2018-02-28 |
Avanir Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
|
PL3194411T3
(pl)
|
2014-09-15 |
2022-06-20 |
The Regents Of The University Of California |
Analogi nukleotydów
|
EP3194446B1
(en)
|
2014-09-18 |
2022-10-26 |
Cedars-Sinai Medical Center |
Compositions and methods for treating fibrosis
|
SG11201701724VA
(en)
|
2014-09-26 |
2017-04-27 |
Gilead Sciences Inc |
Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
US9353093B2
(en)
|
2014-10-07 |
2016-05-31 |
Allergan, Inc. |
Indole-1-carboxamides as kinase inhibitors
|
US9403803B2
(en)
|
2014-10-08 |
2016-08-02 |
Allergan, Inc. |
Indole-3-carboxamides as kinase inhibitors
|
US9359336B2
(en)
|
2014-10-09 |
2016-06-07 |
Allergan, Inc. |
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
|
US9296747B1
(en)
|
2014-10-10 |
2016-03-29 |
Allergan, Inc. |
Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
|
PL3207130T3
(pl)
|
2014-10-14 |
2020-02-28 |
Halozyme, Inc. |
Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
|
WO2016109002A2
(en)
|
2014-10-16 |
2016-07-07 |
Cleveland Biolabs, Inc. |
Methods and compositions for the treatment of radiation-related disorders
|
US10385078B2
(en)
|
2014-10-21 |
2019-08-20 |
Ariad Pharmaceuticals, Inc. |
Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
CA2936748C
(en)
|
2014-10-31 |
2017-08-08 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
ES2858517T3
(es)
|
2014-11-07 |
2021-09-30 |
Sublimity Therapeutics Ltd |
Composiciones que comprenden ciclosporina
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
MX2017007955A
(es)
|
2014-12-16 |
2018-02-19 |
Celgene Corp |
Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
|
MA41252A
(fr)
|
2014-12-23 |
2017-10-31 |
Gilead Sciences Inc |
Formes solides d'un inhibiteur d'ask 1
|
SG11201705088VA
(en)
|
2014-12-23 |
2017-07-28 |
Axikin Pharmaceuticals Inc |
3,5-diaminopyrazole kinase inhibitors
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
JP6787926B2
(ja)
|
2015-01-12 |
2020-11-18 |
レビバ ファーマシューティカルズ,インコーポレイティド |
肺高血圧症の治療方法
|
JP2018502157A
(ja)
|
2015-01-12 |
2018-01-25 |
レビバ ファーマシューティカルズ,インコーポレイティド |
アルツハイマー病の治療方法
|
EP3244926A4
(en)
|
2015-01-14 |
2018-06-27 |
The Brigham and Women's Hospital, Inc. |
Treatment of cancer with anti-lap monoclonal antibodies
|
EP3253753A4
(en)
|
2015-01-20 |
2018-06-27 |
Xoc Pharmaceuticals, Inc |
Ergoline compounds and uses thereof
|
US9676776B2
(en)
|
2015-01-20 |
2017-06-13 |
Xoc Pharmaceuticals, Inc. |
Isoergoline compounds and uses thereof
|
US9918979B2
(en)
|
2015-01-29 |
2018-03-20 |
Johnson Matthey Public Limited Company |
Process of preparing low ABUK oxymorphone hydrochloride
|
WO2016127068A1
(en)
|
2015-02-05 |
2016-08-11 |
Teva Pharmaceuticals International Gmbh |
Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
|
EP3256161A1
(en)
|
2015-02-09 |
2017-12-20 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
|
EP3258916A1
(en)
|
2015-02-20 |
2017-12-27 |
Osmotica Kereskedelmi ES Szolgaltato KFT |
Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
|
CN107660207B
(zh)
|
2015-03-10 |
2020-09-29 |
罗德科技公司 |
丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
CN114366802A
(zh)
|
2015-04-22 |
2022-04-19 |
西达-赛奈医疗中心 |
用于治疗2型糖尿病的肠内递送的苦味寡肽
|
US10010502B2
(en)
|
2015-05-19 |
2018-07-03 |
Amorphex Therapeutics Llc |
Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
|
EP3303361A1
(en)
|
2015-05-27 |
2018-04-11 |
Idenix Pharmaceuticals LLC |
Nucleotides for the treatment of cancer
|
WO2016196664A1
(en)
|
2015-06-01 |
2016-12-08 |
Cedars-Sinai Medical Center |
Methods and use of compounds that bind to rela of nf-kb
|
WO2016202721A1
(en)
|
2015-06-16 |
2016-12-22 |
F. Hoffmann-La Roche Ag |
Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
|
MX2017017015A
(es)
|
2015-06-23 |
2018-02-26 |
Neurocrine Biosciences Inc |
Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
WO2017004532A1
(en)
|
2015-07-02 |
2017-01-05 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
CA2971640C
(en)
|
2015-07-06 |
2020-09-22 |
Gilead Sciences, Inc. |
Cot modulators and methods of use thereof
|
RU2018107227A
(ru)
|
2015-07-28 |
2019-08-28 |
Виоме Терапьютикс Лимитед |
Терапевтические и профилактические антибактериальные средства
|
US10940204B2
(en)
|
2015-07-31 |
2021-03-09 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
PT3385395T
(pt)
|
2015-08-17 |
2020-05-06 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
AU2016310521A1
(en)
|
2015-08-27 |
2018-03-01 |
Massachusetts Institute Of Technology |
Compositions and methods for treatment of pain
|
WO2017044807A2
(en)
|
2015-09-09 |
2017-03-16 |
The Trustees Of Columbia University In The City Of New York |
Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
|
US10172842B2
(en)
|
2015-09-11 |
2019-01-08 |
PharmaDax Inc. |
Sustained release oral dosage form containing dalfampridine
|
WO2017050259A1
(en)
|
2015-09-23 |
2017-03-30 |
Xw Laboratories Inc. |
Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
|
WO2017058828A1
(en)
|
2015-09-28 |
2017-04-06 |
Children's Hospital Los Angeles |
Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
|
CN108473503A
(zh)
|
2015-09-30 |
2018-08-31 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
SG11201801984TA
(en)
|
2015-10-01 |
2018-04-27 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
AU2016332071B2
(en)
|
2015-10-01 |
2019-04-18 |
Elysium Therapeutics, Inc. |
Polysubunit opioid prodrugs resistant to overdose and abuse
|
US10335406B2
(en)
|
2015-10-01 |
2019-07-02 |
Elysium Therapeutics, Inc. |
Opioid compositions resistant to overdose and abuse
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017066719A2
(en)
|
2015-10-14 |
2017-04-20 |
Research Institute At Nationwide Children's Hospital |
Hu specific interfering agents
|
US20180312534A1
(en)
|
2015-10-16 |
2018-11-01 |
Invictus Oncology Pvt. Ltd. |
Fluorescent anticancer platinum drugs
|
US10342778B1
(en)
|
2015-10-20 |
2019-07-09 |
Epicentrx, Inc. |
Treatment of brain metastases using organonitro compound combination therapy
|
US9987270B1
(en)
|
2015-10-29 |
2018-06-05 |
Epicentrix, Inc. |
Treatment of gliomas using organonitro compound combination therapy
|
MA43116B1
(fr)
|
2015-10-30 |
2021-04-30 |
Neurocrine Biosciences Inc |
Ditosylate de valbénazine et polymorphes associés
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
WO2017083348A1
(en)
|
2015-11-11 |
2017-05-18 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
CA3006772A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Tank-binding kinase inhibitor compounds
|
JP6869988B2
(ja)
|
2015-12-23 |
2021-05-12 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
(S)−(2R,3R,11bR)−3−イソブチル−9,10−ジメトキシ−2,3,4,6,7,11b−ヘキサヒドロ−1H−ピリド[2,1−a]イソキノリン−2−イル2−アミノ−3−メチルブタノエートジ(4−メチルベンゼンスルホネート)の調製のための合成方法
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
RU2018127752A
(ru)
|
2015-12-31 |
2020-01-31 |
Конатус Фармасьютикалз Инк. |
Способы применения ингибиторов каспаз при лечении заболеваний печени
|
JP7071922B2
(ja)
|
2016-01-08 |
2022-05-19 |
セルジーン コーポレイション |
2-(4-クロロフェニル)-n-((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-イル)メチル)-2,2-ジフルオロアセトアミドの固体形態、ならびにそれらの薬学的組成物及び使用
|
EP3399980A4
(en)
|
2016-01-08 |
2019-09-04 |
Celgene Corporation |
METHODS OF TREATING CANCER AND USE OF BIOMARKERS AS FACTORS PREDICTIVE OF CLINICAL SENSITIVITY TO TREATMENTS
|
PL3399978T3
(pl)
|
2016-01-08 |
2021-04-06 |
Celgene Corporation |
Związki antyproliferacyjne oraz ich kompozycje farmaceutyczne i zastosowania
|
KR20190040931A
(ko)
|
2016-01-11 |
2019-04-19 |
에피센트알엑스, 인코포레이티드 |
2-브로모-1-(3,3-디니트로아제티딘-1-일)에타논의 정맥내 투여를 위한 조성물 및 방법
|
ES2877568T3
(es)
|
2016-02-05 |
2021-11-17 |
Orionis Biosciences Nv |
Agentes de unión de Clec9A
|
PL3416964T3
(pl)
|
2016-02-19 |
2021-10-18 |
Phoenix Molecular Designs |
Pochodne 6-okso-n-(1-(benzylo)-1h-pirazol-4-ilo)-6,7,8,9-tetrahydropirydo[3’,2’:4,5]pirolo[1,2-a]pirazyno-2-karboksyamidu jako inhibitory kinazy rybosomalnej s6 p90 (rsk) do leczenia nowotworu złośliwego
|
US20190119236A1
(en)
|
2016-02-23 |
2019-04-25 |
Portola Pharmaceuticals, Inc. |
Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
|
EP3423041A4
(en)
|
2016-03-04 |
2019-09-11 |
Charleston Laboratories, Inc. |
PHARMACEUTICAL COMPOSITIONS
|
JP2019510752A
(ja)
|
2016-03-04 |
2019-04-18 |
ギリアード サイエンシーズ, インコーポレイテッド |
オートタキシン阻害剤の組成物及び合剤
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
WO2017168174A1
(en)
|
2016-04-02 |
2017-10-05 |
N4 Pharma Uk Limited |
New pharmaceutical forms of sildenafil
|
EP3442940A1
(en)
|
2016-04-11 |
2019-02-20 |
Clexio Biosciences Ltd. |
Deuterated ketamine derivatives
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
US11497738B2
(en)
|
2016-04-29 |
2022-11-15 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
CN109071518A
(zh)
|
2016-05-04 |
2018-12-21 |
普渡制药公司 |
噁唑啉假二聚体、药物组合物及其用途
|
CN109689087B
(zh)
|
2016-05-13 |
2023-04-04 |
奥里尼斯生物科学私人有限公司 |
靶向性突变干扰素-β及其用途
|
CN109563141A
(zh)
|
2016-05-13 |
2019-04-02 |
奥里尼斯生物科学公司 |
对非细胞结构的治疗性靶向
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
AU2017268006B2
(en)
|
2016-05-20 |
2021-03-11 |
Xenon Pharmaceuticals Inc. |
Benzenesulfonamide compounds and their use as therapeutic agents
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
AU2017289158C1
(en)
|
2016-06-30 |
2020-07-23 |
Gilead Sciences, Inc. |
4,6-diaminoquinazolines as Cot modulators and methods of use thereof
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
US20190282560A1
(en)
|
2016-07-18 |
2019-09-19 |
Pharmena S.A. |
1-Methylnicotinamide for the Treatment of Diseases Associated With C-Reactive Protein
|
JOP20190008A1
(ar)
|
2016-07-26 |
2019-01-24 |
Purdue Pharma Lp |
علاج ومنع اضطرابات النوم
|
SG11201900687VA
(en)
|
2016-07-29 |
2019-02-27 |
Sunovion Pharmaceuticals Inc |
Compounds and compositions and uses thereof
|
UA125519C2
(uk)
|
2016-07-29 |
2022-04-13 |
Суновіон Фармасьютікалз Інк. |
Сполуки і композиції і їх застосування
|
AU2017305392A1
(en)
|
2016-08-03 |
2019-02-21 |
Cymabay Therapeutics, Inc. |
Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
CA3036195A1
(en)
|
2016-09-07 |
2018-03-15 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
US10736905B1
(en)
|
2016-09-09 |
2020-08-11 |
Shahin Fatholahi |
Nefopam dosage forms and methods of treatment
|
US10111882B2
(en)
|
2016-09-14 |
2018-10-30 |
Gilead Sciences, Inc. |
SYK inhibitors
|
TW201822764A
(zh)
|
2016-09-14 |
2018-07-01 |
美商基利科學股份有限公司 |
Syk抑制劑
|
WO2018053437A1
(en)
|
2016-09-19 |
2018-03-22 |
Mei Pharma, Inc. |
Combination therapy
|
WO2018057808A1
(en)
|
2016-09-23 |
2018-03-29 |
Gilead Sciences, Inc. |
Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP4112053B1
(en)
|
2016-10-11 |
2024-02-14 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Treatment of synucleinopathies
|
US11154591B2
(en)
|
2016-10-14 |
2021-10-26 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
BR112019007453A2
(pt)
|
2016-10-14 |
2019-07-16 |
Epicentrx Inc |
organonitro de sulfoxialquila e compostos relacionados e composições farmacêuticas para uso em medicina
|
US11878000B2
(en)
|
2016-10-21 |
2024-01-23 |
Da Zen Theranostics, Inc. |
Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors
|
US11084859B2
(en)
|
2016-10-24 |
2021-08-10 |
Orionis Biosciences BV |
Targeted mutant interferon-gamma and uses thereof
|
MX2019005065A
(es)
|
2016-11-03 |
2019-08-21 |
Kura Oncology Inc |
Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
CN116987014A
(zh)
|
2016-11-09 |
2023-11-03 |
诺沃梅迪科斯有限公司 |
1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
|
AU2017364901A1
(en)
|
2016-11-28 |
2019-06-13 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
US11261188B2
(en)
|
2016-11-28 |
2022-03-01 |
Praxis Precision Medicines, Inc. |
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
|
AR110252A1
(es)
|
2016-11-30 |
2019-03-13 |
Gilead Sciences Inc |
Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
|
EP3548007A4
(en)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
CANCER TREATMENT METHODS
|
EP3548027A1
(en)
|
2016-12-02 |
2019-10-09 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
RU2760303C2
(ru)
|
2016-12-09 |
2021-11-23 |
Ксенон Фармасьютикалз Инк. |
Соединения бензолсульфонамидов и их использование в качестве терапевтических средств
|
WO2018115888A1
(en)
|
2016-12-21 |
2018-06-28 |
N4 Pharma Uk Limited |
Novel formulations of aprepitant
|
US10784877B2
(en)
|
2016-12-21 |
2020-09-22 |
Johnson & Johnson Vision Care, Inc. |
Extended period timer circuits for ophthalmic devices
|
EP3565834A1
(en)
|
2017-01-04 |
2019-11-13 |
The Research Institute at Nationwide Children's Hospital |
Antibody fragments for the treatment of biofilm-related disorders
|
JP2020513838A
(ja)
|
2017-01-04 |
2020-05-21 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Dnabiiワクチンおよび強化された活性を有する抗体
|
KR20200066662A
(ko)
|
2017-01-27 |
2020-06-10 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
WO2018140671A1
(en)
|
2017-01-27 |
2018-08-02 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
US11384154B2
(en)
|
2017-02-06 |
2022-07-12 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
NZ753781A
(en)
|
2017-02-06 |
2022-10-28 |
Spero Therapeutics Inc |
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
|
US10906985B2
(en)
|
2017-02-06 |
2021-02-02 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
JOP20180009A1
(ar)
|
2017-02-06 |
2019-01-30 |
Gilead Sciences Inc |
مركبات مثبط فيروس hiv
|
EP3580230A1
(en)
|
2017-02-07 |
2019-12-18 |
VIB vzw |
Immune-cell targeted bispecific chimeric proteins and uses thereof
|
WO2018148745A1
(en)
|
2017-02-13 |
2018-08-16 |
Praxis Precision Medicines , Inc. |
Compounds and their methods of use
|
JP7146782B2
(ja)
|
2017-02-16 |
2022-10-04 |
サノビオン ファーマシューティカルズ インク |
統合失調症を処置する方法
|
SG11201907594TA
(en)
|
2017-02-21 |
2019-09-27 |
Kura Oncology Inc |
Methods of treating cancer with farnesyltransferase inhibitors
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP4249503A3
(en)
|
2017-02-27 |
2023-12-20 |
Shattuck Labs, Inc. |
Vsig8-based chimeric proteins
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
WO2018165142A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
AU2018234911B2
(en)
|
2017-03-17 |
2024-04-18 |
Elysium Therapeutics, Inc. |
Polysubunit opioid prodrugs resistant to overdose and abuse
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
EP3600553A4
(en)
|
2017-03-26 |
2020-09-02 |
Mapi Pharma Ltd. |
GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
|
CA3058214A1
(en)
|
2017-03-29 |
2018-10-04 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
US11279706B2
(en)
|
2017-03-29 |
2022-03-22 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
US11731966B2
(en)
|
2017-04-04 |
2023-08-22 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
WO2018195471A1
(en)
|
2017-04-21 |
2018-10-25 |
Gilead Sciences, Inc. |
Syk inhibitors in combination with hypomethylating agents
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
WO2018213807A1
(en)
|
2017-05-19 |
2018-11-22 |
Nflection Therapeutics, Inc. |
Fused heteroaromatic-aniline compounds for treatment of dermal disorders
|
MX2019013561A
(es)
|
2017-05-19 |
2022-02-09 |
Nflection Therapeutics Inc |
Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
|
WO2018222831A1
(en)
|
2017-05-31 |
2018-12-06 |
The Children's Medical Center Corporation |
TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA
|
AU2018275873A1
(en)
|
2017-06-01 |
2019-12-19 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
WO2018236873A1
(en)
|
2017-06-19 |
2018-12-27 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION
|
WO2019005874A1
(en)
|
2017-06-26 |
2019-01-03 |
The Trustees Of Columbia University In The City Of New York |
CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
|
IL271777B1
(en)
|
2017-07-07 |
2024-05-01 |
Epicentrx Inc |
Preparations for intravenous administration of medical substances
|
CA3069523A1
(en)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
CA3070993A1
(en)
|
2017-08-02 |
2019-02-07 |
Sunovion Pharmaceuticals Inc. |
Isochroman compounds and uses thereof
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
KR20200051601A
(ko)
|
2017-08-07 |
2020-05-13 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암을 치료하는 방법
|
US11278535B2
(en)
|
2017-08-15 |
2022-03-22 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
TWI687415B
(zh)
|
2017-08-17 |
2020-03-11 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
CA3073376C
(en)
|
2017-08-22 |
2022-07-12 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
US10736874B1
(en)
|
2017-09-08 |
2020-08-11 |
Shahin Fatholahi |
Methods for treating pain associated with sickle cell disease
|
US11446311B2
(en)
|
2017-09-08 |
2022-09-20 |
Shahin Fatholahi |
Methods for treating pain associated with sickle cell disease
|
MX2020002841A
(es)
|
2017-09-21 |
2020-07-22 |
Neurocrine Biosciences Inc |
Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
EA202090932A1
(ru)
|
2017-10-10 |
2021-05-20 |
Нейрокрин Байосайенсиз, Инк |
Способы введения некоторых vmat2-ингибиторов
|
JOP20180092A1
(ar)
|
2017-10-13 |
2019-04-13 |
Gilead Sciences Inc |
مثبطات hiv بروتياز
|
WO2019094777A1
(en)
|
2017-11-13 |
2019-05-16 |
Gilead Sciences, Inc. |
Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
|
EP3713916A1
(en)
|
2017-11-20 |
2020-09-30 |
Kiakos, Konstantinos |
3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
WO2019118984A2
(en)
|
2017-12-15 |
2019-06-20 |
Solarea Bio, Inc. |
Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
|
EP3727387A4
(en)
|
2017-12-18 |
2021-12-15 |
Sterngreene, Inc. |
PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
|
WO2019164593A2
(en)
|
2018-01-08 |
2019-08-29 |
Epicentrx, Inc. |
Methods and compositions utilizing rrx-001 combination therapy for radioprotection
|
CA3087856A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
US20210052529A1
(en)
|
2018-01-10 |
2021-02-25 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
WO2019145850A1
(en)
|
2018-01-24 |
2019-08-01 |
Purdue Pharma L. P. |
Sleep disorder treatment and prevention
|
AU2019215440A1
(en)
|
2018-02-05 |
2020-08-27 |
Orionis Biosciences, Inc. |
Fibroblast binding agents and use thereof
|
AU2019217207A1
(en)
|
2018-02-12 |
2020-08-27 |
Diabetes-Free, Inc. |
Improved antagonistic anti-human CD40 monoclonal antibodies
|
JP7083398B2
(ja)
|
2018-02-15 |
2022-06-10 |
ギリアード サイエンシーズ, インコーポレイテッド |
ピリジン誘導体およびhiv感染を処置するためのその使用
|
CA3175384A1
(en)
|
2018-02-16 |
2019-08-22 |
Gilead Sciences, Inc. |
Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
|
JP2021513972A
(ja)
|
2018-02-16 |
2021-06-03 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
社会的機能障害の治療方法
|
JP2021513987A
(ja)
|
2018-02-16 |
2021-06-03 |
エスペリオン・セラピューティクス・インコーポレイテッドEsperion Therapeutics, Inc. |
ベンペド酸の持続放出製剤
|
CA3090807A1
(en)
|
2018-02-21 |
2019-08-29 |
AI Therapeutics, Inc. |
Combination therapy with apilimod and glutamatergic agents
|
JP7044416B2
(ja)
|
2018-02-28 |
2022-03-30 |
シャンハイ ダブリュディー ファーマシューティカル カンパニー,リミティド |
薬物組成物およびその製造方法と使用
|
SG11202008251TA
(en)
|
2018-03-02 |
2020-09-29 |
Univ Oregon Health & Science |
Amide prodrugs of small molecule nuclear receptor modulators
|
CA3094391A1
(en)
|
2018-03-22 |
2019-09-26 |
The Children's Medical Center Corporation |
Methods and compositions relating to lung repair
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
US11911513B2
(en)
|
2018-05-23 |
2024-02-27 |
Shanghai Wd Pharmaceutical Co., Ltd |
Controlled-release system of active pharmaceutical ingredient and preparation method therefor
|
EP3797818B1
(en)
|
2018-05-23 |
2023-01-18 |
Shanghai WD Pharmaceutical Co., Ltd |
Controlled-release system of active pharmaceutical ingredient and preparation method therefor
|
US11866439B2
(en)
|
2018-05-30 |
2024-01-09 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
CN112262142B
(zh)
|
2018-06-13 |
2023-11-14 |
泽农医药公司 |
苯磺酰胺化合物及其作为治疗剂的用途
|
MA52896A
(fr)
|
2018-06-14 |
2021-04-21 |
Neurocrine Biosciences Inc |
Composés inhibiteurs de vmat2, compositions et méthodes associées
|
US11447497B2
(en)
|
2018-06-29 |
2022-09-20 |
Histogen, Inc. |
(S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
EP3817818A1
(en)
|
2018-07-06 |
2021-05-12 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
CN112384505A
(zh)
|
2018-07-06 |
2021-02-19 |
吉利德科学公司 |
治疗性的杂环化合物
|
KR20210030973A
(ko)
|
2018-07-11 |
2021-03-18 |
액팀 테라퓨틱스, 인코퍼레이티드 |
조작된 면역자극성 박테리아 균주 및 이의 용도
|
KR20210033492A
(ko)
|
2018-07-16 |
2021-03-26 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 치료를 위한 캡시드 억제제
|
MA53329A
(fr)
|
2018-07-27 |
2022-03-02 |
Xenon Pharmaceuticals Inc |
Méthodes de traitement de l'épilepsie
|
TWI766172B
(zh)
|
2018-07-30 |
2022-06-01 |
美商基利科學股份有限公司 |
抗hiv化合物
|
WO2020033420A1
(en)
|
2018-08-07 |
2020-02-13 |
Firmenich Incorporated |
5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
|
CA3104693A1
(en)
|
2018-08-15 |
2020-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
US20210347741A1
(en)
|
2018-08-27 |
2021-11-11 |
Oregon Health & Science University |
Parp inhibitors for treating cancer and asthma
|
JP2021535159A
(ja)
|
2018-08-27 |
2021-12-16 |
スピノジェニックス, インコーポレイテッド |
スパイン形成のためのファシン結合化合物
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
AU2019327493A1
(en)
|
2018-08-29 |
2021-03-04 |
Shattuck Labs, Inc. |
Combination therapies comprising sirp alpha-based chimeric proteins
|
CN112638898B
(zh)
|
2018-08-31 |
2024-04-09 |
泽农医药公司 |
杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途
|
CR20210099A
(es)
|
2018-08-31 |
2021-06-24 |
Xenon Pharmaceuticals Inc |
Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapèuticos
|
EP3846830A4
(en)
|
2018-09-05 |
2022-07-06 |
Solarea Bio, Inc. |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
|
US11980647B2
(en)
|
2018-09-05 |
2024-05-14 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
US11014884B2
(en)
|
2018-10-01 |
2021-05-25 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
US20220009938A1
(en)
|
2018-10-03 |
2022-01-13 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
LT3873903T
(lt)
|
2018-10-31 |
2024-05-10 |
Gilead Sciences, Inc. |
Pakeistieji 6-azabenzimidazolo junginiai, kaip hpk1 inhibitoriai
|
CA3116347A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
CN113286591A
(zh)
|
2018-11-01 |
2021-08-20 |
库拉肿瘤学公司 |
用法尼基转移酶抑制剂治疗癌症的方法
|
US10570127B1
(en)
|
2018-11-05 |
2020-02-25 |
Renexxion, Llc |
Material and methods for the treatment of gastro-intestinal disorders
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
JP2022509091A
(ja)
|
2018-11-19 |
2022-01-20 |
グローバル ブラッド セラピューティクス インコーポレイテッド |
ヘモグロビンのモジュレーター
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
WO2020106307A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
JP2022513089A
(ja)
|
2018-11-20 |
2022-02-07 |
エヌフレクション セラピューティクス インコーポレイテッド |
皮膚癌の処置のためのアリールアニリンおよびヘテロアリールアニリン化合物
|
CN113473978A
(zh)
|
2018-11-20 |
2021-10-01 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病氰基芳烃-苯胺化合物
|
US20220144819A1
(en)
|
2018-11-20 |
2022-05-12 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
WO2020113135A1
(en)
|
2018-11-29 |
2020-06-04 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating rna
|
AU2019397067A1
(en)
|
2018-12-12 |
2021-07-22 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
EP3894416B1
(en)
|
2018-12-13 |
2022-11-09 |
Global Blood Therapeutics, Inc. |
Ferroportin inhibitors and methods of use
|
WO2020132071A1
(en)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
|
US20220071941A1
(en)
|
2018-12-21 |
2022-03-10 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
JP2022523146A
(ja)
|
2019-02-06 |
2022-04-21 |
オレゴン ヘルス アンド サイエンス ユニバーシティ |
ビスホスホネート連結化合物
|
EP3921038A1
(en)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
CN113677681A
(zh)
|
2019-02-11 |
2021-11-19 |
凤凰分子设计公司 |
Rsk抑制剂的结晶形式
|
CN113950479A
(zh)
|
2019-02-22 |
2022-01-18 |
克洛诺斯生物股份有限公司 |
作为syk抑制剂的缩合吡嗪的固体形式
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
EP3931186A1
(en)
|
2019-02-25 |
2022-01-05 |
CHDI Foundation, Inc. |
Compounds for targeting mutant huntingtin protein and uses thereof
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
WO2020176809A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
WO2020180663A1
(en)
|
2019-03-01 |
2020-09-10 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
CN113784950A
(zh)
|
2019-03-01 |
2021-12-10 |
速通医疗公司 |
新型拟甲状腺素药
|
AU2020231396A1
(en)
|
2019-03-07 |
2021-10-21 |
Nobo Medicine Inc. |
Caspase inhibitors and methods of use thereof
|
AU2020236225A1
(en)
|
2019-03-14 |
2021-09-16 |
Sunovion Pharmaceuticals Inc. |
Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
US11000488B2
(en)
|
2019-03-22 |
2021-05-11 |
Syntrix Biosystems Inc. |
Treating pain using desmetramadol
|
WO2020193431A1
(en)
|
2019-03-22 |
2020-10-01 |
Deutsches Krebsforschungszentrum |
Novel inhibitors of histone deacetylase 10
|
EP3712127A1
(en)
|
2019-03-22 |
2020-09-23 |
Deutsches Krebsforschungszentrum |
Novel inhibitors of histone deacetylase 10
|
WO2020205486A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
EP3946261A1
(en)
|
2019-04-03 |
2022-02-09 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202104210A
(zh)
|
2019-04-17 |
2021-02-01 |
美商基利科學股份有限公司 |
Hiv蛋白酶抑制劑
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
JP2022531388A
(ja)
|
2019-05-03 |
2022-07-06 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1阻害剤および使用する方法
|
WO2020237025A1
(en)
|
2019-05-23 |
2020-11-26 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
US11773099B2
(en)
|
2019-05-28 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
Compounds and their methods of use
|
US11505554B2
(en)
|
2019-05-31 |
2022-11-22 |
Praxis Precision Medicines, Inc. |
Substituted pyridines as ion channel modulators
|
US11279700B2
(en)
|
2019-05-31 |
2022-03-22 |
Praxis Precision Medicines, Inc. |
Ion channel modulators
|
EP3978076A4
(en)
|
2019-06-03 |
2023-02-22 |
Irimajiri Therapeutics Inc. |
CYCLIC AMIDE COMPOUNDS FOR THE TREATMENT OF RABIES AND METHOD THEREOF
|
TWI770527B
(zh)
|
2019-06-14 |
2022-07-11 |
美商基利科學股份有限公司 |
Cot 調節劑及其使用方法
|
WO2020257722A2
(en)
|
2019-06-19 |
2020-12-24 |
Solarea Bio, Inc. |
Microbial compositions and methods for producing upgraded probiotic assemblages
|
CA3145385A1
(en)
|
2019-07-08 |
2021-01-14 |
Steven D. Goodman |
Antibody compositions for disrupting biofilms
|
CA3146159A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
CA3146157A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
WO2021007487A1
(en)
|
2019-07-11 |
2021-01-14 |
Praxis Precision Medicines, Inc. |
Formulations of t-type calcium channel modulators and methods of use thereof
|
CN114126593A
(zh)
|
2019-07-26 |
2022-03-01 |
埃斯佩尔维塔治疗股份有限公司 |
可用于预防或治疗疾病的官能化的长链烃一元和二元羧酸
|
US11654124B2
(en)
|
2019-07-29 |
2023-05-23 |
Amneal Pharmaceuticals Llc |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US10792262B1
(en)
|
2019-07-29 |
2020-10-06 |
Saol International Limited |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CN115551530A
(zh)
|
2019-08-27 |
2022-12-30 |
通尼克斯制药有限公司 |
经修饰的tff2多肽
|
JP2022547617A
(ja)
|
2019-09-16 |
2022-11-14 |
ダイス アルファ,インク. |
Il-17aモジュレーターおよびその使用
|
US20230008367A1
(en)
|
2019-09-26 |
2023-01-12 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
TW202126651A
(zh)
|
2019-09-26 |
2021-07-16 |
美商艾克塞里克斯公司 |
吡啶酮化合物及使用方法
|
KR20220091488A
(ko)
|
2019-10-01 |
2022-06-30 |
몰레큘러 스킨 테라퓨틱스, 인코포레이티드 |
Klk5/7 이중 억제제로서의 벤족사지논 화합물
|
TW202128627A
(zh)
|
2019-10-10 |
2021-08-01 |
加拿大商再諾製藥公司 |
選擇性鉀通道調節劑之固態晶型
|
KR20220097442A
(ko)
|
2019-11-01 |
2022-07-07 |
기안알엑스 사이언스 인코포레이티드 |
글리콜레이트 산화효소 억제제로서의 헤테로사이클릭 카르복실레이트 화합물
|
CA3177479A1
(en)
|
2019-11-12 |
2021-05-20 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
WO2021097339A1
(en)
|
2019-11-13 |
2021-05-20 |
Rapt Therapeutics, Inc. |
Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
|
CN114980864A
(zh)
|
2019-11-22 |
2022-08-30 |
哈佛大学校长及研究员协会 |
用于药物递送的离子液体
|
CN114727999A
(zh)
|
2019-11-26 |
2022-07-08 |
吉利德科学公司 |
用于预防hiv的衣壳抑制剂
|
JP2023505150A
(ja)
|
2019-12-02 |
2023-02-08 |
セルジーン コーポレーション |
がんの処置のための治療法
|
EP4110779A1
(en)
|
2020-02-24 |
2023-01-04 |
Exelixis, Inc. |
Compounds and methods of use
|
US11697652B2
(en)
|
2020-02-24 |
2023-07-11 |
Gilead Sciences, Inc. |
Tetracyclic compounds and uses thereof
|
US20230093147A1
(en)
|
2020-03-09 |
2023-03-23 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
KR20220161438A
(ko)
|
2020-03-30 |
2022-12-06 |
길리애드 사이언시즈, 인코포레이티드 |
Cot 억제제 화합물, (S)-6-(((1-(바이사이클로[1.1.1]펜탄-1-일)-1H-1,2,3-트라이아졸-4-일)2-메틸-1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)메틸)))아미노8-클로로-(네오펜틸아미노)퀴놀린-3-카르보니트릴의 고체 형태
|
WO2021202284A1
(en)
|
2020-03-31 |
2021-10-07 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin
|
WO2021202796A1
(en)
|
2020-04-01 |
2021-10-07 |
Global Blood Therapeutics, Inc. |
Pyrrolidine-pyrazoles as pyruvate kinase activators
|
WO2021202688A1
(en)
|
2020-04-02 |
2021-10-07 |
Gilead Sciences, Inc. |
Process for preparing a cot inhibitor compound
|
WO2021222196A1
(en)
|
2020-04-28 |
2021-11-04 |
President And Fellows Of Harvard College |
Methods and compositions relating to ionic liquid adjuvants
|
CA3181583A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Methods of use for pyrimidines as ferroportin inhibitors
|
WO2021222359A1
(en)
|
2020-04-28 |
2021-11-04 |
Global Blood Therapeutics, Inc. |
Thieno pyrimidines as ferroportin inhibitors
|
EP4143178A1
(en)
|
2020-04-28 |
2023-03-08 |
Global Blood Therapeutics, Inc. |
Cycloalkyl pyrimidines as ferroportin inhibitors
|
WO2021226033A1
(en)
|
2020-05-07 |
2021-11-11 |
President And Fellows Of Harvard College |
Hyaluronic acid drug conjugates
|
CA3180060A1
(en)
|
2020-05-29 |
2021-12-02 |
Zongmin ZHAO |
Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
|
WO2021242970A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
FI4153136T3
(fi)
|
2020-06-10 |
2024-03-19 |
Auspex Pharmaceuticals Inc |
Osmoottisia annosmuotoja, jotka käsittävät deutetrabenatsiinia, ja menetelmiä niiden käyttämiseksi
|
EP4168414A1
(en)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
US20230102840A1
(en)
|
2020-06-23 |
2023-03-30 |
President And Fellows Of Harvard College |
Compositions and methods relating to combinatorial hyaluronic acid conjugates
|
US11680064B2
(en)
|
2020-06-25 |
2023-06-20 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of HIV
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
WO2022008976A1
(en)
|
2020-07-10 |
2022-01-13 |
Institut Pasteur |
Use of gdf11 to diagnose and treat anxiety and depression
|
CA3190593A1
(en)
|
2020-08-03 |
2022-02-10 |
Global Blood Therapeutics, Inc. |
Urea derivatives as pyruvate kinase activators
|
CA3191433A1
(en)
|
2020-08-12 |
2022-02-17 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
IL300626A
(en)
|
2020-08-14 |
2023-04-01 |
Siteone Therapeutics Inc |
Ketone-free inhibitors of NAV1.7 for the treatment of pain
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
JP2023543059A
(ja)
|
2020-09-30 |
2023-10-12 |
ギリアード サイエンシーズ, インコーポレイテッド |
架橋三環式カルバモイルピリドン化合物及びその使用
|
WO2022069701A1
(en)
|
2020-10-01 |
2022-04-07 |
Nogra Pharma Limited |
Methods of treating pulmonary fibrosis
|
US20220133669A1
(en)
|
2020-10-30 |
2022-05-05 |
Ds Biopharma Limited |
Pharmaceutical compositions comprising 15-hetre and methods of use thereof
|
US11773088B2
(en)
|
2020-11-02 |
2023-10-03 |
Praxis Precision Medicines, Inc. |
KCNT1 inhibitors and methods of use
|
EP4267559A1
(en)
|
2020-12-22 |
2023-11-01 |
Gilead Sciences, Inc. |
Substituted indole compounds
|
WO2022140325A1
(en)
|
2020-12-22 |
2022-06-30 |
Gilead Sciences, Inc. |
6-substituted indole compounds
|
WO2022155410A1
(en)
|
2021-01-15 |
2022-07-21 |
President And Fellows Of Harvard College |
Methods and compositions relating to anti-mfsd2a antibodies
|
SI4196479T1
(sl)
|
2021-01-19 |
2024-01-31 |
Gilead Sciences, Inc. |
Substituirane piridotriazinske spojine in njihove uporabe
|
US20240115607A1
(en)
|
2021-01-26 |
2024-04-11 |
Cytocares (Shanghai) Inc. |
Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
WO2022170200A1
(en)
|
2021-02-08 |
2022-08-11 |
Global Blood Therapeutics, Inc. |
1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
|
JP2024505721A
(ja)
|
2021-02-09 |
2024-02-07 |
ギリアード サイエンシーズ, インコーポレイテッド |
チエノピロール化合物
|
WO2022178205A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
WO2022187573A1
(en)
|
2021-03-05 |
2022-09-09 |
President And Fellows Of Harvard College |
Methods and compositions relating to cell membrane hybridization and camouflaging
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
IL305752A
(en)
|
2021-03-10 |
2023-11-01 |
Dice Molecules Sv Inc |
INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
|
CA3211496A1
(en)
|
2021-03-19 |
2022-09-22 |
Tiba Biotech Llc |
Artificial alphavirus-derived rna replicon expression systems
|
IL307203A
(en)
|
2021-04-16 |
2023-11-01 |
Gilead Sciences Inc |
THIENOPYRROLE COMPOUNDS
|
EP4326721A1
(en)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
WO2022241278A1
(en)
|
2021-05-14 |
2022-11-17 |
Global Blood Therapeutics, Inc. |
Solid forms of a modulator of hemoglobin
|
EP4347568A1
(en)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
TW202304435A
(zh)
|
2021-06-04 |
2023-02-01 |
美商基利科學股份有限公司 |
治療nash之方法
|
WO2022265880A1
(en)
|
2021-06-16 |
2022-12-22 |
President And Fellows Of Harvard College |
Improved methods and compositions for drug delivery relating to ionic liquids
|
WO2022266370A1
(en)
|
2021-06-17 |
2022-12-22 |
Aria Pharmaceuticals, Inc. |
Sparsentan for treating idiopathic pulmonary fibrosis
|
TW202311256A
(zh)
|
2021-06-18 |
2023-03-16 |
美商基利科學股份有限公司 |
用於治療fxr誘發之搔癢之il-31調節劑
|
WO2022271537A1
(en)
|
2021-06-25 |
2022-12-29 |
President And Fellows Of Harvard College |
Compositions and methods relating to injectable microemulsions
|
TW202317533A
(zh)
|
2021-07-02 |
2023-05-01 |
美商雅斯治療公司 |
奧沙奈坦(osanetant)之固體形式
|
CN117980309A
(zh)
|
2021-08-05 |
2024-05-03 |
百时美施贵宝公司 |
用作her2抑制剂的三环稠合嘧啶化合物
|
US20230144855A1
(en)
|
2021-09-01 |
2023-05-11 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin
|
WO2023034504A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
|
WO2023034508A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for promoting adipocyte beiging
|
WO2023034507A1
(en)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
|
WO2023034530A1
(en)
|
2021-09-02 |
2023-03-09 |
Teon Therapeutics, Inc. |
Methods of improving growth and function of immune cells
|
WO2023039162A1
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating enteroendocrine cells
|
WO2023039164A2
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating goblet cells and for muco-obstructive diseases
|
US20230270734A1
(en)
|
2021-09-10 |
2023-08-31 |
Gilead Sciences, Inc. |
Thienopyrrole compounds
|
WO2023043827A2
(en)
|
2021-09-14 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for perturbing monocyte and neutrophil lineages
|
AU2022349462A1
(en)
|
2021-09-24 |
2024-04-11 |
Xenon Pharmaceuticals Inc. |
Pyridine derivatives and their use as sodium channel activators
|
AU2022349463A1
(en)
|
2021-09-24 |
2024-03-14 |
Xenon Pharmaceuticals Inc. |
Pyridinyl derivatives as sodium channel activators
|
TW202328091A
(zh)
|
2021-09-24 |
2023-07-16 |
加拿大商再諾製藥公司 |
做為鈉通道活化劑之吡啶基乙醯胺衍生物
|
WO2023055457A1
(en)
|
2021-09-29 |
2023-04-06 |
Amneal Pharmaceuticals Llc |
Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
|
WO2023060134A1
(en)
|
2021-10-06 |
2023-04-13 |
Global Blood Therapeutics, Inc. |
Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
|
EP4162933A1
(en)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Compound for treating non-alcoholic fatty liver disease and related diseases
|
AU2022359915A1
(en)
|
2021-10-08 |
2024-05-02 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
WO2023076404A1
(en)
|
2021-10-27 |
2023-05-04 |
Aria Pharmaceuticals, Inc. |
Methods for treating systemic lupus erythematosus
|
WO2023081730A1
(en)
|
2021-11-03 |
2023-05-11 |
Teon Therapeutics, Inc. |
4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
|
WO2023092150A1
(en)
|
2021-11-22 |
2023-05-25 |
Solarea Bio, Inc. |
Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
|
WO2023097233A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097234A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
WO2023097230A1
(en)
|
2021-11-23 |
2023-06-01 |
Genentech, Inc. |
Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
|
TW202327590A
(zh)
|
2021-11-30 |
2023-07-16 |
美商庫拉腫瘤技術股份有限公司 |
大環化合物及組合物以及其製備及使用方法
|
TW202342448A
(zh)
|
2021-12-03 |
2023-11-01 |
美商基利科學股份有限公司 |
用於hiv病毒感染之治療性化合物
|
TW202342447A
(zh)
|
2021-12-03 |
2023-11-01 |
美商基利科學股份有限公司 |
用於hiv病毒感染之治療性化合物
|
WO2023102239A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
AU2022408097A1
(en)
|
2021-12-10 |
2024-05-30 |
Global Blood Therapeutics, Inc. |
Methods of administering a modulator of hemoglobin
|
US20230190834A1
(en)
|
2021-12-21 |
2023-06-22 |
Solarea Bio, Inc. |
Immunomodulatory compositions comprising microbial entities
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
WO2023137178A1
(en)
|
2022-01-17 |
2023-07-20 |
Chandrasekhar Satishchandran |
Combinations of vitamin d3, niacinamide and lipoic acid for use in the maintenance of healthy blood glucose levels
|
WO2023147134A2
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Methods for treating patients having low estrogen with nk3 antagonists
|
WO2023147135A1
(en)
|
2022-01-31 |
2023-08-03 |
Acer Therapeutics, Inc. |
Nk receptor antagonists for treatment of prostate cancer
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023178283A1
(en)
|
2022-03-18 |
2023-09-21 |
Epicentrx, Inc. |
Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
|
TW202400593A
(zh)
|
2022-03-28 |
2024-01-01 |
美商艾索司特瑞克斯公司 |
Myst家族離胺酸乙醯轉移酶之抑制劑
|
TW202342070A
(zh)
|
2022-03-30 |
2023-11-01 |
美商拜奧馬林製藥公司 |
肌萎縮蛋白外顯子跳躍寡核苷酸
|
WO2023192506A1
(en)
|
2022-03-31 |
2023-10-05 |
Rarified Biosciences, Inc. |
Malt1 modulators and uses thereof
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
TW202400172A
(zh)
|
2022-04-06 |
2024-01-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
TW202406901A
(zh)
|
2022-04-14 |
2024-02-16 |
美商必治妥美雅史谷比公司 |
新穎gspt1化合物以及新穎化合物之使用方法
|
WO2023201348A1
(en)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
|
WO2023211990A1
(en)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
|
WO2023215220A1
(en)
|
2022-05-02 |
2023-11-09 |
Esperion Therapeutics, Inc. |
Macrocyclic inhibitors of atp citrate lyase
|
WO2023215227A1
(en)
|
2022-05-02 |
2023-11-09 |
Epicentrx, Inc. |
Systems and methods to improve exercise tolerance
|
WO2023215229A1
(en)
|
2022-05-02 |
2023-11-09 |
Epicentrx, Inc. |
Compositions and methods for treatment of pulmonary hypertension
|
WO2023215781A1
(en)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Method of treating duchenne muscular dystrophy
|
US20240101529A1
(en)
|
2022-05-20 |
2024-03-28 |
Gilead Sciences, Inc. |
Antiviral indolinyl compounds and uses thereof
|
WO2023230524A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of secretory and/or catalytic cells and methods using the same
|
WO2023240186A1
(en)
|
2022-06-08 |
2023-12-14 |
Auspex Pharmaceuticals, Inc. |
Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
|
US20240101531A1
(en)
|
2022-06-08 |
2024-03-28 |
Xenon Pharmaceuticals Inc. |
Pyridinamine derivatives and their use as potassium channel modulators
|
WO2023244973A1
(en)
|
2022-06-13 |
2023-12-21 |
Epicentrx, Inc. |
Compositions and methods for reducing adverse side effects in cancer treatment
|
US20230399315A1
(en)
|
2022-06-14 |
2023-12-14 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
US20230399299A1
(en)
|
2022-06-14 |
2023-12-14 |
Amygdala Neurosciences, Inc. |
Aldh-2 inhibitor compounds and methods of use
|
WO2024015827A1
(en)
|
2022-07-12 |
2024-01-18 |
Hotspot Therapeutics, Inc. |
Solid forms of a triazine derivative as cbl-b modulator
|
WO2024015372A1
(en)
|
2022-07-14 |
2024-01-18 |
Teon Therapeutics, Inc. |
Adenosine receptor antagonists and uses thereof
|
WO2024015416A1
(en)
|
2022-07-15 |
2024-01-18 |
Celloram Inc. |
Celastrol derivatives
|
WO2024047394A1
(en)
|
2022-08-31 |
2024-03-07 |
Otsuka Pharmaceutical Co., Ltd. |
Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
|
WO2024054832A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
|
US20240131005A1
(en)
|
2022-09-30 |
2024-04-25 |
Boulder Bioscience Llc |
Compositions and methods for treating non-hemorrhagic closed head injury
|
WO2024086246A2
(en)
|
2022-10-18 |
2024-04-25 |
Eluciderm Inc. |
2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
|
WO2024091863A1
(en)
|
2022-10-25 |
2024-05-02 |
Starrock Pharma Llc |
Combinatorial, and rotational combinatorial therapies for obesity and other diseases
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
US20240174672A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridone Compounds
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
WO2024089668A1
(en)
|
2022-10-28 |
2024-05-02 |
Basecamp Bio Inc. |
Somatostatin receptor 2 agonists and uses thereof
|
WO2024097940A1
(en)
|
2022-11-04 |
2024-05-10 |
Bristol-Myers Squibb Company |
Therapy for the treatment of cancer
|
WO2024098009A1
(en)
|
2022-11-04 |
2024-05-10 |
Epicentrx, Inc. |
Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
|
US11931224B1
(en)
*
|
2022-12-19 |
2024-03-19 |
Robert Parker |
Tooth pod
|